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Abstract: 
Development of CXCR4-Inhibiting Nanoparticles for the Treatment of Metastatic 
Cancer 
Yan Wang, Ph.D. 
University of Nebraska Medical Center, 2016 
Supervisor: David Oupický, Ph.D. 
Metastasis is the main cause of cancer mortality and morbidity, leading to several 
million deaths every year. Less than 20% of pancreatic cancer (PC) patients are 
candidates for surgery due to spread beyond the pancreas. Desmoplasia presents 
substantial barriers to perfusion, diffusion, and convection of antitumor therapeutics into 
the PC tissues. We focus on developing novel therapies that regulates tumor 
microenvironment, chemosensitizing tumor to therapeutics and preventing metastasis.  
Gene therapy is emerging as a promising new therapeutic agents for cancer 
treatment. A targeted, systemic, effective and safe gene delivery system should be 
developed. CXCR4/SDF-1 axis plays a crucial role in the crosstalk between cancer cells 
and their microenvironment, and is involved in tumor progression, angiogenesis, 
metastasis and survival. We successfully designed dual-function polymeric CXCR4 
inhibitors (PCX) as gene delivery vectors.  
To enhance the CXCR4 antagonism, we reported synthesis of novel monocyclam 
monomers and their polymerization to PCX. In order to improve the physical properties 
and safety of PCX, it was modified by PEGylation. The negative effect of PEG on 
transfection activity of PEG-PCX polyplexes could be overcome by using polyplexes 
formulated with a mixture of PCX and PEG-PCX. Moreover, modification of PCX with 
cholesterol, the enzymatic stability against RNase and siRNA delivery efficiency were 
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enhanced dramatically. NCOA3 silencing can downregulate mucin expression and 
regulate tumor microenvironment. Using a series of PCX, we optimized formulation of 
PCX/siNCOA3 polyplexes to simultaneously target CXCR4 and NCOA3 in PC. 
Cholesterol-modified PCX showed maximum CXCR4 antagonism, NCOA3 silencing and 
inhibition of PC cell migration in vitro. The optimized PCX/siNCOA3 polyplexes were used 
in evaluating antitumor and antimetastatic activity in orthotopic mouse model of metastatic 
PC. The polyplexes displayed significant inhibition of primary tumor growth, which was 
accompanied by a decrease in tumor necrosis and increased tumor perfusion. These dual-
function polyplexes also showed significant antimetastatic effect and effective suppression 
of metastasis to distant organs. Overall, dual-function PCX/siNCOA3 polyplexes can 
effectively regulate the tumor microenvironment to decrease progression and 
dissemination of PC. 
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Chapter 1. Introduction 
Please note that part of this chapter was taken from a review titled“Potential of 
CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery” published in Drug Delivery [1]. 
The authors of the book chapter include Ying Xie, Prof. David Oupický and me. I wrote 
the draft of manuscript, Ying gave me suggestions, Dr. David Oupický revised it and made 
it published. All the authors agreed with including their contributions in this dissertation. 
 
1.1 Cancer metastasis 
Metastasis is the major reason for the failure of cancer therapy and accounts for 
approximately 90% mortality of cancer patients [2]. It requires several successive steps 
for cancer cells spreading from the primary site and continuous growth into secondary 
tumors in distant organs. Metastasis is a complex process that begins with invasion into 
local stroma, followed by intravasation of cancer cells into blood and lymphatic vessels, 
movement of cancer cells through the lymphatic system or blood circulation, extravasation 
into the parenchyma of distant tissues, adaption to a new environment at secondary site, 
formation of micrometastases, and finally the growth into macroscopic tumors [3, 4]. 
During the process of intravasation, cancer cells should be survival without adhesion and 
escape from recognition by the host immune system [5]. The complex molecular 
mechanism of metastasis includes the alteration of multistep, multistage and multigene. 
However, cancer cells tightly interact with their surrounding microenvironment during each 
step, which plays a critical part in the cancer metastasis [6].  
Tumor microenvironment consists of the extracellular matrix (ECM) and stromal 
cells, involving endothelial cells, fibroblasts, immune cells, bone marrow-derived cells, 
progenitor cells and stem cells. Clarification of the relationship between the tumor 
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microenvironment and metastasis will suggest a key point to prevent cancer metastasis 
and improve the life quality of patients [7]. Stromal cells interact with cancer cells directly 
and indirectly to influence the progress of tumorigenesis and development. There are two 
complementary strategies facilitate cancer cells take advantage of the primary tumor 
microenvironment to initiate metastasis [2]. First, cancer cells alter their gene expression 
pattern to utilize the signals from tumor stroma and migrate to a different site. Second, 
stromal cells will be vigorously recruited to primary tumor site to promote metastasis. In 
another words, cancer cells gain metastatic potential at the primary tumor site, which is 
supported by the comparability in the investigations that gene expressions of metastases 
and the corresponding primary tumor are similar in various cancers, such as breast, 
colorectal, prostate and pancreatic cancer [8-10].  
1.1.1 Epithelial to mesenchymal transition (EMT) 
EMT is a key developmental program and often activated in the initiating steps of 
primary tumor invasion. Tumor cells lose epithelial markers, acquire mesenchymal traits, 
express stem cell markers and obtain a migratory phenotype [11]. In a normal tissue, 
epithelial cells connect tightly with each other by epithelial adherens junctions with the aid 
of protein E-cadherin and their migratory capacity is prohibited. However, in the first step 
of cancer metastasis, cancer cells have to break the ECM. Epithelial cells are separated 
from multiple layers of stroma by ECM [2]. In EMT, the expression of E-cadherin is 
suppressed, resulting in the detachment of cancer cells from epithelial sheets [12]. 
Moreover, the mesenchymal state is related with the ability of cancer cells to subsequently 
differentiate into multiple cell types during the initiation and development of metastasis. 
Researchers reported that the stroma plays an critical role in the phenotypic 
transitions in cancer by the expression of transforming growth factor β (TGF-β) [12]. 
Labelle et al. investigated that platelet-tumor cell interactions were sufficient to prime 
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tumor cells for subsequent metastasis. The TGF-β/Smad and NF-ĸB pathways were 
synergistically activated in cancer cells by the interaction of platelet-derived TGF-β and 
direct platelet-tumor cell, leading to the transition to an invasive mesenchymal-like 
phenotype and increased metastasis in vivo. However, inhibition of NF-ĸB signaling 
pathway or the expression of TGF-β1 alone in platelets prevents lung metastasis in vivo 
[13]. Bonde et al. found that tumor associated macrophages regulated EMT intratumorally 
through TGF-β signaling and activation of the β-catenin pathway [14]. Long term exposure 
of teratocarcinoma cells to macrophage-conditioned medium resulted in reduced 
expression of E-cadherin, activation of the EMT-mediating β-catenin signaling pathway, 
enhanced mesenchymal marker and an invasive phenotype [14]. Moreover, it was proved 
that intratumor macrophage densities, EMT markers and TGF-β levels have a positive 
correlation by an immunohistochemical study of a series of non-small cell lung cancer 
patients’ samples. 
1.1.2 Recruitment of immune and stromal cells 
In order to alter tumor microenvironment to a metastasis-promoting position, 
stromal cells will be transformed to support cancer cells invasion or metastasis-promoting 
stromal cells will be recruited to remodel the microenvironment [2]. Researchers revealed 
that direct communication between macrophages and tumor cells in the microenvironment 
resulted in invasion and intravasation of tumor cells into the blood or lymphatic vessels. 
Macrophages promote the angiogenesis, facilitate ECM breakdown/remodeling and 
enhance the motility of cancer cells, suggesting a potential target for anticancer drugs [15]. 
Recruited immature myeloid cells can facilitate cancer cells evade the host immune 
response through inhibiting the differentiation of antigen-presenting DCs after 
accumulation in cancer microenvironment. In the normal conditions, myeloid cells are the 
most abundant nucleated hematopoietic cells and terminally differentiated into three 
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groups, including macrophages, dendritic cells and granulocytes, which are necessary for 
the innate and adaptive immune systems. However, in the tumor microenvironment, 
myeloid cells would be changed into effect immunosuppressive cells and support tumor 
immune evasion [16]. Van Zijl et al. found that myofibroblasts or cancer-associated 
fibroblasts (CAFs) induced invasion of hepatocellular carcinoma was through TGF-β and 
platelet-derived growth factor (PDGF) signaling pathway using a collagen gel-based three 
dimensional hepatocellular carcinoma model in vitro. Thus, TGF-β/PDGF axis is very 
important during hepatic tumor-stroma crosstalk to regulate tumor growth and progression 
[17]. Moreover, CAFs keeps continuously activated in tumors. The long-term activation of 
fibroblasts contributes to the perpetual secretion of activating cytokines, such as SDF-1, 
VEGF, PDGF and HGF [18, 19]. Orimo et al. demonstrated that CAFs within invasive 
breast carcinomas secreted SDF-1, which promoted the recruitment of endothelial cells 
and contributed to tumor promotion by acting the cognate receptor CXCR4 expressed by 
carcinoma cells [20]. 
1.1.3 ECM remodeling 
Proteolysis and breakdown of ECM is an essential component of 
microenvironment remodeling and important in the early step of local invasion of cancer 
cells into adjacent tissue. During the process of ECM remodeling, matrix 
metalloproteinases (MMPs) are crucial effectors [21]. For instance, tumor-associated 
fibroblasts differentiate into myofibroblasts and promote tumor progression by protease-
catalysed remodeling of the stroma using MMP9 [22]. MMP9 is recruited to the cell surface 
of fibroblasts by lysyl hydroxylase via fibronectin-like domain and facilitate the 
differentiation of tumor-associated fibroblasts.  
1.1.4 Hypoxia 
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Due to the rapid proliferation of primary cancer cells, the concentration of oxygen 
is much lower in the region of tumor cells than in the normal tissues. Hypoxia-inducible 
factors (HIFs) are the most critical transcription factors, which response to hypoxia, induce 
the formation of angiogenesis and promote the survival of cancer cells. Cancer cells alter 
their intrinsic gene expression and adapt to the hypoxic environment by the HIF signaling 
pathway [23]. Moreover, hypoxia is also a main driving force for recruiting stromal cells to 
tumors. Chouaid et al. reported that hypoxia contributed to the tumor tolerance to immune 
surveillance through the recruitment of regulatory T cells and myeloid derived suppressor 
cells by activating HIF-1 and vascular endothelial growth factor (VEGF) pathways [24]. 
After stromal cell recruitment medicated by hypoxia, cancer invasion is promoted at the 
edge of tumor periphery. Simultaneously, hypoxia provides an aggressive selection 
pressure for cancer stem cells migrate to the tumor periphery to facilitate cancer cell 
escape. Therefore, hypoxia and stromal cells work together to promote cancer metastasis 
[6].  
1.1.5 Intravasation and selection at distant site 
The possibility of cancer metastasis to a specific organ is determined by various 
reasons, including routes of blood circulation, the ability of cancer cell intravasation into 
vasculature and modulating tumorigenesis at secondary organs. During this process, 
cancer cells also need to deal with the microenvironments. Macrophages localizing to 
blood vessels facilitate cancer cells intravasate into the circulation [25]. Platelets play an 
important role in the enemy microenvironment of the vasculature and support tumor 
metastasis by directly interacting with cancer cells. In circulation, platelets can form 
protective clusters with cancer cells, impacting NK cell-mediated cytotoxicity, preventing 
the recognition by immune cells, promoting the arrest at the endothelium and supporting 
the establishment of secondary lesions [26]. However, most disseminated cancer cells die 
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at the secondary site and only 0.01% of cancer cells intravasating into circulation are able 
to form detectable metastasis [27]. The metastatic outgrowth is affected by the 
microenvironment factors in the secondary organs [28]. After cancer cells initially reach 
distant organs, the microenvironment may suppress metastatic cancer growth by inhibitory 
stromal factors. For instance, immune cells (cytotoxic T cells or natural killer cells) of 
adaptive and innate immune system form a critical barrier for the survival and proliferation 
of cancer cells. Stroma cells from the secondary sites release apoptotic signals (Fas-L 
and Trail), which inhibit the cancer cell proliferation and cause elimination. However, 
cancer cells can induce alternation of stroma and regulation of microenvironment to 
support cancer growth and metastasis. For example, cancer-associated fibroblasts 
secrete various cytokines and growth factors, such as SDF-1, PDGF, VEGF and HGF. 
Modified ECM and secreted growth factors can reactivate metastatic cancer cells from 
dormancy, inducing angiogenesis and enhance the survival as well as multi-functionality 
of metastatic cancer cells. Furthermore, the recruitment of macrophages, myeloid 
progenitors and mesenchymal cells establish an inflammatory environment and secrete 
various signals to enhance the metastatic cancer growth. 
1.2 Pancreatic Cancer 
In 2016, it is expected to have 53,070 new cases and 41,780 deaths of pancreatic 
cancer (PC) in the US. From 2000 to 2012, the incidence rate enhanced by 1.2% per year 
and since 2000, the death rate increased slightly by 0.4% per year. PC is predicted to 
become the second leading cause of cancer-related mortalities by 2030 [29]. The patients 
usually do not feel the symptoms until the disease has progressed, including weight loss, 
abdominal discomfort and occasionally the development of diabetes. Diagnosis at an early 
stage is difficult for PC, except that tumor develops near the common bile duct and cause 
jaundice. Until now, there is no reliable method for the early detection of PC. PC patients 
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at advanced stage may have nausea, vomiting and severe abdominal pain. Smoking 
cigarette is one of the significant risk factors of PC (~2 fold vs. nonsmokers). About one-
fifth of PC patients are because of smoking. Also, family history of PC, history of chronic 
pancreatitis, obesity, diabetes and genetic syndromes (BRCA1&2 mutation) can cause 
high risk of PC. 
The main treatment options for PC are surgery, radiation therapy, and 
chemotherapy to extend survival or relieve symptoms, however, seldom produce a cure. 
The one-year and five-year survival rates remain consistently low (~29% and ~7% 
respectively), which are due to late diagnosis, early metastasis, and complex 
microenvironment in PC. PC microenvironment contributes to inherent resistance to 
available therapies and severely limits drug delivery [30-32]. More than half (53%) of 
patients are diagnosed at a distant stage, for which the 1- and 5-year survival is 15% and 
2%, respectively. Less than 20% of patients are candidates for surgery because PC is 
usually detected after it has spread beyond the pancreas. Thus, there is a urgent need to 
develop better therapeutic strategies for the treatment of PC [33].  
1.3 Desmoplasia and Treatment Strategies 
PC is unique among solid tumors due to the extremely dense desmoplastic 
reaction which wraps the cancer cells. The emergence of desmoplasia in PC is becoming 
a problem which presents substantial barriers to perfusion, diffusion, and convection of 
antitumor therapeutics into the PC tissues and leads to acquired resistance [34]. 
Desmoplasia contains extracellular matrix (ECM) proteins, myofibroblastic pancreatic 
stellate cells (PaSCs), and immune cells, which modulate the growth of PC by providing 
a scaffold for the cancer cells to grow as well as growth factors and immune modulators 
(Scheme 1) [35]. Researchers reported that extensive fibroblastic cell proliferation in PC 
relates to poor disease outcomes [36]. The prominence of desmoplastic reaction has 
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caught researchers’ eyes as one of the major factors responsible for the severe and 
malignant biologic behavior of PC. Tumor local environment plays any important role in 
cancer initiation, progression, metastasis and resistance [37, 38]. Desmoplastic PC 
microenvironment shows high interstitial pressure and a dense stroma with vascular 
dysfuction, which results from the proliferation of fibroblasts and increased stromal fibrosis 
[39, 40]. The key regulatory pathways to regulate desmoplasia include Hyaluroran-CD44 
and Hedgehog (Hh), which are aberrantly overexpressed in PC [39, 41, 42].  
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Scheme 1. Components of desmoplasia in PC. Pancreatic cancer cells and pancreatic 
duct cells promote each other’s growth and proliferation and together regulate processes 
of ECM deposition, angiogenesis, and disordered immune surveillance (Adapted from 
[35]). 
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1.3.1 Hyaluronan-CD44 pathway 
One strategy to overcome the dense stromal barrier is to target the ECM 
component. In the desmoplastic reaction, a key role of fibroblasts is hyaluronan synthesis 
and its interaction with CD44. CD44 has been associated with malignant transformation 
of pancreatic tumors. It is an integral cell-surface glycoprotein and overexpresses in its 
variant forms, which is driven by IFN-γ [43]. Meanwhile, CD44 is also the major cell surface 
receptor for hyaluronan as well as matrix metalloproteinases, playing a critical role in 
pancreatic carcinogenesis. Hyaluronan is a non-sulphated glycosaminoglycan. In 
response to factors released from tumor cells, such as lactate, or by direct cell-cell contact, 
hyaluronan is produced by activated fibroblasts [44]. Hyaluronan-rich stroma is associated 
with poor prognosis in many epithelial cancers including pancreatic and together with 
CD44 promotes tumor cell growth, migration, and metastases [42]. Hyaluronan-CD44 
interaction reorganizes the desmoplasmic barrier and enhances its integrity, so that the 
drug is impeded from entering into the PC tissue and causes the failure of therapy [42]. 
Researchers have taken a lot of efforts to design novel strategies to minimize 
desmoplasia and improve the delivery of therapeutics to PC tissues. Disruption of 
hyaluronan-CD44 interaction would be a critical method to prevent drug resistance in PC. 
Provenzano et al. reported that systemic administration of PEGPH20, a PEGylated human 
recombinant PH20 hyaluronidase, could ablate stromal HA from autochthonous murine 
PC, normalize interstitial fluid pressure and re-expand the microvasculature. Combination 
of PEGPH20 with gemcitabine treatment resulted a near doubling of overall survival [45]. 
37]. 4-Methylumbelliferone (4-MU) is a hyaluronan synthesis inhibitor, which has been 
shown to slow down the development of human PC cell lines both in vitro and in vivo as 
well as inhibit cancer cell migration, proliferation and invasion [46, 47]. 4-MU also 
prolonged the survival time of nude mice bearing abdominally transplanted pancreatic 
11 
 
cancer cells and enhanced the efficacy of gemcitabine, suggesting that its potential usage 
in patients with end-stage pancreatic cancer [48]. Diop-Frimpong et al. found that 
angiotensin receptor inhibitor losartan led to a dose-dependent reduction in stromal 
collagen and hyaluronan production in desmoplastic models of human breast, pancreatic, 
and skin tumors in mice, thus enhanced the efficacy of chemotherapy [49]. 
1.3.2 Hedgehog pathway 
Hh signaling pathway is genetically changed and aberrantly activated in most of 
PC, which causes tumor initiation, progression, and metastatic spread. Moreover, it has 
been involved in the initiation and maintenance of desmoplastic reaction Scheme 2 [50]. 
Hh pathway consists of Sonic (Shh), Indian (IHh), patched (PTCH) and smoothened 
(SMO), which are almost undetectable in normal human pancreas, however, become 
prominently visible during PC [41]. Myofibroblast differentiation and stroma-derived growth 
promoting molecules are induced by Hh signaling pathway, which promote tumorigenesis. 
Moreover, Hh ligands intensify desmoplastic reaction and fibrosis by stimulating the 
interaction with TGF-β1 and MMPs [51]. This pathway is activated when Shh bind to the 
PTCH receptor relieving the inhibitory effects of SMO receptor from PTCH and thus 
activating the glioma-associated oncogene (GLI) family of transcription factors [52]. 
Activated GLI induces the expression of the Hedgehog genes such as PTCH, epidermal-
derived, platelet-derived, and vascular-endothelial growth factors, cyclins B, D, and E and 
GLI1, which promotes the tumor progression and desmoplastic reaction [53].  
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Scheme 2. The Hedgehog pathway (Adapted from [54]). 
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Inefficient drug delivery may be an important contributor to chemoresistance in PC. 
Inhibition of Hh signaling pathway is a promising strategy to overcome the desmoplastic 
reaction in PC and thus increase the delivery of anticancer therapeutics into tumors. Olive 
et al. reported that the efficacy of gemcitabine in the mice could be improved by co-
administration of a small molecule inhibitor of Hh pathway (IPI-926). The combination 
treatment depleted tumor-associated stromal tissue and produced a transient increase in 
intratumoral vascular density, resulting in improved intratumoral concentration of 
gemcitabine and transient stabilization of disease [55]. Kumar et al. designed a self-
assembled copolymer to simultaneously encapsulate Hh inhibitor GDC-0449 and complex 
tumor suppressor miR-let7b into micelles to treat athymic nude mice bearing ectopic 
pancreatic tumor, resulting decreased tumor proliferation and enhanced apoptosis [56]. 
Feldmann et al. investigated that blocking the Hh pathway with the small molecule 
cyclopamine, which is a naturally occurring inhibitor of SMO receptor, resulted in 
prevention of PC metastases and enhancement in chemo-delivery to tumors [57].  
The survival rate of PC patients has not been significantly improved during the past 
30 years. Due to PC is highly resistant to the currently available chemotherapy and 
radiotherapy, the new effective patterns for the treatment are urgently needed. In recent 
a few years, gene engineering technology is becoming a rapidly and potentially developing 
area of modern medicine to treat tumor with the promising progress of modern biology 
and nanomedicine. Therefore, the treatment of patients who are not curable by current 
therapies will be improved by gene modification [58]. 
1.4 Gene Therapy 
Gene therapy is an experimental technique that uses genes to treat or prevent 
disease by inserting a gene into patients’ nidus instead of using drug or surgery. Gene 
therapy aims at delivering genetic material into target cells or tissue and to express it with 
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the intention to gain a therapeutic effect. There are several approaches for gene therapy, 
including replacing a mutated gene that causes disease with a healthy copy of the gene, 
or inactivating a mutated gene that is functioning improperly, or introducing a new gene 
into the body to help against a disease. 
In 1989, the US Food and Drug Administration (FDA) approved the first gene 
therapy protocol. A marker gene was ex vivo transduced into the tumor infiltrating 
lymphocytes, which were collected from advanced melanoma patients. The transduced 
cells were expanded in vitro and re-infused to the patients. In the following year, tumor 
infiltrating lymphocytes were genetically modified ex vivo to express tumor necrosis factor 
and used to treat patients with advanced melanoma, which was the first clinical trial on 
cancer using gene therapy with an therapeutic intend [59]. Significant progresses in gene 
therapy have been obtained since the first clinical trial in 1990. It was reported that two 
patients with metastatic melanoma were received a successful immunogene therapy. Until 
June 2012, the entries for 1843 trials undertaken in 31 countries were reported and most 
of which were focused on cancer treatment [60]. Jones et al. performed a comprehensive 
genetic analysis of 24 pancreatic cancers and determined the sequences of 23,219 
transcripts, as well as representing 20,661 protein-coding genes. After they searched for 
homozygous deletions and amplifications in the tumor DNA by using microarrays 
containing probes for about 106 single-nucleotide polymorphisms, an average of 63 
genetic alterations were found in pancreatic cancers, the majority of which were point 
mutations. These alterations defined a core set of 12 cellular signaling pathways and 
processes that were each genetically altered in 67 to 100% of the tumors [61]. Therefore, 
genes in these cellular pathways would be potential targets for PC gene therapy. However, 
the highly efficient gene therapy is based on selection of efficient targets, effective gene 
delivery, tumor targeted therapy and low toxicity.  
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1.4.1 Vector systems for gene delivery 
An ideal gene delivery system is the foundation of gene therapy, which should 
have the properties, such as non-invasive mode of administration, tumor-specific targeting, 
including primary lesion and distant metastatic lesion, sustained gene expression, and 
high insertion capacity, bio-safety, stability and easy preparation [58]. Vector systems are 
divided as viral and non-viral methods. The advantages of viral vector system includes 
higher transfection efficiency and long-term gene expression. However, viral method may 
cause toxicity, immunogenicity, high cost and inability to transfer large size genes, which 
can be avoided by non-viral delivery systems. Non-viral methods have the advantages of 
easy preparation and modification with ligands for tissue and cell specific targeting [62].  
In gene delivery systems, viral vectors are the most commonly studied and applied. 
More than two-thirds of clinical trials used viral vectors, including adenovirus (AdV), 
retrovirus (RV), adeno-associated virus (AAV), lentivirus, herpes simplex virus (HSV), 
influenza virus, Newcastle disease virus, pox virus, and Epstein-Barr virus (EBV). Viruses 
can take advantage of the innate mechanism of infection to enter and transfer DNA 
molecules into cells without any physical or chemical processing. Then the therapeutic 
gene would be expressed after entering the nucleus and integrating into the host gene 
pool [63]. 
Non-viral vectors consist of physical methods, biological vectors, and chemical 
vectors to introduce naked DNA (plasmid DNA), RNA molecules, or oligonucleotides into 
cells. Microinjection, microparticle bombardment and electroporation are most commonly 
used in physical delivery. Even though physical techniques can achieve high transfection 
efficiency, they are laborious, impractical, invasion and difficult to apply in a clinical setting 
[62]. Both bacteria and mammalian cells (hematological cells or mesenchymal stem cells) 
can be used as biological vectors for gene therapy. Bacteria is engineered to express 
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therapeutic genes and deliver both therapeutic gene and protein product to recipient cells. 
For instance, a bacterial cancer vaccine was prepared using a live attenuated Listeria 
strain of bacteria to express mesothelin and demonstrated antitumor effect in an early-
phase clinical trial [64]. The commonly used chemical vectors can be divided into two 
types based on the materials, cationic lipids (liposomes) and cationic polymers. Cationic 
lipids consist of an aqueous compartment enclosed in a phospholipid bilayer and bind with 
nucleic acids based on the electrostatic interaction. After fusion with target cell membrane 
and endocytosis, nucleic acid will be delivered into cytoplasm. Cationic polymers include 
a wide range of chemical compounds, such as chitosan, polyamidoamine, polypeptides 
and so on. They form nanosized particles with negatively charged nucleic acids through 
electrostatic interaction. Cationic polymers increase cellular uptake by endocytosis, 
protects nucleic acids from nuclease degradation and facilitate endosome escape. Then, 
nucleic acids would be released into cytoplasm and regulate gene expression [58]. The 
combination system of lipid/polymer/DNA has been developed to exhibit further 
condensation, protection and increase circulating half-life in vivo [62]. Furthermore, 
ligands or peptides can be conjugated to polymer to improve cell/tissue specificity by 
receptor-directed gene delivery. 
1.4.2 Nucleic acids 
Plasmid is a double stranded circular DNA with transgene to encode for specific 
protein. Besides the transgene, plasmid DNA consists other regulatory signals such as 
the promoter, enhancer sequences, splicing and polyadenylation sites to regulate gene 
expression [65]. The size of plasmid ranges from hundreds of to several thousand base 
pairs. Engineering the plasmid with tissue or tumor specific promoters would improve the 
efficiency of initiating the transcription process by recognizing the RNA polymerase. The 
commonly used promoters are derived from viral origins such as cytomegalovirus (CMV) 
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and roux sarcoma virus. Enhancers locate in either upstream or downstream of the 
promoter region, which are the binding sites for proteins to enhance the initiation of gene 
transcription [66]. Splicing and polyadenylation sites are responsible for the correction of 
mRNA obtained from transcription. 
Antisense Oligonucleotide (AON) is a short single-stranded segments (18-21 base 
pairs) of DNA or RNA artificially synthesized in vitro. It has a complementary sequence to 
the target mRNA to inhibit gene expression by different mechanisms, including 
translational arrest by steric hindrance of ribosomal activity and the induction of RNase H 
endonuclease activity [67]. RNase H enzyme cleaves the mRNA in the RNA-DNA 
heteroduplex and leaves AON intact. AON can also inhibit gene expression by interfering 
with mRNA maturation or destabilizing the pre-mRNA in the nucleus [68]. Therefore, AON 
can be used to treat diseases which are associated with dysregulated gene expression. 
RNA interference (RNAi) is emerging as a novel way for the treatment of PC. The 
sequence-specific small interfering RNAs (siRNAs) are a length of 20–25 base pairs, 
which mediate the degradation of the homologous mRNA and consequently regulate the 
expression of the targeted gene [69, 70]. siRNAs can be artificially synthesized in vitro 
and directly delivered into target cells. siRNAs also can be produced in the genetically 
modified target cells, in which a gene encoding siRNA is introduced via appropriate 
vectors with the help of endogenous RNAase [58]. After releasing into cytoplasm, siRNAs 
bind to ribozyme compunds and form RNA-induced silencing complexes (RISCs). RISCs 
bind to the target mRNA and induce the degradation of mRNA. RNAi takes more 
advantages in comparison with other gene blockade technologies, such as high degree of 
specificity to mRNAs, non-immunogenic property and high resistance to ribonucleases. 
RNAi has turned into one of the most promising method for gene therapy. Yang et al. 
developed a biodegradable charged polyester-based vector for K-ras siRNA delivery to 
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MiaPaCa-2 PC cells and initiated a cascade gene regulation of downstream proteins, 
which significantly reduced the growth, migration and invasion of MiaPaCa-2 cells were 
as well as promoted the apoptosis [71]. Owing to high expression of hypoxia-inducible 
factor 1α (HIF1α) increasing the resistance of gemcitabine for PC, Zhao et al employed 
biocompatible lipid-polymer hybrid nanoparticles to co-deliver siHIF1α and gemcitabine 
for PC treatment [72].  This nanoparticle absorbed negatively charged siHIF1α on the 
surface and encapsulated gemcitabine to the hydrophobic core to prevented siRNA 
degradation in serum as well as gemcitabine leakage, which exhibited significant 
synergistic antitumor effects and inhibited metastasis in orthotopic PC model. To 
investigate the efficiently systemic delivery of siRNA, Pittella et al. reported an efficient 
and biocompatible nanocarrier comprising poly(ethylene glycol)-block-charge-
conversional polymer (PEG-CCP)/calcium phosphate (CaP) hybrid micelles for systemic 
delivery of siRNA to spontaneous PC model in transgenic mice [73]. All these results have 
shown great potential towards a breakthrough in siRNA therapy for PC. 
1.5 Nuclear Receptor Coactivator-3 
Nuclear receptor coactivator (NCOA) belongs to the p160/steroid receptor 
coactivator (SRC) family, which consists of SRC-1, TIF-2 (GRIP1) and AIB1 
(ACTR/RAC3/TRAM-1/SRC-3/NCOA3) [74-77]. NCOA3 plays an important role in 
hormone-sensitive tumors, such as breast cancer, ovarian cancer, prostate cancer, and 
meningioma [78-80]. NOCA3 is the rate limiting step in estrogen-mediated growth 
signaling, such as insulin-like growth factor I and epidermal growth factor, and increases 
the transcriptional activity of many steroid nuclear receptors and growth factors, 
suggesting that transcriptional activation medicated by estrogen receptor might provide a 
growth advantage to cancer cells. For instance, Reiter et al reported that NCOA3 
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overexpressed in breast cancers and strongly improved epidermal growth factor-
medicated transcription in squamous cell carcinoma cells [81].  
NCOA3 is one of the frequently mutated genes in PC [82]. High-level amplification 
of NCOA3 has been found in four of nine pancreatic cancer cell lines and >37% of archival 
PC tissues [83, 84]. Henke et al reported that NCOA3 did not show in normal pancreatic 
tissue, however, high expressed in pancreatic adenocarcinoma and high-grade pancreatic 
intraepithelial neoplasia (PanIN) lesions [84]. Detectable levels of NCOA3 mRNA or 
protein were rarely detected in normal pancreas ducts (<6% of sample positive). There 
was an increase of NCOA3 expression in pancreatitis and low-grade intraepithelial 
neoplasia with >14 and >23% of samples positive, respectively (P<0.01, vs. normal 
tissues). The highest frequency of NCOA3 expression at mRNA or protein levels was with > 
65% of samples positive, which were found in adenocarcinoma as well as high-grade 
PanIN (P<0.0001 vs. the other groups). Moreover, NCOA3 is also elevated in lung, lymph 
and liver metastatic lesions [85]. Therefore, NCOA3 can serve as an important diagnostic 
indicator due to its overexpression in pancreatic adenocarcinoma and its precursor lesions. 
In 2014, Kumar et al. found that NCOA3 worked as a chromatin remodeling 
enzyme and modulated the expression of mucins via transcriptional and post-translational 
changes in the development of PC [85]. Mucins, such as Muc1, Muc4, Muc5ac and Muc16, 
aberrantly express early in PanIN and enhance with the PC progression, promoting the 
processes of metastasis and chemoresistance [86-92]. In PC, constitutive active 
mutations of K-ras initiate the cellular signaling to create pro-inflammatory 
microenvironment, which caused the development of dense stroma and de novo 
expression of mucins. Mucins promote PC tumorigenicity via the interaction of their 
cytoplasmic tails with intracellular signaling, such as enhancement of EGFR signaling 
pathway and activation of focal adhesion kinases to increase cancer motility [90, 93-97]. 
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De novo expression of mucins would require chromatin modifications at transcription level. 
NCOA3 interacts with nuclear receptors and transcription factors and remodels chromatin 
for active transcription  due to its intrinsic histone-acetyltransferase activity [98]. Silencing 
of NCOA3 expression in PC cell lines led to significant reduction in transcripts and proteins 
of both Muc4 and Muc1 [85].  
In addition to regulation of mucin expression, NCOA3 also plays a critical role in 
regulation of PC microenvironment. It upregulates the expression of multiple chemokines 
that are responsible for the recruitment of immune cells to pancreatic tumors, and 
perpetuation of pro-inflammatory conditions. Activated pancreatic stellate cells secret 
collagen and other extracellular matrix proteins in the tumor microenvironment, which 
were crosslinked by lysyl oxidases (LOX). NCOA3 may involve in the development of ECM 
by upregulating the expression of lysyl oxidase-like-2 (LOXL2). LOXL2 is associated with 
the aggressiveness of PC [99]. It participates in fibroblast activation and results in 
hardening of desmoplasia and subsequent collapse of the blood vessels, poor tumor 
perfusion, increased interstitial pressure, extreme hypoxia, and poor delivery of 
therapeutics [99]. Therefore, NCOA3 will be a novel target for PC diagnosis and therapy. 
1.6 C-X-C chemokine receptor type 4 
Chemokines are signaling proteins secreted by various stromal and epithelial cells 
capable of inducing concentration gradient-driven chemotactic migration of cells through 
interaction with their respective chemokine receptors [100]. Based on the number and 
spacing of N-terminal cysteines, chemokine receptors are divided into four groups (CXC, 
CX3C, CC and CX) [101]. There are 19 different chemokine receptors that all belong to 
the seven-transmembrane G-protein-coupled receptor family. In tumors, a complex 
network of chemokines and chemokine receptors controls cell trafficking into and out of 
the tumor microenvironment and thus mediate crucial parts of the metastatic spread of 
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tumor cells [102]. The corresponding chemokines expressed at the site of metastasis 
provide chemo-attractive signaling that guides trafficking of tumor cells to distant organ 
sites. Even though cells from different types of cancer may have different expression 
profiles of chemokine receptors, CXC receptor 4 (CXCR4) is the most widely expressed 
chemokine receptor in human cancers, which makes it among the most-promising targets 
within the chemokine network for cancer therapy. 
1.6.1 CXCR4/CXCL12 signaling 
CXCL12 binding to CXCR4 initiates multiple downstream signaling pathways and 
results in various responses, such as increasing intracellular calcium flux, gene 
transcription, chemotaxis, cell survival, and proliferation [103]. The heterotrimeric G 
protein is activated and dissociated into GTP-bound α and βγ subunits [104]. Gβγ subunits 
activate two major enzymes, phospholipase C-β (PLC-β) and a phosphatidylinositol-3-OH 
kinase (PI3K). Phosphatidylinositol (4, 5)-bisphosphate is cleaved by PLC-β into two 
secondary messengers, inositol (1, 4, 5)-trisphosphate (IP3) and diacylglycerol (DAG). IP3 
causes the release of Ca2+ from intracellular stores and DAG activates protein kinase C 
and mitogen-activated protein kinase (MAPK) in conjunction with Ca2+, thus contributing 
to cell migration [105]. Gα or Gβγ subunits activate PI3K leading to tyrosine 
phosphorylation of components of focal adhesions, including the related adhesion focal 
tyrosine kinase (RAFTK), the adaptor molecule p130 Cas, and the cytoskeletal protein 
paxillin, thus contributing to reorganization of the actin cytoskeleton and changes 
necessary for cell migration [106]. Transcription and gene expression are regulated by 
Gαi signaling through the PI3K-AKT-NF-κB, MEK1/2, and ERK1/2 axes [107]. The 
activated AKT can regulate the survival of cells. Dimerization of CXCR4 leads to G protein 
independent signaling via JAK/STAT pathway, which promotes cell morphology changes 
and chemotactic responses [108].  
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1.6.2 The role of CXCR4 in cancer and cancer metastasis 
CXCR4 overexpression has been reported in more than 20 human tumor types, 
including mammary, ovarian, prostate, esophageal, pancreatic, melanoma, and renal cell 
carcinoma [109]. The upregulation of CXCR4 is associated with changes in multiple 
growth factors, transcription factors, and hypoxia-inducible factors [110-112]. Many 
preclinical and clinical studies observed significant correlation between CXCR4 
expression and metastasis and found that CXCR4 expression is associated with poor 
survival and aggressive type of cancers. CXCR4 overexpression has been identified as a 
poor prognostic biomarker. For instance, a microarray study of 2,000 invasive breast 
carcinomas and 214 pre-invasive breast samples revealed the critical role of CXCR4 in 
cancer progression [113]. Elevated levels of CXCR4 in primary tumors were associated 
with a higher risk of developing bone metastasis [114]. Another clinical studies showed 
that CXCR4 promotes metastasis through the lymphatic system [115]. Elevated levels of 
CXCR4 in cancer cells have also correlated with increasing risk of cancer recurrence [116].  
By activating intracellular signaling pathways, such as PI3K, MAPK and Erk1/2, 
CXCR4 plays a critical role in cancer cell survival, proliferation, invasion and migration 
[117-120]. The influence of CXCR4-induced activation of focal adhesion complexes and 
matrix metalloproteinases mediates degradation of extracellular matrix and contributes to 
invasion of cancer cells. CXCL12 expression levels are elevated in brain, bone marrow, 
lungs, and liver. The CXCL12 concentration gradients then drive movement of CXCR4-
positive tumor cells in circulation and are responsible for the process of extravasation and 
organ-specific metastasis [121].  
Among various chemokine pathways associated with the pathology of PC, the 
CXCR4/SDF1 axis plays critical role in the invasion and metastasis of PC [122-124]. The 
stromal cells produce abundant SDF-1, which activates CXCR4 in PC cells and results in 
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enhanced chemotaxis, transendothelial migration, and invasion [125]. CXCR4 
upregulation can also augment the Sonic Hedgehog pathway, promotes stem-cell-like 
phenotype, enhanced desmoplasia,  chemoresistance, and invasiveness of PC [126]. 
Multiple retrospective clinical studies have directly linked the expression of CXCR4 with 
poor survival and metastasis in PC patients [127, 128]. 
CXCR4/CXCL12 axis is an important emerging target for developing novel delivery 
strategies for improved cancer therapies [129, 130]. In addition to utilizing CXCR4 
overexpression as a simple target for improved ligand-mediated delivery of drugs to 
tumors, blocking CXCR4/CXCL12 interaction using CXCR4 antagonists or silencing 
CXCR4 expression by siRNA has potential to prevent primary tumor growth and reduce 
metastasis, especially when combined with chemotherapy and radiotherapy. This review 
focuses on the role of CXCR4 in cancer metastasis and its potential in drug delivery 
systems for cancer therapy. Multiple targeting ligands and CXCR4 antagonists have been 
developed, including peptides, antibodies and small organic molecules. The main uses of 
CXCR4 in drug delivery for cancer therapy are summarized in Scheme 3 and 
representative examples that explore CXCR4 in drug delivery are summarized in Table 1. 
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Scheme 3. Summary of the main approaches utilizing CXCR4 in cancer drug delivery 
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Table 1. Examples of CXCR4-targeted drug delivery systems 
Targeting 
moiety 
Delivery 
system 
Delivered 
cargo 
Application 
Refere
nces 
T22 peptide Fused 
fluorescent 
protein 
nanoparticle 
Green 
fluorescent 
protein 
Increase nanoparticle 
delivery to colorectal 
cancer (in vivo) 
[131] 
LFC131 
peptide  
Chitosan and 
PLGA 
nanoparticles 
Docetaxel 
and 
doxorubicin 
Increase anticancer drug 
delivery in lung cancer (in 
vitro) 
[132, 
133] 
DV3 peptide  Cationic 
peptide 
transduction 
domain 
(PTD) 
Anticancer 
peptides 
Increase targeting and 
killing of CXCR4-positive 
lymphoma cells 
[134] 
Azide-
containing 
T22 
analogue 
peptide 
Mesoporous 
silica 
nanoparticles 
Doxorubicin Increase anticancer drug 
delivery in lymphoma 
cells (in vitro) 
[135] 
N-terminal 
sequence of 
CXCL12  
Polyplexes Reporter 
plasmid 
DNA  
Increase gene delivery to 
CXCR-positive human 
glioblastoma and cervical 
carcinoma cells 
[136, 
137] 
Peptide 
analog 4F-
benzoyl-
TE14011 
Lipoplexes Reporter 
plasmid 
DNA  
Increase gene delivery to 
rat glioma cells 
[138] 
Ac-TZ14011 
peptide 
Radiopharm
aceutical 
111In Image CXCR4 
expression in metastatic 
pancreatic tumors in vivo  
[139] 
Ac-TZ14011 
peptide 
Dendrimers 111In and 
Cy5.5 dye 
Image CXCR4 
expression in breast 
cancer in vivo 
[140, 
141] 
X4-2-6 
peptide 
Self-
assembled 
peptide 
nanoparticles 
Anticancer 
drug HKH-
40A 
Inhibit breast tumor 
metastasis in vivo 
[142] 
Anti-CXCR4 
antibody 
Liposomes Doxorubicin Increase delivery and 
efficacy of anticancer 
drug in breast cancer (in 
vitro) 
[143] 
Anti-CXCR4 
antibody 
Liposomes Anti-
lipocalin-2  
siRNA 
Inhibit both the CXCR4 
and Lcn2 mediated 
migratory pathways in 
metastatic breast cancer 
(in vitro) 
[144] 
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Anti-CXCR4 
antibody 
Radiopharm
aceutical 
111In Image brain tumor by 
SPECT/CT (in vivo) 
[145] 
AMD3100 Lipoplexes 
and 
polyplexes  
Reporter 
plasmid 
DNA  
Increase gene 
transfection in CXCR4-
positive human 
lymphoma Jurkat cells 
[146] 
AMD3100 PLGA 
nanoparticles 
siRNA (anti-
GFP) 
Increase uptake, 
suppress CXCR4 
signaling and deliver 
siRNA in triple negative 
breast cancer and 
metastatic breast cancer 
(in vitro) 
[147] 
AMD3100 PLGA 
nanoparticles 
Sorafenib Target malignant 
hepatocellular carcinoma 
and improve anticancer 
effect with sorafenib (in 
vivo) 
[148] 
AMD3100 Polyplexes siRNA 
(siPLK1) 
Simultaneously deliver 
gene and block CXCR4 to 
inhibit metastasis (in vivo, 
in vitro) 
[149-
152] 
AMD3100 
derivatives 
Polyplexes Reporter 
plasmid 
DNA  
Simultaneously deliver 
gene and block CXCR4 to 
inhibit cell invasion (in 
vitro) 
[153] 
Viologen 
dendrimers 
Dendrimer 
polyplexes 
TNFα 
plasmid 
DNA  
Simultaneously prevent 
CXCR4-mediated cancer 
cell invasion and facilitate 
TNFα-mediated cancer 
cell killing (in vitro) 
[154] 
AMD3100 Radiopharm
aceutical 
64Cu Image lung metastasis 
derived from human 
breast cancer by PET (in 
vivo) 
[155] 
AMD3465 Radiopharm
aceutical 
64Cu Image brain tumor and 
colon tumor by PET/CT 
(in vivo) 
[156] 
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1.6.3 CXCR4 as target for ligand-mediated delivery and imaging 
Multiple reports explored the use of CXCR4-binding ligands as a way of improving 
drug delivery to CXCR4-overexpressing tumors. The most popular ligands are based on 
short CXCR4-binding peptides, but small organic molecules and antibodies have also 
been explored and are discussed in this section. 
1.6.3.1 CXCR4-binding peptides 
Peptide ligands that bind CXCR4 has been widely used to direct drug delivery 
systems to CXCR4 overexpressing tumor cells with the goal of improving intracellular 
delivery of antitumor agents by receptor-medicated cellular uptake. Among the most 
successful has been a peptide T22 derived from horseshoe crab polyphemusin II. The 
T22 peptide binds CXCR4 and efficiently penetrates target cells via a rapid receptor-
specific endosomal route. When conjugated to nanoparticles, T22 mediates delivery and 
accumulation of the nanoparticles in the perinuclear region of the target cells both in cell 
culture and in metastatic cancer models in vivo. The T22 peptide has been used for 
intracellular delivery of proteins, nanoparticles, and imaging agents [131]. Torre et al. have 
described a CXCR4-targeted delivery system using mesoporous silica nanoparticles that 
were loaded with doxorubicin and capped with an azide-containing modified T22 peptide 
by a click reaction [135]. Residues Tyr5, Lys7, and Tyr12 dramatically enhanced the affinity 
of the T22 peptide for the CXCR4 receptor overexpressed in B-cell non-Hodgkin’s 
lymphoma cells. The peptide capped the pores in the porous nanoparticles to block the 
release of doxorubicin and facilitated uptake via the CXCR4 receptor. In lysosomes, 
proteolytic enzymes degraded the T22 peptide and allowed intracellular doxorubicin 
release.  
Wang et al. have investigated a low-molecular-weight CXCR4 peptide antagonist 
LFC131 (Tyr-Arg-Arg-Nal-Gly). The authors conjugated the LFC131 peptide to O-
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carboxymethyl chitosan nanoparticles and poly(lactide-co-glycolide) (PLGA) 
nanoparticles for enhanced targeted delivery of docetaxel and doxorubicin to CXCR4 
overexpressing lung cancer cells [132, 133].  
To enhance the targeting and killing of tumor cells, Snyder et al. linked another 
CXCR4 ligand, DV3, to two transducible anticancer peptides: a p53-activating peptide 
(DV3-TATp53C’) and a cyclin-dependent kinase 2 antagonist peptide (DV3-TAT-RxL). 
Treatment with either of the targeted peptides resulted in an enhancement of tumor cell 
killing compared with treatment with non-targeted parent peptides [134].  
CXCR4-binding peptides have also been successfully used to improve nucleic acid 
delivery with cationic peptides and cationic polymers. Egorova et al. have developed 
chemokine-derived peptides as carriers for gene delivery [136]. The authors used three 
synthetic peptides for CXCR4 receptor targeting: two derived from N-terminal sequence 
of CXCL12 and one from viral macrophage inflammatory protein (vMIP)-II. One of the 
peptides (KPVSLSYRSPSRFFESH-K9-biotin) derived from CXCL12, consisting of an N-
terminal sequence of CXCL12 (KPVSLSYR) and an RFFESH motif (residues 12–17), was 
able to specifically target cells overexpressing CXCR4 and to exhibit high transfection 
efficacy. In a follow-up study, the authors found that the use of the oligolysine (K9) as the 
DNA-binding moiety compromised the gene delivery due to instability in physiological 
conditions and lack of endosomolytic properties. To circumvent these problems, the 
authors developed a gene delivery system using CXCL12-derived cross-linking peptides 
and demonstrated that a modular peptide KPVSLSYRSPSRFFESH-Ahx-Ahx-
CHRRRRRRHC could be used as efficient gene delivery carrier. The flanking cysteines 
formed intermolecular disulfide bonds to stabilize the particles and tightly condense DNA. 
Subsequent internalization and intracellular disulfide breakage resulted in enhanced gene 
expression when compared with the K9-based peptides, in part also because of the 
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buffering capacity and membrane activity of the peptide containing histidine and arginine 
residues [137].  
Feasibility of CXCR4 targeting using lipoplexes containing peptide analog 4F-
benzoyl-TE14011 was also demonstrated [138]. The peptide ligand (4-fluorobenzoyl-RR-
Nal-CY-Cit-KEPYR-Cit-CR) binds CXCR4 with high affinity (Kd 1.5 nM) and when 
covalently linked to a phospholipid used in lipoplex formulation resulted in CXCR4-
targeted gene delivery.  
1.6.3.2 CXCR4-binding small molecule organic ligands 
Synthetic small molecule organic molecules that bind CXCR4 have been among 
the most successful CXCR4 antagonists. In fact, the only currently FDA-approved CXCR4 
antagonist is a cyclam derivative AMD3100 (Plerixafor). AMD3100 has been shown to 
bind and block CXCR4 signaling in multiple animal models as well as in clinical trials [157, 
158]. Several reports exist on the use of drug and gene delivery systems conjugated with 
small molecule ligands like AMD3100. Probably the first report described a nonviral carrier 
in which AMD3100 was covalently attached to polyethylenimine (PEI) and cationic lipids 
[146]. The study showed that the CXCR4-targeted polyplexes could effectively deliver 
genes into CXCR4-positive Jurkat cells. The role of CXCR4 in the uptake of the polyplexes 
was clearly demonstrated when nonspecific internalization pathways were minimized or 
when phorbolmyristate acetate (PMA) was used to enhance CXCR4 receptor endocytosis. 
AMD3100 has also been successfully used to target multicompartment PLGA 
nanoparticles to CXCR4-overexpressing breast cancer cells [147]. In this case, AMD3100 
was conjugated to the surface of the nanoparticles by using PLGA with terminal acrylate 
groups that were reacted with AMD3100 amines via Michael addition. The targeted 
nanoparticles were then selectively taken up by CXCR4-overexpressing breast cancer 
cells and they also effectively blocked CXCR4 signaling. When loaded with siRNA, the 
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AMD3100-PLGA nanoparticles allowed for more effective gene silencing in vitro than their 
corresponding nontargeted nanoparticles. 
1.6.3.3 Anti-CXCR4 antibodies 
Multiple anti-CXCR4 antibodies have been developed and applied as experimental 
treatments in animal models of cancer metastasis [159, 160]. Such antibodies can be also 
used as ligands to facilitate improved delivery of drug carriers, similar to the peptide and 
small molecule ligands discussed above [143, 144]. For example, liposomes targeted with 
anti-CXCR4 antibody were used to improve doxorubicin activity in CXCR4-overexpressing 
breast cancer cells [143]. The liposomes were prepared by the extrusion using 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-dodecanoyl (N-dod-PE) and 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), followed by conjugation of mouse anti-human 
CXCR4 monoclonal antibody via N-dod-PE anchor by EDC/NHS chemistry. 
Overexpression of CXCR4 was observed in HCC1500 and MDA-MB-175VII breast cancer 
cells relative to normal control cells MCF10As. Expression levels of CXCR4 in the breast 
cancer cells directly correlated with increased liposome binding and enhanced drug 
activity. Based on this study, the knowledge of the levels of CXCR4 expression may be 
used to predict the efficacy of CXCR4-targeted drug delivery systems.  
1.6.3.4 Imaging agents that target CXCR4 
Due to the established role of CXCR4 in cancer metastasis, there is a growing 
interest and potential in using CXCR4-binding ligands for imaging of primary and 
metastatic tumors. CXCR4-binding imaging agents have been developed based on 
peptide and small molecule organic ligands. For example, using systematic structure-
activity relationship study, Hanaoka et al. have developed a radiopharmaceutical for the 
imaging of CXCR4-expressing tumors in vivo based on the T22 peptide [139]. The authors 
designed a peptidic CXCR4 ligand named Ac-TZ14011 (Ac-RR-Nal-CY-Cit-RKPYR-Cit-
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CR). The ligand contains four residues (Arg2, Nal3, Tyr5, and Arg14) that formed the intrinsic 
pharmacophore and were necessary for the CXCR4 inhibition. 111In was then used as 
radionuclide for radiolabeling of the peptide containing diethylenetriaminepentaacetic acid 
(DTPA) attached to the side chain of D-Lys8. The resulting 111In-DTPA-Ac-TZ14011 
inhibited the binding of CXCL12 to CXCR4 in a concentration-dependent manner with an 
IC50 of 7.9 nM. Biodistribution studies in athymic nude mice bearing subcutaneous 
CXCR4-overexpressing pancreatic carcinoma cells showed preferential accumulation of 
111In-DTPA-Ac-TZ14011 in the tumor. Similarly, Kuil et al. have developed peptide-
conjugated dendrimers using Ac-TZ14011 peptide to obtain constructs capable of 
multimodal imaging. The constructs consisted of a Cy5.5-like fluorophore and a DTPA 
chelating group for 111In labeling and were used to image CXCR4 expression in breast 
cancer animal model using both SPECT/CT and fluorescence imaging [140, 141].  
The cyclam-based CXCR4 antagonists like AMD3100 constitute a diverse class of 
compounds with common ability to chelate transition metals in the cyclam macrocycle. 
These compounds have been used in multiple studies to chelate PET-positive 
radioisotope 64Cu for imaging of CXCR4-expressing tumors. For example, Nimmagadda 
et al. have reported the development and evaluation of [64Cu]-AMD3100 to image lung 
metastasis derived from human MDA-MB-231 breast cancer by PET [155]. Another 
cyclam-containing CXCR4 ligand, AMD3465, was also used for imaging CXCR4 
expression. De Silva et al. reported that [64Cu]-AMD3465 was capable of detecting tumor 
lesions using dynamic and whole-body PET/CT in a CXCR4 dependent fashion with high 
target selectivity in both U87 brain tumor and HT-29 colon tumor animal models [156].  
Anti-CXCR4 antibodies are commonly used for fluorescence microscopy imaging 
but they also showed potential in SPECT/CT imaging in vivo. Using 125I-labeled anti-
CXCR4 monoclonal antibody (12G5), the results of a recent study showed successful 
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SPECT/CT imaging of CXCR4-positive U87 brain tumors [145]. Compared with isotype 
control, the tumor-to-tissue uptake ratio for 125I-12G5 was 2.5-fold higher at 48 h after 
injection, indicating the feasibility of antibody-targeted tumor imaging. 
1.6.4 Inhibition of CXCR4 in anticancer therapies 
Due to its significant role in multiple steps involved in cancer progression, inhibition 
of CXCR4 has been explored in various drug delivery systems with the goal of reducing 
cancer cell proliferation and metastasis. Several strategies have been employed to either 
directly silence expression of CXCR4 gene in malignant cells using siRNA or to codeliver 
small-molecule CXCR4 antagonists with other antitumor therapeutics to achieve 
enhanced anticancer effect. 
1.6.4.1 Silencing of CXCR4 gene 
Specific targeting and silencing of CXCR4 expression with siRNAs has been 
proposed to slow down cancer cell growth and metastasis both in vitro and in vivo. CXCR4 
expression was significantly downregulated in liver metastasis of colorectal cancer when 
anti-CXCR4 siRNA was delivered by nanoparticles based on spermine-modified dextran 
[161, 162]. In the study, spermine was conjugated to oxidized dextran by reductive 
amination process to obtain cationic dextran and the results showed that CXCR4 silencing 
decreased the extent of cancer cell and lymphocyte infiltrationin in the liver of treated 
animals. In a study of the effect of CXCR4 silencing on metastasis of breast cancer, a 
fusion protein based on HER2-scFv and arginine nonamer peptide (e23sFv-9R) was 
developed and tested as siRNA carrier [163]. Delivery of anti-CXCR4 siRNA by the 
e23sFv-9R carrier resulted in decreased CXCR4 expression and subsequent reduction in 
proliferation and metastasis in HER2-positive breast cancer BT-474 cell line in vitro. 
Importantly, systemic delivery of the anti-CXCR4 siRNA by the fusion protein was able to 
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suppress tumor growth, reduce metastasis, and prolong survival in mice bearing HER2-
positive xenografts.  
Tumor progression is associated with intratumoral hypoxia and an abnormal 
vascular architecture, which provides heterogeneous perfusion within the tumor tissue 
[164]. Hypoxia regulates the expression of multiple genes involved in angiogenesis, 
epithelial-mesenchymal transition, extracellular matrix degradation, and chemotaxis [165]. 
CXCR4 is a potential target in the events associated with hypoxia because of its hypoxia-
triggered upregulation. Romain et al. have demonstrated that hypoxia upregulated CXCR4 
expression in colon cancer cells and that CXCR4 expression remained elevated for up to 
48 h even when the cancer cells were returned to normoxic conditions [166]. As a result 
of the CXCR4 upregulation, the migration of the colon cancer SW480 cells increased up 
to 6-fold in hypoxia when compared with normoxic conditions. Importantly, the increased 
invasiveness of the cancer cells could be reduced significantly by CXCR4 gene silencing.  
1.6.4.2 Inhibition of CXCR4 in cancer metastasis 
In addition to offering a simple targeting to CXCR4-overexpressing cancer cells, 
many of the existing CXCR4-binding ligands also function as receptor antagonists and 
thus inhibit CXCR4/CXCL12 signaling. The inhibition of the CXCR4 signaling can utilized 
to achieve additional antitumor and antimetastatic benefits, especially when combined 
with other simultaneously delivered drugs. There has been a growing number of 
successful examples of drug and gene delivery vectors that combine delivery function with 
a pharmacological CXCR4-inhibiting activity and they will be discussed in this section. 
Multiple innovative drug delivery systems that combine CXCR4 inhibition and drug 
delivery have been reported in recent years. Taking advantage of the structural plasticity 
of transmembrane peptides, biologically active nanoparticles that effectively inhibit tumor 
metastasis in vivo have been developed based on a 24-amino acid peptide X4-2-6 which 
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corresponds to the second transmembrane helix of the CXCR4. The peptide self-
assembled into nanoparticles that inhibited CXCR4 function in vitro and prevented 
CXCR4-dependent tumor metastasis in MDA-MB-231 breast cancer xenograft model 
[142]. These nanoparticles could additionally encapsulate hydrophobic antitumor drugs, 
thus providing an effective combination delivery system. The peptides were capable of 
assembling into a variety of structures including spherical, fibrous, tubular and discoid 
shapes [167]. The ability to control the morphology of the assemblies may allow improved 
delivery of such peptide particles as it was found that stronger intermolecular interactions 
observed in nanospheres than in fibrils resulted in slower rates of particle disassembly 
and in improved protection against proteolytic degradation. 
As part of our long-term efforts to develop dually functioning polycations for 
combination drug/gene delivery, we have designed polycations (PAMD) based on the 
cyclam CXCR4 antagonist AMD3100. The PAMD polymers showed dual functionality as 
efficient nucleic acid (gene and siRNA) delivery vectors and CXCR4 antagonists that 
inhibited invasion of cancer cells in vitro and decreased metastasis in several tumor 
models in vivo [149, 150]. Modification of PAMD with PEG was used to improve the in vivo 
applicability [151]. Modification with cholesterol was used as a way of enhancing siRNA 
delivery efficacy of PAMD, while preserving the CXCR4-inhibiting activity of the polymers 
[152]. Although based on an approved drug and easy to synthesize, PAMD synthesis 
resulted in the formation of highly branched polymers and in a relatively low CXCR4 
antagonistic activity when compared with the original AMD3100. Based on the knowledge 
of the AMD3100 pharmacophore, we developed a second generation of CXCR4-inhibiting 
polycations based on a series of linear poly(amido amine)s using Michael-type 
polyaddition of novel monocyclam monomers. The use of monocyclam monomers allowed 
preparation of polymers with well-defined architecture and the CXCR4-binding moieties 
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present in the sidechain of the polymers, which resulted in improved presentation and 
accessibility for CXCR4 binding, resulting in greatly increased CXCR4 antagonism [153]. 
In addition to naturally derived peptides and lipids and polymers based on existing 
small molecule CXCR4 inhibitors, dendrimers based on viologen (dialkylated 4, 4’-
bipyridinium salts) have been found to exhibit potent antagonistic activity against CXCR4 
[168]. Viologen dendrimers (VGD) were also recently used as a promising class of gene 
delivery vectors when they demonstrated promising synergistic anticancer activity when 
used to deliver TNFα plasmid DNA [154]. 
Similar to the other types of CXCR4 inhibitors, anti-CXCR4 antibodies have been 
used both for their drug targeting ability to CXCR4-overexpressing cancers as well as for 
their ability to block the CXCR4/CXCL12 signaling in antimetastatic approaches. For 
example, pH-responsive CXCR4-targeted liposomes were prepared to achieve combined 
inhibition of CXCR4 and siRNA silencing of lipocalin-2 (Lcn2) [144]. The liposomes were 
composed of a mixture of DOPC, 1, 2-dioleoyl-3-dimethylammoniumpropane (DODAP) 
and N-dod-PE and were modified with anti-CXCR4 antibody to target metastatic breast 
cancer cells and block cell migration. Liposomes incorporating DODAP responded to the 
acidic endosomal environment by increasing the cationic character, fusing with the 
endosomal membrane, and delivering siRNA into the cytoplasm. The combined liposomes 
significantly reduced migration in triple negative human breast cancer cells (88% for MDA-
MB-436 and 92% for MDA-MB-231) when compared with inhibition of the CXCR4 or Lcn2 
pathways alone. 
1.6.4.3 Inhibition of CXCR4 as a chemosensitizing approach 
Drug resistance remains a serious problem in cancer chemotherapy. Anticancer 
potency can be greatly improved by combining chemotherapy with a chemosensitizing 
effect of CXCR4 inhibition. For example, a multikinase inhibitor sorafenib is an anti-
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angiogenic agent used in the treatment of advanced hepatocellular carcinoma (HCC) and 
its use results in a significant increase in overall patient survival. However, prolonged 
sorafenib treatment increases tumor hypoxia due to decreased neovasculature, which in 
turn upregulates the expression of CXCR4. This causes HCC to acquire more invasive 
phenotype and to rapidly develop resistance to antiangiogenic therapy with sorafenib [169-
171]. AMD3100 can sensitize HCC to sorafenib treatment by inhibiting CXCR4 axis-
induced cancer cell proliferation and polarization of the tumor-promoting 
microenvironment [171]. To take advantage of the chemosensitizing ability of AMD3100, 
Gao et al. encapsulated sorafenib in lipid-coated PLGA nanoparticles. The surface of the 
nanoparticles was modified with AMD3100 to allow systemic delivery of the 
sorafenib/AMD3100 combination into HCC [148]. The results of the study demonstrated 
that the nanoparticles could efficiently deliver sorafenib and AMD3100 in HCC and that 
the combined treatment showed improved anti-angiogenic effect and decreased infiltration 
of tumor-associated macrophages in vivo. The combined nanoparticle treatment 
significantly inhibited primary HCC growth and distal metastasis and thus increased 
overall survival in vivo, indicating clinical potential of CXCR4 inhibition in overcoming 
acquired drug resistance in HCC. 
1.6.5 CXCR4 and PC 
CXCR4/SDF-1 axis plays an important role in PC pathology, involving in 
metastasis, invasion, angiogenesis, and proliferation [123, 124]. Clinical data indicates 
that CXCR4 has been directly linked to poor survival of PC patients [127, 128, 172]. 
CXCR4 expression is overexpressed in majority of PC tissues and precancerous lesions, 
suggesting its role in PC pathogenesis [173]. The stromal cells produce abundant CXCL12, 
which activates CXCR4-expressing PC cells and results in enhanced chemotaxis, 
transendothelial migration and invasion [125]. PC cells are easily mediated by CXCR4 
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activation and migrate towards the gradient of SDF-1 in distant organs, such as lymph 
nodes, lung and liver [174]. Furthermore, activation of CXCR4/SDF-1 signaling confers 
drug resistance to pancreatic cancer cells by potentiating survival. Singh et al. reported 
that gemcitabine induced chemoresistance was partly mediated by the activation of Akt 
and Erk signaling pathways [175]. However, a small-molecule antagonist AMD3100 
against CXCR4 could effectively abrogate the survival signals and resensitise the PC cells 
to gemcitabine cytotoxicity. Moreover, CXCR4/SDF-1 signaling confers chemoresistance 
not only by directly impacting the tumor cells but also indirectly through SHH-induced 
pancreatic fibrosis, suggesting the potential of the CXCL12-CXCR4 pathway as a 
therapeutic target in PC [176]. 
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Chapter 2. Statement of the Problem and Hypothesis 
Metastasis is the one of the major reasons for cancer mortality and morbidity. Each 
year, several million patients died from cancer metastasis. Existing therapeutic 
approaches rarely reverse or stop metastatic progression. Late diagnosis, early 
metastasis, and complex microenvironment caused extremely low survival rate of PC. The 
one-year and five-year survival rates are ~29% and ~7% respectively. Complicated PC 
microenvironment contributes to inherent resistance to available therapies and severely 
limits drug delivery [30-32]. Gemcitabine is the first-line treatment for metastatic pancreatic 
cancer. However, the objective response is less than 10%. Thus, there is an urgent need 
to develop novel therapies for the treatment of PC [33, 177].  
PC is unique among solid tumors because of the extremely dense desmoplstic 
reaction which wraps the cancer cells. It forms a barrier to chemotherapy penetration due 
to the growth of dense, collagen rich, extracellular matrix and stroma with high interstitial 
pressure around PC tumors. Desmoplastic reaction creates a unique microenvironment 
that paradoxically promotes both tumor growth and metastatic spread. Furthermore, 
mucins, such as Muc1, Muc4, Muc5ac and Muc16, aberrantly express early in PanIN and 
enhance with the PC progression, promoting the processes of metastasis and 
chemoresistance [86-92].  
NCOA3 is one of the frequently mutated genes in PC [82]. High-level amplification 
of NCOA3 has been found not only in PC cell lines, but also in PC tissues and metastatic 
lesions [83, 84]. It works as a chromatin remodeling enzyme and modulates the 
expression of mucins via transcriptional and post-translational changes in the 
development of PC [85]. In addition to regulation of mucin expression, NCOA3 may involve 
in the development of ECM by upregulating the LOXL2. LOXL2 participates in fibroblast 
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activation and results in hardening of desmoplasia, which is associated with the 
aggressiveness of PC [99].  
CXCR4/SDF-1 axis plays a critical role in PC metastasis, invasion, angiogenesis, 
and proliferation [123, 124]. Abundant SDF-1 is produced by PC stromal cells and 
activates CXCR4 expression in PC cells, which also augments Shh pathway to elevate 
desmoplasia, enhance chemoresistance as well as promote invasion in PC [125, 126]. 
Gemcitabine induced chemoresistance was medicated by activation of CXCR4/SDF-1 
signaling pathway [175]. However, a small-molecule CXCR4 inhibitor AMD3100 could 
effectively abrogate the survival signals and resensitize the PC cells to gemcitabine 
cytotoxicity. Multiple retrospective clinical studies have directly linked the expression of 
CXCR4 with poor survival and metastasis in PC patients [127, 128]. 
Targeting components of the tumor stroma that contribute to the desmoplastic 
reaction is a promising new platform of investigation. Most strategies aim to enhance 
chemotherapeutic and even radiotherapeutic efficacy, by increasing tumor accumulation, 
penetration, and drug-distribution and targeting signaling pathways, which are directly 
implicated in the formation of desmoplastic reaction. Changes in the tumor 
microenvironment that decrease desmoplasia can improve access of drugs to the tumor 
but they may also inadvertently promote metastasis. PC metastasizes readily and early in 
its progression.  
Based on the critical role of NCOA3 and CXCR4 as well as the therapeutic 
challenges of PC, we designed novel treatment that relies on delivery of NCOA3-silencing 
siRNA using polyplexes formed by polymeric CXCR4 inhibitors (PCX). We hypothesized 
that the ability of the developed polyplexes to simultaneously downregulate mucin 
expression via NCOA3 silencing and inhibition of CXCR4 will lead to improved antitumor 
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and antimetastatic activity. The use of PCX to deliver siNCOA3 is in part selected to 
minimize the chances of increased metastasis. 
The working hypothesis for this dissertation is that PCX will not only exhibit CXCR4 
antagonism but will also effectively deliver siRNA to inhibit NCOA3. The hypothesis is 
supported by successful synthesis of PCX and the demonstration of PCX’s ability to 
deliver multiple types of nucleic acids (DNA, siRNA). Development of functional 
poly(amido amine) CXCR4 antagonists with increased CXCR4 inhibitory activity is 
explored in the results and discussion part of 4.1. Part 4.2 focuses on modification of PCX 
with PEGylation to enhance colloidal stability and safety for gene therapy in cancer. In 4.3 
we investigate cholesterol modification of PCX to improve siRNA delivery for combined 
anticancer therapies. The combination of NCOA3 silencing and CXCR4 inhibition by PCX 
nanoparticles to improve antitumor and antimetastasis in PC is described in 4.4. The 
central hypothesis is that the combination of NCOA3 gene silencing and CXCR4 
antagonism by PCX will decrease mucin expression, regulate tumor microenvironment, 
reduce metastasis, and chemosensitize PC to improve the treatment. We will pursue the 
following specific aims. 
Aim 1. Develop and modify PCX polymers to inhibit CXCR4 and deliver nucleic 
acids to cancer cells.  
Aim 2. Screen PCX capable of efficient delivery of siRNA to inhibit NCOA3 in PC.  
Aim 3. Determine if combination of NCOA3 silencing and CXCR4 inhibition by 
PCX nanoparticles improves antitumor and antimetastatic activity in orthotopic PC model. 
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Chapter 3 - Materials and Methods 
3.1 Materials 
N,N’-hexamethylenebisacrylamide (HMBA) was purchased from Polysciences, Inc. 
(Warrington, PA). Cyclam (1,4,8,11-tetraazacyclotetradecane) was from Alfa Aesar (Ward 
Hill, MA). Cholesteryl chloroformate and branched polyethylenimine (PEI, 25 kDa) was 
obtained from Sigma-Aldrich (St. Louis, MO). mPEG-Acrylamide (2 kDa) was from 
Creative PEGworks (Winston-Salem, NC). N,N-diisopropylethylamine (DIPEA) was from 
Acros Organics (New Jersey, US). Trifluoroacetic acid (TFA) and 4-amino-1-butanol 
(ABOL) were purchased from ACROS Organics (Fair Lawn, NJ). AMD3100 (base form) 
was from Biochempartner (Shanghai, China). Plasmid DNA, gWiz high-expression 
luciferase (gWiz-Luc), containing luciferase reporter gene was from Aldevron (Fargo, ND). 
Dulbecco’s modified Eagle medium (DMEM), Dulbecco’s phosphate buffered saline (PBS), 
and fetal bovine serum (FBS) were from Thermo Scientific (Waltham, MA). Cell culture 
inserts (for 24-well plates, 8.0 μm pores, Translucent PET Membrane, cat# 353097) and 
BD MatrigelTM Basement Membrane Matrix (cat# 354234) were purchased from BD 
Biosciences (Billerica, MA). Human SDF-1α was from Shenandoah Biotechnology, Inc. 
(Warwick, PA). Non-targeting siRNA control (siScr, 5’-UUCUCCGAACGUGUCACGUUU-
3’), siGENOME human polo-like kinase 1 (PLK1) siRNA Smartpool (siPLK1) and stability 
enhanced NCOA3 siRNA (siNCOA3, 5’-GACAGGCACUUGAAUUGAAUU-3’) were 
purchased from GE Healthcare Dharmacon, Inc. (Lafayette, CO). Succinimidyl ester of 
Alexa Fluor® 647 carboxylic acid was from Life Technologies (Eugene, OR). Rotor-Gene 
SYBR Green RT-PCR Kit was from QIAGEN (Hilden, Germany). TRIzol® reagent, human 
CXCR4 primers (F 5’-GCATGACGGACAAGTACAGGCT-3’, R 5’-
AAAGTACCAGTTTGCCACGGC-3’), and primers of gWiz Luciferase (F 5’-
GAAGAGCTGTTTCTGAGG, R 5’-CGAAGAAGGAGAATAGGGT) were purchased from 
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Life Technologies (Carlsbad, CA). Allophycocyanin (APC) mouse anti-human CXCR4 
antibody and APC mouse lgG2a, ĸ isotype controls were from BD Biosciences (San Jose, 
CA). Anti-CXCR4 antibody [UMB2] was purchased from Abcam (ab124824, Cambridge, 
MA). Anti-NCOA3 antibody was purchased from Santa Cruz Biotechnologies (sc25742, 
Dallas, TX). The MUC4 monoclonal antibody (8G7) used in this study was developed by 
Dr. Batra group [178]. All other reagents were from Fisher Scientific and used as received 
unless otherwise noted.  
3.2 Synthesis of monocyclam-based monomers  
Tri-tert-butyl-1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (2): A solution 
of Boc2O (3.27 g, 15.0 mmol) in CH2Cl2 (75 mL) was added dropwise over a period of 2 h 
to a solution of 1 (1.00 g, 5.0 mmol) in CH2Cl2 (200 mL) at 0°C. The mixture was allowed 
to warm to room temperature and stirred overnight. The mixture was concentrated and 
purified by chromatography (AcOEt→10:1 AcOEt:CH3OH) to first give tetra-Boc cyclam 
as a white foam and then tri-Boc cyclam (compound 2, 2.10 g, 84%) as a white set foam: 
1H NMR (400 MHz, CDCl3, δ) 1.46 (s, 27H), 1.65–1.76 (m, 2H), 1.80–2.00 (m, 2H), 2.62 
(bt, J = 5.6 Hz, 2H), 2.79 (t, J = 4.8 Hz, 2H), 3.31 (t, J = 6.4 Hz, 8H), 3.34–3.47 (m, 4H).  
Tri-tert-butyl-11-(4-(chloromethyl)benzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8-
tricarboxylate (3): to a solution α,α’-dichloro-p-xylene (7.44 g, 41.6 mmol) in CH3CN (100 
mL), anhydrous K2CO3 (1.44 g, 10.4 mmol) was added followed by 2 (4.17 g, 8.33 mmol) 
dissolved in CH3CN (50 mL). The mixture was refluxed for 6 h before filtering and washing 
the solid with acetone. The filtrate was concentrated to give a white solid that was heated 
with 2:1 hexanes:AcOEt and concentrated to a small volume to allow the excess 
dichloroxylene to crystallize out. The filtrate was then further purified by chromatography 
(2:1→1:1 hexanes:AcOEt) to first give more excess dichloroxylene and then the desired 
mono-cyclam product (compound 3, 4.31 g, 81%) as a white set foam: 1H NMR (400 MHz, 
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CDCl3, δ) 1.44 (s, 18H), 1.47 (s, 9H), 1.68 (bs, 2H), 1.90 (bs, 2H), 2.30–2.47 (m, 2H), 
2.50–2.70 (m, 2H), 3.15–3.48 (m, 12H), 3.52 (s, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 
7.2 Hz, 2H).  
Tri-tert-butyl-11-(4-((2-hydroxyethylamino)methyl)benzyl)-1,4,8,11-tetraaza 
cyclotetradecane-1,4,8-tricarboxylate (4a): To a mixture of 3 (2.17 g, 3.39 mmol) and 
anhydrous K2CO3 (0.70 g, 5.1 mmol) in CH3CN (15 mL), ethanolamine (2.1 mL, 2.1 g, 34 
mmol) was added and the mixture stirred overnight. The formed solid was filtered and 
washed with AcOEt (50 mL). The filtrate was washed with water (2  10 mL), saturated 
NaCl (10 mL), then dried (MgSO4) and concentrated to give a viscous liquid, which was 
purified by chromatography (10:1 CH2Cl2:CH3OH, adding 0.5% NH3 later) to give the 
amino alcohol as a white foam (compound 4a, 2.08 g, 92%): 1H NMR (400 MHz, CDCl3, 
δ) 1.44 (s, 18H), 1.47 (s, 9H), 1.67 (bs, 2H), 1.90 (bs, 2H), 2.20–2.46 (m, 4H), 2.52–2.70 
(m, 2H), 2.80 (t, J = 6.0 Hz, 2H), 3.18–3.44 (m, 12H), 3.50 (s, 2H), 3.67 (t, J = 5.2 Hz, 2H), 
3.80 (s, 2H), 7.19–7.26 (m, 4H).  
Tri-tert-butyl-11-(4-((3-hydroxypropylamino)methyl)benzyl)-1,4,8,11-tetraazacyclo 
tetradecane-1,4,8-tricarboxylate (4b): To a solution of 3 (2.14 g, 3.35 mmol) and 
anhydrous K2CO3 (0.69 g, 5.0 mmol) in CH3CN (15 mL), 3-amino-1-propanol (2.6 mL, 2.55 
g, 33.5 mmol) was added and the mixture stirred overnight. The formed solid was filtered 
and washed with AcOEt (50 mL). The filtrate was washed with water (2  10 mL), saturated 
NaCl (10 mL), dried (MgSO4) and concentrated to give a viscous liquid, which was then 
purified by chromatography (10:1 CH2Cl2:CH3OH, adding 0.5% NH3 later) to give the 
amino alcohol as a white foam (compound 4b, 2.16 g, 95%): 1H NMR (400 MHz, CDCl3, 
δ) 1.44 (s, 18H), 1.47 (s, 9H), 1.67 (bs, 2H), 1.74 (quintet, J = 5.6 Hz, 2H), 1.90 (bs, 2H), 
2.36 (bs, 2H), 2.52–2.68 (m, 2H), 2.91 (t, J = 5.6 Hz, 2H), 3.18–3.44 (m, 12H), 3.51 (s, 
2H), 3.79 (s, 2H), 3.81 (t, J = 5.2 Hz, 2H), 7.22 (s, 4H).  
44 
 
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(2-hydroxyethyl)amino) methyl)benzyl)-
1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (5a): To a solution of 4a (1.67 g, 
2.52 mmol) in CH2Cl2 (25 mL), Boc2O (0.82 g, 3.8 mmol) in CH2Cl2 (5 mL) was added and 
the mixture stirred overnight. It was concentrated to give a light yellow liquid and purified 
by chromatography (1:1 hexanes:AcOEt) to give the Boc protected amino alcohol as a 
white set foam (compound 5s, 1.90 g, 99%): 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 18H), 
1.47 (s, 18H), 1.67 (bs, 2H), 1.90 (bs, 2H), 2.36 (bs, 2H), 2.53–2.68 (m, 2H), 3.18–3.44 
(m, 14H), 3.51 (bs, 2H), 3.68 (bs, 2H), 4.40–4.54 (m, 2H), 7.12–7.25 (m, 4H).  
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(3-hydroxypropyl)amino)methyl)benzyl)-
1,4,8,11-tetraazacyclotetra decane-1,4,8-tricarboxylate (5b): To a solution of 4b (2.16 g, 
3.18 mmol) in CH2Cl2 (30 mL), Boc2O (1.08 g, 4.77 mmol) in CH2Cl2 (5 mL) was added 
and the mixture stirred overnight. It was concentrated to give a light yellow liquid and 
purified by chromatography (1:1 hexanes:AcOEt) to give the Boc protected amino alcohol 
as a white set foam (compound 5b, 2.24 g, 91%): 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 
18H), 1.47 (s, 18H), 1.57–1.78 (m, 4H), 1.91 (bs, 2H), 2.36 (bs, 2H), 2.51–2.70 (m, 2H), 
3.18–3.44 (m, 14H), 3.47–3.59 (m, 4H), 3.82 (bs, 2H), 4.35 (bs, 2H), 7.11–7.25 (m, 4H).  
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(2-(1,3-dioxoisoindolin-2-
yl)ethyl)amino)methyl) benzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 
(6a): A mixture of 5a (1.41 g, 1.85 mmol), PPh3 (0.98 g, 3.7 mmol), phthalimide (0.29 g, 
1.93 mmol) and anhydrous THF (20 mL) was heated under N2 until all the solid dissolved. 
The mixture was cooled to 0°C and diethyl azodicarboxylate (DEAD) (0.60 mL, 0.67 g, 3.7 
mmol) was added dropwise and the mixture warmed to room temperature, after which it 
was concentrated to give a white solid. The solid was heated with 2:1 hexanes:AcOEt until 
all the solid dissolved and filtered through silica gel, collecting the fractions that contained 
product. These fractions where concentrated to a small volume and any solid that 
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crystallized out was removed by filtration. The filtrate was further purified by 
chromatography (2:1 hexanes:AcOEt) to give the phthalimide as a white set foam 
(compound 6a, 1.65 g, 100%): 1H NMR (400 MHz, CDCl3, δ) 1.43 (s, 18H), 1.47 (s, 18H), 
1.66 (bs, 2H), 1.89 (bs, 2H), 2.35 (bs, 2H), 2.58 (bs, 2H), 3.14–3.40 (m, 12H), 3.40–3.48 
(m, 3H), 3.51 (t, J = 5.2 Hz, 1H), 3.81 (t, J = 5.6 Hz, 1H), 3.86 (t, J = 5.2 Hz, 1H), 4.41 (s, 
1H), 4.47 (s, 1H), 7.17 (s, 4H), 7.65–7.75 (m, 2H), 7.80–7.86 (m, 2H).  
Tri-tert-butyl-11-(4-((tert-butoxycarbonyl(3-(1,3-dioxoisoindolin-2-yl)propyl)amino) 
methyl) benzyl)- 1,4,8,11-tetraazacyclo tetradecane-1,4,8-tricarboxylate (6b): A mixture of 
5b (0.89 g, 1.14 mmol), PPh3 (0.61 g, 2.3 mmol), phthalimide (0.19 g, 1.3 mmol) and 
anhydrous THF (15 mL) was heated under N2 until all the solid dissolved, before it was 
cooled to 0°C. DEAD (0.37 mL, 0.41 g, 2.3 mmol) was added dropwise and the mixture 
warmed to room temperature, after which it was concentrated to give a white solid. This 
was heated with 2:1 hexanes:AcOEt until all the solid dissolved and filtered through silica 
gel, collecting the fractions that contained product. These fractions where concentrated to 
a small volume and any solid that crystallized out was removed by filtration. The filtrate 
was further purified by chromatography (2:1 hexanes:AcOEt) to give the phthalimide as a 
white set foam (compound 6b, 1.03 g, 100%): 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 27H), 
1.47 (s, 9H), 1.67 (bs, 2H), 1.88 (bs, 4H), 2.36 (bs, 2H), 2.61 (bs, 2H), 3.12–3.45 (m, 12H), 
3.50 (s, 2H), 3.65 (bs, 2H), 4.18–4.25 (m, 2H), 4.43 (bs, 2H), 7.10–7.20 (m, 4H), 7.69–
7.75 (m, 2H), 7.81–7.86 (m, 2H).  
Tri-tert-butyl-11-(4-(((2-aminoethyl)(tert-butoxycarbonyl)amino)methyl)benzyl)-
1,4,8,11-tetraazacyclotetrade cane-1,4,8-tricarboxylate (7a). To a solution of 6a (1.54 g, 
1.7 mmol) in CH3OH (20 mL), NH2NH2 (0.54 mL, 0.55 g, 17 mmol) was added and the 
mixture stirred overnight. It was concentrated to give a white solid that was mixed with 
CH2Cl2 and filtered. This was repeated until no more amine was extracted from the solid. 
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The combined filtrates were concentrated to give a white foam (compound 7a, 1.31 g, 
100%). This was further purified by chromatography (10:1 CH2Cl2:CH3OH, adding 0.5% 
NH3 latter). 1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 18H), 1.47 (s, 18H), 1.67 (bs, 2H), 1.91 
(bs, 2H), 2.06 (bs, 2H), 2.36 (bs, 2H), 2.62 (bs, 2H), 2.79 (bs, 2H), 3.13–3.45 (m, 14H), 
3.51 (s, 2H), 4.43 (bs, 2H), 7.11–7.24 (m, 4H).  
Tri-tert-butyl-11-(4-(((3-aminopropyl)(tert-butoxycarbonyl)amino)methyl)benzyl)-
1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (7b): To a solution of 6b (1.03 g, 
1.1 mmol) in CH3OH (20 mL), NH2NH2 (0.36 mL, 0.36 g, 11 mmol) was added and the 
mixture stirred overnight. It was concentrated to give a white solid that was mixed with 
CH2Cl2 and filtered. This was repeated until no more amine was extracted from the solid. 
The combined filtrates were concentrated and purified by chromatography (10:1 
CH2Cl2:CH3OH, adding 0.5% NH3 latter) to give a white foam (compound 7b, 0.66 g, 75%). 
1H NMR (400 MHz, CDCl3, δ) 1.44 (s, 18H), 1.47 (s, 18H), 1.66 (bs, 4H), 1.91 (bs, 2H), 
2.17 (bs, 2H), 2.36 (bs, 2H), 2.52–2.78 (m, 4H), 3.13–3.44 (m, 14H), 3.51 (s, 2H), 4.33–
4.47 (m, 2H), 7.09–7.23 (m, 4H). 
3.3 Polymer synthesis 
3.3.1 Synthesis of PCXG1 
Polymeric Plerixafor PCXG1 was synthesized by Michael-type polyaddition of equal 
molar ratio of HMBA and a corresponding cyclam monomer AMD3100. Typically, each 
reactant was dissolved at a concentration at 80 mg/mL in a glass vial containing 
MeOH/water (7/3 v/v) mixture. Polymerization was carried out under nitrogen atmosphere 
and in dark at 37 °C for 4 days. Then, additional 10% of AMD3100 was added and the 
reaction mixture was stirred for further one day to consume all residual acrylamide groups. 
PCXG1 was isolated by double precipitation in diethyl ether, collected by centrifugation, 
and dried in vacuum for further modification. The final PCXG1 was obtained by adjustment 
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of pH to 4 using 1 M HCl and dialysis against deionized water (membrane molecular 
weight cut-off 3.5 kDa) with yield higher than 80%. 
3.3.2 Synthesis of PCXG2 
Polymeric CXCR4 antagonists PCXG2 based on the monocyclam monomers were 
synthesized by Michael-type addition copolymerization of HMBA with a mixture of 7a or 
7b and different amount of ABOL. In a typical polymerization reaction, 7a (76.3 mg, 0.1 
mmol), ABOL (8.9 mg, 0.1 mmol) and HMBA (44.8 mg, 0.2 mmol) were dissolved in 0.65 
mL of MeOH/water (7/3 v/v). Polymerization was carried out for 14 days at 50 °C in dark 
under nitrogen. Then, in order to remove any residual acrylamide groups, excess of 
cyclam (4 mg, 0.02 mmol) was added and the reaction mixture was stirred for additional 
2 days. The resultant Boc-protected polymers were isolated by evaporating solvent using 
oil vacuum pump. The protecting Boc groups were then removed by dissolving the 
obtained polymers in TFA at concentration of 20 mg/mL and stirring for 15 h at room 
temperature. The product was dried under oil vacuum pump and dissolved in acidified 
water (pH 4). The product was then dialyzed against acidified water (pH 4) with molecular 
weight cut-off of 3.5 kDa. Final product was obtained by lyophilization as hydrochloride 
salt. The typical yield after dialysis was 58-63%. Control polymer PABOL without cyclam 
moiety was synthesized as hydrochloride salt using the same conditions described as 
above by copolymerization of equal molar ratio of ABOL (89.1 mg, 1 mmol) and HMBA 
(224.2 mg, 1 mmol) with yield of 30.4% after dialysis. 
3.3.3 PEGylation of PCXG1 
The PEGylation of PCXG1 was carried out by Michael addition between the 
secondary amines in the cyclam groups of PCXG1 and acrylamide group of mPEG-
acrylamide. PCXG1 (72.3, 66.4 or 69.7 mg) and mPEG-acrylamide (8.0 mg, 35.8 mg or 
69.7 mg) were dissolved in MeOH/water mixture (7/3 v/v) at a total concentration of 120 
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mg/mL and the solution was stirred for 2 days at 37 °C, followed by 1 day at 50 °C. The 
reaction was cooled to room temperature and the pH was adjusted to 4 using 1 M HCl. 
The resulting copolymers (PEG-PCXG1) were isolated by precipitation in diethyl ether, 
centrifugation, and drying in vacuum, and finally dialyzed against deionized water (pH 4, 
membrane molecular weight cut-off 3.5 kDa). Typical yield was 70-80%.  
3.3.4 Cholesterol modification of PCXG1 
In order to synthesize Chol-PCXG1 with various degrees of cholesterol substitution, 
PCXG1 was first dissolved in a mixture of anhydrous methylene chloride and DIPEA. 
Different calculated amounts of cholesteryl chloroformate (15.4 mg, 32 mg or 55.62 mg) 
in anhydrous methylene chloride were added drop wise to the ice-cold PCXG1 (83.4 mg, 
86.3 mg or 90 mg) solution over 1 h. The reaction was continued under stirring for another 
24 h. The product was isolated by evaporating the solvent and washing with diethyl ether 
three times to remove unreacted cholesteryl chloroformate. The product was further 
dissolved in ethanol/water (v/v 1/1) mixture, followed by adjusting the pH to 4.0 using 1 M 
HCl. The polymers were then obtained by lyophilization after extensive dialysis against 
ethanol/water mixture (v/v 1/1) for 2 days and distilled water for another day (membrane 
molecular weight cut-off 3.5 kDa). Typical yield of Chol-PCXG1 ranged from 61% to 88%. 
3.4 Polymer characterization 
The molar mass of PCX was analyzed by gel permeation chromatography (GPC) 
operated in 0.3 M sodium acetate buffer (pH 5) using Agilent 1260 Infinity LC system 
equipped with a miniDAWN TREOS multi-angle light scattering (MALS) detector and a 
Optilab T-rEX refractive index detector from Wyatt Technology (Santa Barbara, CA). GPC 
data were analyzed using Astra 6.1 software from Wyatt Technology. The content of PEG 
or cholesterol in modified PCXG1 was determined using 1H-NMR on Varian INOVA (500 
MHz). The molecular weights of PEG-PCXG1 or Chol-PCXG1 were calculated on the basis 
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of the determined molar mass of PCXG1 by GPC and the known PEG or cholesterol 
substitution degree determined by 1H-NMR. 
3.5 Critical Micelle Concentration (CMC) 
Fluorescence spectroscopy was used to determine CMC of Chol-PCXG1 polymers 
using pyrene as a hydrophobic fluorescent probe. Different concentrations of Chol-PCXG1 
in water were allowed to equilibrate with 600 nM pyrene overnight at room temperature 
after 1 h sonication. Each fluorescence intensity index ratio at 335ex/384em nm (I3) vs. 
335ex/373em nm (I1) (I3/I1) was measured, and plotted against the logarithmic concentration 
of the polymer. The concentration at the inflection point was determined as CMC [179]. 
3.6 DNA condensation by ethidium bromide exclusion assay 
The ability of the synthesized polymers to condense DNA was determined by 
ethidium bromide (EtBr) exclusion assay by measuring the changes in EtBr/DNA 
fluorescence. 1 mL of DNA solution (20 μg/mL) was prepared in 10 mM HEPES buffer (pH 
7.4) and mixed with EtBr (1 μg/mL). Raw fluorescence intensity was measured and set to 
100% using an excitation wavelength of 540 nm and an emission wavelength of 590 nm. 
The fluorescence of ethidium bromide only in HEPES buffer was defined as background 
and set as 0%. Fluorescence readings were recorded following a stepwise addition of 
polymer solution and condensation curves (relative fluorescent intensity % vs. w/w ratio) 
were constructed.  
3.7 Preparation and characterization of DNA polyplexes 
Plasmid DNA solution at a concentration of 20 µg/mL was prepared in 10 mM 
HEPES buffer (pH 7.4). Polyplexes were formed by adding predetermined volume of a 
polymer to achieve desired polymer/DNA w/w ratio. The mixture was vigorously vortexed 
for 10 s and then stablized at room temperature for 30 min before further analysis. To 
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prepare mixed polyplexes, solutions of PCXG1 and PEG-PCXG1 were initially mixed at 
desired ratios and then added to the DNA solution. Hydrodynamic diameter and zeta 
potential of the polyplexes were determined by dynamic light scattering (DLS) using a 
ZEN3600 Zetasizer Nano-ZS (Malvern Instruments Ltd., Worcestershire, UK). The results 
were expressed as mean ± standard deviation (SD) of three measurements. 
3.8 Preparation and characterization of siRNA polyplexes 
siRNA polyplexes were formed by mixing equal solution volumes of siRNA (20 
μg/mL) and polymer by pipetting, followed by incubation at room temperature for 20 min 
before further use. Complexation of siRNA by polymers was examined by agarose gel 
electrophoresis. PCX/siRNA polyplexes were prepared at various polymer/siRNA w/w 
ratios, loaded onto a 2% agarose gel containing 0.5 μg/mL ethidium bromide. Gels were 
run at 75 V in 0.5x Tris/Borate/EDTA (TBE) buffer for 30 min and then imaged under UV. 
Hydrodynamic diameter and zeta potential of the polyplexes in 10 mM HEPES buffer (pH 
7.4) were determined by DLS. The results were expressed as mean ± standard deviation 
(SD) of three measurements. 
3.9 Colloidal stability 
Polypelxes were prepared accordingly as described above. To evaluate colloidal 
stability of the polyplexes, 10x phosphate-buffered saline (PBS) was added to the 
polyplexes to obtain a final 1x PBS solution (pH 7.4) with the following composition: 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4. The hydrodynamic diameter 
was then measured using DLS after 15 min, 1 h, and 12 h incubation at 25 °C. Results 
were expressed as mean ± standard deviation (SD) of three measurements.  
3.10 Enzymatic stability 
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To study the resistance of PCX/siRNA polyplexes to RNase I, polyplexes 
containing a total amount of 0.2 μg siRNA were incubated with 2.5 units of RNase I at 
37 °C for 30 min, followed by incubation at 90°C for 30 min to inactivate the enzyme. 
Heparin (200 µg/mL) was added to the samples and the mixture was incubated for 
additional 30 min to release the siRNA. Gel electrophoresis was then used to determine 
siRNA integrity.  
3.11 Cell culture 
Human hepatocellular carcinoma, HepG2 cells were purchased from ATCC 
(Manassas, VA) and cultured in MEM supplemented with 10% FBS. Human epithelial 
osteosarcoma U2OS cells stably expressing functional EGFP-CXCR4 fusion protein were 
purchased from Fisher Scientific and cultured in DMEM supplemented with 2 mM L-
glutamine, 1% Pen-Strep, 0.5 mg/ml G418 and 10% FBS. Mouse melanoma B16F10 cells 
were a kind gift from Dr. Rakesh Singh (UNMC) and maintained in DMEM supplemented 
with 10% FBS. Mouse mammary carcinoma 4T1 cell line was from ATCC (Manassas, VA) 
and cultured in RPMI supplemented with 10% FBS. Human PC cell line CD18/HPAF was 
originally derived from the parental heterogeneous HPAF pancreatic tumor cell line by a 
limiting dilution technique [180]. Luciferase-expressing CD18/HPAF (CD18/HPAF.luc) cell 
line was obtained by transfecting CD18/HPAF cells with pbabe.puro-Fluci vector as 
described previously [181]. The cell line was cultured in DMEM with 1% Pen-Strep and 
10% FBS. All cells were maintained in an incubator at 37 °C and 5% CO2. 
3.12 Cytotoxicity  
Cytotoxicity of the synthesized polycations was evaluated by CellTiter 
96®AQueous Non-Radioactive Cell Proliferation Assay or CellTiter-Blue Cell Viability 
Assay (Promega, Madison, WI). Single cell suspension was seeded in 96-well plates and 
incubated overnight. Culture medium was then replaced by 150 µL of serial dilutions of a 
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polymer in serum-supplemented medium. Cells were incubated at 37 °C for 24 h, and the 
medium was replaced with a mixture of 100 μL medium and 20 μL of assay reagent. After 
1 h incubation, the absorbance [A] or fluorescence intensity [I]  was measured using 
SpectraMax®M5e Multi-Mode Microplate Reader (Molecular Devices, CA) at a 
wavelength of 490 nm or at λex/λem 560/590 nm.. The relative cell viability (%) was 
calculated as [A]sample/[A]untreated × 100% or [I]sample/[I]untreated × 100%. The IC50 were 
calculated in GraphPad Prism using a built-in dose-response analysis as the polymer 
concentration that causes 50% decrease in cell viability relative to untreated cells. 
3.13 CXCR4 antagonism 
CXCR4 antagonism of the polycations and polyplexes was measured by CXCR4 
redistribution assay using a high-contant fluorescence microscopy analysis. U2OS cells 
stably expressing functional EGFP-CXCR4 fusion protein were seeded at a density of 
8,000 cells/well in 96-well black plates with optical bottom 24 h before the experiment. On 
the day of the assay, cells were washed twice with 100 μL assay buffer (DMEM 
supplemented with 2 mM L-glutamine, 1% FBS, 1% Pen-Strep, and 10 mM HEPES) and 
incubated with different concentrations of the polycations, polyplexes, or AMD3100 in the 
assay buffer containing 0.25% DMSO at 37 °C for 30 min. Then, 10 nM SDF-1 was added 
to each well and the cells were incubated at 37 °C for 1 h. Cells were fixed with 4% 
paraformaldehyde at room temperature for 20 min, washed 4 times with PBS and stained 
in 1 µM Hoechst 33258 solution for 30 min before imaging (EVOS fl microscope). 
Cellomics ArrayScan VT1 High Content Analysis Reader (Thermo Scientific) was then used 
to quantify the internalization of the CXCR4 receptors, and the images were analyzed by 
SpotDetectorV3 BioApplication software. CXCR4 antagonism was determined based on % 
CXCR4 internalization inhibition calculated relative to the positive (AMD3100, 100%) and 
negative (SDF-1 only, 0%) controls, and the results were expressed as mean % inhibition 
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± SD (n = 3 or 4). EC50 values (polymer concentrations that cause 50% CXCR4 inhibition) 
were determined in Prism Graghpad software using a three-parameter inhibitor dose-
response analysis method.  
3.14 Cell invasion 
Transwell cell culture inserts were coated with 40 μL ice-cold Matrigel which was 
diluted 1:3 (v/v) with serum-free medium. The 24-well plates with coated inserts were then 
placed in 37 °C incubator for 2 h. U2OS cells were harvested and resuspended with PCX 
polymers or polyplexes before adding to the inserts at a final concentration of 50,000 cells 
in 300 μL serum-free medium per insert. 20 nM SDF-1 in serum-free medium was added 
as the chemoattractant to the lower chamber of the wells. After 19 h, the non-invaded cells 
on the top surface of the insert membrane were removed by cotton swabs and the invaded 
cells on the bottom surface were fixed in 100% methanol and stained with 0.2% Crystal 
Violet solution for 10 min at room temperature. The number of invaded cells was counted 
under microscope set to 20× magnification. The results were expressed as average 
number of cells/imaging area ± SD (n = 5-10 random imaging areas). 
3.15 Cell uptake DNA polyplexes by flow cytometry 
Fluorescent gWiz-Luc DNA was prepared by using Label IT-TrackerTM CX-
Rhodamine Kit (Mirus, Madison, WI) according to manufacturer’s protocol. B16F10 and 
U2OS cells were seeded in 24-well plate at density of 200,000 and 100,000 cells/well 24 
h prior to transfection. On the next day, cells were incubated with PCXG2/DNA polyplexes 
containing 0.8 μg labeled DNA per well at w/w 5 in 300 μl of medium with or without 10% 
FBS. After incubation for 4 h, polyplexes were removed, and cells were washed with PBS, 
detached and resuspended for flow cytometry. The results were processed using flow 
cytometry data analysis software Flowjo (Tree Star Inc., Ashland, OR) and expressed as 
mean relative fluorescence intensity (n=3). To detect the possibility of CXCR4 receptors 
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involving into the process of cellular uptake of PCXG2 polyplexes, U2OS cells were 
pretreated with 0.3 µM AMD3100 in serum-free medium for 1 h before adding PCXG2/DNA 
polyplexes (n=2). 
3.16 DNA transfection activity 
The transfection experiments were carried out in 48-well cell culture plates with 
cells at logarithmic growth phase. B16F10 (40,000 cells/well) and U2OS (20,000 cells/well) 
cells were seeded 24 h prior to transfection. On the day of transfection, culture medium in 
each well was removed and replaced with 150 μL of antibiotic-free medium with or without 
10% FBS before adding 20 μL of polyplexes (DNA dose 0.4 μg/well). After 4 h incubation, 
polyplexes were completely removed and the cells were cultured in complete culture 
medium for 24 h prior to measuring luciferase expression. The medium was discarded 
and the cells were lysed in 100 μL of 0.5x cell culture lysis reagent buffer (Promega, 
Madison, WI) for 30 min. To measure the luciferase content, 100 μL of 0.5 mM luciferin 
solution was automatically injected into each well of 20 μL of cell lysate and the 
luminescence was integrated over 10 s using GloMax 96 Microplate Luminometer 
(Promega). Total cellular protein in the cell lysate was determined by the bicinchoninic 
acid protein assay using calibration curve constructed with standard bovine serum 
albumin solutions (Pierce, Rockford, IL). Transfection activity was expressed as relative 
light units (RLU)/mg cellular protein ± SD (n=3).  
3.17 Mobilization of peripheral blood leukocytes (PBL) 
6 weeks old female BALB/c mice were purchased from Charles River Laboratories 
and housed under controlled temperature, humidity and lighting conditions in facilities 
accredited by the American Association for Accreditation of Laboratory Animal Care, 
operating in accordance with standards set by the Guide for the Care and Use of 
Laboratory Animals (The National Academies Press, 1996). All procedures were approved 
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by the University of Nebraska Medical Center Institutional Animal Care and Use 
Committee. For cell mobilization studies, mice were randomized into three groups (n=5). 
Mice in the experiment group were administered intravenously with PCXG2-4 at 1.25 mg 
kg−1 in 100 μL PBS. Positive control group was administered subcutaneously with 
AMD3100 at the dose of 5 mg/kg in 100 μL PBS. Negative control mice received matched 
subcutaneous injection of 100 μL PBS. Whole blood samples were collected into 
heparinized tubes after 1 h of injection and PBL were counted with an automatic 
hematology analyzer HEMAVET 950FS (Drew Scientific Inc., Dallas, TX).  
3.18 siRNA transfection of siPLK1 polyplexes 
siRNA transfection efficiency of the polyplexes was evaluated in U2OS cells using 
human siPLK1 as a therapeutic siRNA. Cells were seeded at a density of 2,500 cells/well 
in 96-well plates 24 h prior to the experiment. On the next day, culture medium was 
carefully removed and replaced with 50 µL medium with or without 10% FBS and 12.5 µL 
polyplexes (siRNA dose: 5 pmol per well). After 4 h of incubation, polyplexes were 
removed and cells were maintained in 200 µL fresh culture medium for another 44 h. 
CellTiter-Blue Cell Viability Assay (Promega) was used to measure % cell viability. Activity 
was expressed as % cell death induced by PLK1 gene silencing compared with scrambled 
siRNA (n=3 or 4).  
3.19 Cellular uptake and intracellular distribution of polyplexes by confocal 
microscropy 
Chol-PCXG1 polymers were fluorescently labelled with AlexaFluor 647 following 
manufacturer’s instructions and purified by dialysis against distilled water to remove 
unreacted dye. Fluorescently labelled siRNA (Block-iTTM Alexa Fluor® Red) was 
purchased from Invitrogen (Carlsbad, CA). 100,000 of U2OS cells were seeded in a 23 
mm glass-bottom dish (Nioptechs Inc. Cat# 0420041500C) one day before the experiment. 
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Cells were then incubated with Chol-PCXG1/siRNA polyplexes (containing 25 nM siRNA) 
for 1 h, washed twice with PBS, fixed with 4% paraformaldehyde, washed with PBS for 
additional 4 times and stained in 1 µM Hoechst 33258 solution. All the images were taken 
using Zeiss 710 confocal laser scanning microscope equipped with a 63x oil objective 
and 4 lasers (Blue Diode 405 nm, Argon 458/488/514 nm, DPSS 561 nm and He-Ne 633 
nm). 
3.20 DNA biodistribution in mice 
6 weeks old female BALB/c mice were purchased from Charles River Laboratories 
and housed under controlled temperature, humidity and lighting conditions in facilities 
accredited by the American Association for Accreditation of Laboratory Animal Care, 
operating in accordance with standards set by the Guide for the Care and Use of 
Laboratory Animals (The National Academies Press, 1996). All procedures were approved 
by the University of Nebraska Medical Center Institutional Animal Care and Use 
Committee. The mice were inoculated with 5 ×105 4T1 cells in left hind flank zone. After 
two weeks, mice were sacrificed 1 h after tail-vein injection of polyplexes (15 µg DNA/mice, 
w/w 3 in 200 µL HEPES-buffered glucose (20 mM HEPES, 5% Glucose, pH 7.4; HBG)) 
and organs were harvested. The samples were suspended in PCR lysis buffer (0.5 mg/ml 
Proteinase K, 2 mg/ml poly-L-aspartic acid) at a concentration of 50 mg of tissue per 
milliliter and homogenized using TissueLyser II (Qiagen, Hilden, Germany). After 
homogenization, 2 μl of homogenized solution was mixed with 25 μl PCR lysis buffer and 
incubated in 37°C for 12 h. The luciferase DNA contents in different organs were analyzed 
by RT-PCR. The PCR cycle was 2 min at 50°C, 10 min at 95°C, 40 cycles for 15 s at 95°C, 
and 1 min at 60°C. A series of luciferase plasmid DNA dilution solutions (20 μg/ml, 2 μg/ml, 
200 ng/ml, 20 ng/ml, 2 ng/ml, and 0.2 ng/ml) were used to construct the calibration curve. 
3.21 NCOA3 knockdown 
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The efficiency of the PCX to deliver siNCOA3 and to downregulate NCOA3 gene 
was evaluated in CD18/HPAF.luc cells. Cells were seeded at a density of 100,000 
cells/well in 12-well plates one day before experiment. On the next day, culture medium 
was carefully removed and replaced with 800 µL medium and 200 µL polyplexes. The 
PCX polyplexes were prepared at w/w ratio of 2 using either siNCOA3 or a negative control 
siRNA (siScr). PEI/siRNA polyplexes prepared at w/w of 1.5 were used as controls. After 
4 h of incubation, polyplexes were removed and cells were maintained in 2 mL fresh 
culture medium for another 72 h. Cells were washed with PBS twice and prepared for 
western blot. NCOA3 silencing at protein level was compared with that of scrambled 
siRNA.  
3.22 CXCR4 expression by flow cytometry  
CD18/HPAF.luc cells were seeded in 6-well plates in DMEM with 10% FBS 
overnight. On the day of experiment, fresh DMEM with or without 10 µM gemcitabine was 
added. After 24 h of incubation, cells were washed with PBS twice, detached using 
enzyme-free PBS-based cell dissociation buffer (Gibco by Life Technologies, Grand Island, 
NY), and resuspended in PBS. After centrifugation at 800 rpm for 5 min, the supernatant 
was removed and the cells were resuspended in FACS buffer (1% BSA, 0.1% NaN3 in 
PBS) to obtain final cell concentration of 5 x 106/mL. The cell suspension (100 μL) was 
mixed with 20 µL of APC mouse anti-human CXCR4 antibody or the corresponding isotype 
control. After incubation at room temperature for 30 min, the cells were washed three times 
with FACS buffer to remove free antibody and resuspended in 500 µL of FACS buffer for 
the measurement by flow cytometry. The data were processed and analyzed using FlowJo 
software (Tree Star Inc., Ashland, OR) and expressed as percentage of CXCR4-positive 
cells.  
3.23 Western blotting  
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Whole-cell lysate was prepared in Pierce® RIPA lysis buffer (Thermo Scientific, 
Rockford, IL) supplemented with 1x protease and phosphatase inhibitor cocktail. Total 
protein content was quantified using BCA assay, and samples were normalized by dilution 
with RIPA buffer to obtain equal protein concentration. Equal volume of 2x Laemmli 
sample buffer (BIO-RAD, Hercules, CA) was added, followed by boiling in water for 5 min. 
Equal amounts of total protein (20-40 µg) were loaded to SDS-polyacrylamide 
electrophoresis gel, run first at 80 V for 30 min and then at 120 V for 2 h. The protein 
contents were transferred to polyvinylidene difluoride (PVDF) membrane, and the 
membrane was blocked with 5% skim milk at room temperature for 1 h, and incubated 
overnight with the primary antibodies at 4 °C. Next day, the blot was washed three times 
with TBST buffer (20 mM Tris, 500 mM NaCl, 0.1% Tween 20, pH 7.5) and incubated with 
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The 
protein signals were visualized by Pierce® ECL Western blotting substrate (Thermo 
Scientific, Rockford, IL). The band intensity was evaluated using ImageJ software. 
3.24 RNA isolation and Real Time PCR analysis 
The total RNA from the cells was isolated using TRIzol® reagent and the RNA from 
tissues was isolated using mirVana miRNA isolation kit according to the protocols from 
Life Technologies. Cells were washed with PBS and lysed in the TRIzol® Reagent. The 
homogenized samples were incubated at room temperature for 5 min to complete 
dissociation of the nucleoprotein complex. Chloroform was added and the samples were 
centrifuged. RNA was precipitated by addition of 0.5 mL of isopropanol to the aqueous 
phase. RNA pellet was resuspended in RNase-free water and stored at -80 °C. For 
isolation of RNA from tissues, tumor tissues were homogenized in liquid nitrogen and 
lysed in the lysis/binding buffer. miRNA Homogenate Additive was added to the tissue 
lysates and acid-phenol: chloroform was added and vortexed for 1 min. The aqueous 
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phase was collected, mixed with equal volume of ethanol, and the mixture was passed 
through a filter cartridge. The RNA isolated from cells and tissues was reverse-transcribed 
to cDNA using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, 
Foster City, CA) using a thermal cycler in Rotor-Gene Q RT-PCR (Qiagen, Hilden, 
Germany). The thermal cycling conditions used were 25 °C for 10 min, 37 °C for 120 min, 
and 85 °C for 5 min. The expression pattern of the gene of interest was analyzed and the 
fold change in gene expression was calculated using the 2-ΔΔCT method. Results were 
expressed as mean expression compared with untreated cells ± SD (n=3) 
3.25 Cell migration 
CD18/HAPF.luc cells were pretreated with 10 µM gemcitabine for 24 h, trypsinized, 
and resuspended with 1 μg/mL PCX in serum-free medium for 15 min. The cell suspension 
with PCX was then added to transwell inserts at a final cell density of 200,000 cells in 300 
μL medium per insert. DMEM with 10% of FBS was added as the chemoattractant in the 
companion plate. After 24 h, the non-invaded cells on the upper surface of the insert 
membrane were removed by cotton swabs. The invaded cells on the bottom surface were 
fixed in 100% methanol and stained with 0.2% Crystal Violet solution for 10 min at room 
temperature. The migrated cells were counted at 10× magnification. The results were 
expressed as percentage of migrated cells relative to untreated cells/imaging area ± SD 
(n = 4 random imaging areas of triplicate samples). 
3.26 Orthotopic implantation of tumor cells and analysis of anticancer activity  
Female athymic nude mice (6 weeks old) were purchased from Harlan 
Laboratories and housed under controlled humidity, temperature and lighting conditions 
in facilities accredited by the American Association for Accreditation of Laboratory Animal 
Care, operating in accordance with standards set by the Guide for the Care and Use of 
Laboratory Animals (The National Academies Press, 1996). All procedures were approved 
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by the University of Nebraska Medical Center Institutional Animal Care and Use 
Committee. Orthotopic implantation of pancreatic cancer cells was performed as 
described previously [182]. Briefly, CD18/HPAF.luc cells were trypsinized, washed and 
resuspended in sterile PBS. Prior to surgery, mice were anesthetized with 350 µL of 
intraperitoneal injection of a 4:1 mixture of ketamine (100 mg/mL) and xylazine (20 mg/mL) 
diluted 10 times in sterile water. The surgical site was sterilized with 70% ethanol wipe 
and a 1-cm incision was made in the peritoneum at the mid-abdomen region below the 
sternum by scissors. 2.5 x 105 of CD18/HPAF.luc cells were injected into the head of 
pancreas without causing injury and torsion. The abdomen was closed using a 2-layer 
suture with 5-0 chromic catgut and soft staple. The skin staples were removed 10 days 
after surgery. The animals inoculated with tumor cells were housed in the animal facilities. 
After 10 days of growth, the luciferase-expressing tumors were imaged by IVIS and the 
mice were randomly assigned into three groups: saline (n=7), negative siRNA control 
polyplexes (Chol17-PCXG1/siScr, n=7) and combination polyplexes (Chol17-PCX 
G1/siNCOA3, n=6) group. The PCX/siRNA polyplexes were prepared at w/w 2 and 
administered three times per week through tail vein (40 µg siRNA/mouse). The mice were 
observed and weighed every other day. Tumor growth and total tumor burden were 
monitored by palpation and whole-body IVIS bioluminescence imaging. Magnetic 
resonance imaging (MRI), a non–invasive approach, was used to assess tumor perfusion 
in the above mouse model of PC before sacrifice. Mice were sacrificed after 39 days of 
tumor growth. Changes in tumor growth and sites of metastasis were evaluated in each 
experimental group. Pancreatic tumors from different experimental groups were collected 
for immunohistochemistry (IHC) analysis.  
3.27 Immunohistochemistry analysis (IHC)  
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To analyze the histopathology, the tumor tissues were fixed in 10% formalin for 72 
h and stored in 75% ethanol. The tissues were embedded in paraffin and 5 µm sections 
were cut and stained with haematoxylin & eosin (H&E) as well as requisite antibodies as 
described previously [85]. Typically, tissue slides were baked at 58 °C overnight. Next day, 
tissues were deparaffinized, hydrated and antigens were recovered by boiling in citrate 
buffer. Tissue sections were blocked with 2.5% horse serum and incubated with indicated 
primary antibody (8G7) overnight at 4 °C. Tissues were washed and incubated with HRP-
conjugated secondary antibody. Subsequently, tissues slides were washed and 
developed using 3.3’-diaminobenzidine kit (Vector Laboratories, Burlingame, CA) for 
colorimetric detection and counterstained with hematoxylin. Tissues were dehydrated, 
dried and mounted with Permount and evaluated by a pathologist.  
3.28 Tumor perfusion analysis 
Mice were evaluated at the end of the treatment before euthanasia by magnetic 
resonance imaging (MRI) to assess tumor vascular function using perfusion imaging, after 
acquiring a reference T2-weighted image set to visualize the tumor location. For these 
procedures, all equipment that direct contacted with animals were treated with disinfectant 
and animals were handled as described below. Mice were anesthetized by inhalation 
anesthesia (1.5% isoflurane). The anesthetized mice were positioned in a Plexiglas holder 
and placed in an RF coil for imaging. The anesthetized animal was secured in place to a 
support platform upon which the animal's body rested horizontally for MRI acquisition. The 
breathing rate and temperature of the anesthetized animals were monitored continuously 
with this holder design using an SA Instruments (Stony Brook, NY) model 1025 small 
animal monitoring and gating system. During image acquisition, animals were maintained 
on 0.5-1.5% isoflurane, in oxygen with an output of 1 L/min with gases continuously 
vacuumed from the opposite side of the chamber using the facility vacuum line regulated 
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at a flow rate of 1 L/min. Animals were monitored during the procedure and respiration 
rates were maintained at 40-60 bpm by adjusting isoflurane during examinations. The 
holder with the mouse was inserted into a birdcage quadrature transmit/receive coil and 
mounted at the magnet center. Studies began with a localizer to center the head in the 
magnet and coil. After localization and system shimming, T2-weighted high-resolution 
anatomical image was obtained for each animal, followed by the acquisition of perfusion 
maps. Perfusion maps were acquired and analyzed using Flow Sensitive Alternating 
Inversion Recovery (FAIR) [183]. Perfusion maps were generated with a Rapid Acquisition 
with Relaxation Enhancement (RARE) readout. Images were acquired with a RARE factor 
of 16, 16 inversion recovery times ranging from 30-2300 ms, 1 mm slice thickness, 
selective inversion slab thickness of 4 mm, 30 mm x 30 mm field of view, 128 x 128 matrix. 
Total imaging time for MRI was 0.5-1 hour per animal. 
3.29 Statistical analysis 
Statistical analyses were performed using GraphPad InStat 3 software. Student’s 
t-test was used to determine the statistical significance between groups and statistical 
differences among multiple groups were analyzed using non-parametric ANOVA with 
Tukey-Kramer multiple comparisons test. Fisher’s exact test was used to compare the 
incidence of metastasis between groups. P<0.05 was considered as significant difference.  
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Chapter 4 - Results and Discussion 
4.1 Development of Functional Poly(amido amine) CXCR4 Antagonists with 
Increased CXCR4 Inhibitory Activity to Deliver Therapeutic Nucleic Acids 
Please note that the data of this part was from the paper published in the Advanced 
Healthcare Materials [153]. The authors include Dr. Stuart Hazeldine, Dr. Jing Li, Dr. David 
Oupický and me. Dr. Hazeldine proposed and developed synthetic strategy for the novel 
cyclam monomers and copolymers. As the first author, I performed all the other 
experiments to characterize the copolymers in vitro and in vivo. I collected all the data, 
participated in their analysis, and wrote early draft of the manuscript. Drs. Li and Oupický 
analyzed data, wrote the manuscript, and handled its submission and publication. All the 
authors agreed with including their work in this dissertation. 
 
Scientists have undertaken extensive researches to control cancer over half a 
century. For early stage cancer patients, surgical intervention is a potential treatment. 
However, most of the cancer patients are diagnosed with advanced stage due to scarce 
symptoms until the disease has progressed and the treatment is limited to chemotherapy 
or radiation [184]. The vast amount of chemodrugs used in clinic are low molecular-weight 
compounds, which lack of selectivity and cause high toxicity in vivo. Small molecular-
weight chemodrugs distribute fast and uniformly into healthy tissues, exhibit a short half-
life and a rapid clearance in the systemic circulation. The frequent severe systemic side 
effects include neurotoxicity, cardiotoxicity, nephrotoxicity, bone marrow toxicity, mucositis 
and gastrointestinal toxicity [185].  
Polymer therapeutics are becoming popular in recent years to treat cancer, which 
are a class of delivery systems, including polymeric drugs, polymer conjugates of proteins, 
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drugs and aptamers, block copolymers micelles, as well as multicomponent non-viral 
vectors with covalent linkages [186]. The pathophysiological properties of solid tumor have 
been utilized to design polymer therapeutics to improve the drug efficiency in vivo. Tumor 
tissues exhibited enhanced extravasation and retention of macromolecules from tumor 
blood vessels, which is not observed in normal vasculature and termed as “enhanced 
permeability and retention (EPR) effect” [187, 188]. Macromolecular drugs can more easily 
extravasate through the leaky tumor endothelium and get trapped in the poorly developed 
lymphatic system of the tumor, leading to prolonged circulation time. In comparison with 
conventional chemodrugs, polymer therapeutics enhance the selectivity of cancer 
targeting, improve the anti-cancer efficiency and diminish the side effects [189, 190].  
In contrast to drug delivery systems containing non-covalently therapeutic agents, 
the complex and multicomponent constructs of polymer therapeutics work as actual drugs 
and macromolecular prodrugs. Polymeric drug Copaxone has been successfully 
developed as a treatment for multiple sclerosis and progressed to market, which is a 
random copolymer of three amino acids (Glu, Ala and Tyr) [191]. The Oral polymeric 
sequestrants Renagel binds phosphate and is used to treat chronic kidney disease [192]. 
SMANCS is a polymer-protein conjugate consisting of the anticancer protein 
neocarcinostatin and a synthetic copolymer of styrene and a maleic acid anhydride drug, 
which has been approved for the treatment of hepatocellular cancer in Japan [189].  
In tumors, a complex network of chemokines and chemokine receptors controls 
cell trafficking into and out of the tumor microenvironment [193]. Cells from different cancer 
types have different expression profiles of chemokine receptors. However, CXCR4 is the 
most widely expressed chemokine receptor in human cancers, which makes it and its 
ligand SDF-1 the most-promising targets within the chemokine network. CXCR4/SDF-1 
axis regulates survival, proliferation, migration and invasion of cancer cells by activating 
65 
 
various intracellular signaling transduction pathways that affect cell survival and migration. 
Those pathways include phosphatidylinositol-3-kinase (PI3K) and the mitogen-activated 
protein kinase pathways. CXCR4 also activates Erk1/2, which phosphorylates 
transcription factors including Elk-1 to promote cancer cell proliferation and survival [117]. 
CXCR4/SDF-1 is also involved in activating focal adhesion complexes and promoting 
adhesion through integrins. All this, combined with increasing secretion of matrix 
metalloproteinases that mediate degradation of extracellular matrix, contributes to 
invasion of cancer cells [118-120]. Clinical evidence shows that certain anticancer 
therapies increase CXCR4 expression and inadvertently enhance the metastatic potential 
of tumors [194]. Animal studies of several types of cancer show that CXCR4 antagonists 
inhibit macrophage infiltration, induce tumor growth arrest and apoptosis, and prevent 
metastatic spread.  
Our lab has developed the first generation of polymeric antagonists of the CXCR4 
chemokine receptor (PCXG1) based on a commercial CXCR4 antagonist AMD3100 
(Plerixafor) (Figure 1a), which was approved by FDA in 2008 for mobilization of 
hematopoietic stem cells in bone marrow transplantation procedures [195]. PCXG1 worked 
as a dual-function polymeric drug suitable for simultaneous delivery of nucleic acids and 
inhibition of cancer metastasis [149, 150, 196]. Based on the proof-of-principle studies, it 
is difficult to control the polymerization due to the presence of six reactive secondary 
amines in AMD3100, which contributed to the generation of poorly defined highly 
branched polymers. The highly branched PCXG1 also showed compromised the CXCR4 
antagonistic activity when compared with the original AMD3100. Therefore, we designed 
the second generation of polymeric CXCR4 antagonists (PCXG2) based on novel 
monocyclam monomers with improved presentation of CXCR4-binding moieties and 
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better-controlled polymerization (Figure 1b). The novel linear PCXG2 were able to function 
dually as gene delivery vectors and inhibitors of cancer cell invasion (Figure 1c).  
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Figure 1. (a) Chemical structure of AMD3100 (Plerixafor). (b) Chemical structure of PCXG2. 
(c) Mechanism of action of polymeric CXCR4 antagonists (PCXG2) and PCX G2 polyplexes. 
 
  
(a) 
(b) 
(c) 
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4.1.1 Synthesis of monocyclam monomers 
By sequential replacement or deletion of the amino groups within the azamacrocyclic ring 
systems of AMD3100, Bridger et al reported that all eight amino groups are not required 
for CXCR4 inhibition. This approach results in the design of several single ring 
azamacrocyclic analogues with high potency as AMD3100 [197]. Two novel monocyclam 
monomers were developed and synthesized according to the AMD3100 pharmacophore. 
The synthesis scheme was summarized in Figure 2. Three of the four secondary amines 
in cyclam (1) were protected by Boc to gain compound 2 with yield of 84%. Chloro-
compund 3 was achieved by reaction of excess dichloroxylene or dibromoxylene with 
unprotected amine in compound 2. Amino-alcohols were added to obtain compound 4 with 
secondary amine and terminal hydroxyl group. The secondary amine of 4 was also 
protected by Boc and the terminal hydroxyl was converted into primary amine by 
Mitsunobu reaction using phthalimide, triphenylphosphine (PPh3) and 
diethylazodicarboxylate (DEAD) to obtain protected amine 6. Hydrazine was added to get 
the final monocyclam monomers (7a and 7b) with ethylene and propylene spacer 
respectively. 
4.1.2 Synthesis and characterization of polymeric CXCR4 antagonists (PCXG2) 
We hypothesized that when compared with PCXG1, well-defined liner PCXG2 would 
improve the CXCR4 antagonism due to better presentation of CXCR4 binding moiety in 
the polymer side chain and easier accessibility to CXCR4 receptor. In order to conduct 
side-by-side comparison and study the influence of cyclam content and spacer length on 
the physicochemical characterizations and pharmacological activity of PCXG2, a series of 
PCXG2 were synthesized by Michael-type polyaddition (Figure 1b). The reaction of 
equimolar amount of HMBA and Boc-protected monomer 7a or 7b resulted in 
homopolymers PCXG2-2 and PCXG2-4. Copolymers PCXG2-1 and PCXG2-3 were obtained 
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by polymerization of equimolar amounts of HMBA with a mixture of 4-amino-1-butanol 
(ABOL) and 7a or 7b. Negative control polymer (PABOL) without CXCR4 antagonism was 
obtained by polymerization of HMBA and ABOL. To achieve desirable molecular weights, 
the polymerization conditions of PCXG2 were more rigorous than that of PCXG1. The bulky 
Boc-protected monocyclam monomers were polymerized at enhanced temperature (50 °C) 
and extended reaction time (2 weeks) to get PCXG2. Excess amount of cyclam was added 
and reacted for another two days to consume the unreacted acrylamide residues to 
terminate the polymerization. As show in Figure 3, the disappearance of HMBA 
acrylamide bonds (5.76 and 6.21 ppm) in 1H-NMR confirmed the completion of the 
polymerization. Additional larger amount of cyclam was added to quench all acrylamide 
bond residues of PCXG2-2. The content of monocyclam in the PCXG2-1 and PCXG2-3 was 
calculated from integral intensities of the phenylene protons (7.3-7.7 ppm) in 7a and 7b 
and of the methylene protons (CH2CH2OH) in ABOL (3.65 ppm). Due to the steric 
hindrance of the bulky Boc-protected cyclam, the incorporation of the monocyclam 
monomers into the copolymers was lower than in feed ratio, suggesting weaker reactivity 
of the primary amines in 7a and 7b in comparison with the amine in ABOL. Based on the 
analysis of GPC in Table 2, the molecular weight of PCXG2 ranged from 5.2 to 9.0 kDa 
with low polydispersity, indicating the linear structure of the polymers. 
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Figure 2. Synthesis of monocyclam monomers. 
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Figure 3. 1H-NMR of PCXG2 in D2O (a. PABOL, b. PCXG2-1, c. PCXG2-2, d. PCXG2-3, e. 
PCXG2-4 and f. PCXG2-2 after consuming all of the acrylamide bonds). 
  
  
  
 
a) b) 
c) d) 
e) f) 
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Table 2. Characterization of polymers 
 
Polymer 
Cyclam 
monomer 
In feed (mol %) 
In polymer 
(mol %)a 
Mw Mw/Mn 
ABOL 
Cyclam 
monomer 
PABOL -- 100 0 0 5,250 1.26 
PCXG2-1 7a 50 50 33 5,910 1.11 
PCXG2-2 7a 0 100 100 9,030 1.11 
PCXG2-3 7b 50 50 45 6,580 1.29 
PCXG2-4 7b 0 100 100 5,230 1.27 
 
a Content of the cyclam monomer units determined from 1H-NMR. 
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4.1.3 Cytotoxicity of PCXG2 
Safety is the major challenge of synthetic polycations to apply nucleic acid 
therapeutics to patients. Cytotoxicity study will help with design and selection of safer 
polycationic vectors for clinical gene therapy [198]. Hepatocellular carcinoma HepG2 was 
widely used for prediction of the potential liver toxicity and human osteosarcoma U2OS 
cells was used to define the safe dosing window of PCXG2 for further studies about CXCR4 
antagonism and gene transfection [199]. Typically high molecular weight and high charge 
density typically related with high cytotoxicity of polycations, which corresponds with the 
cytotoxicity result of PCXG2-2 [198]. Figure 4 showed that PCXG2-2 with the highest 
molecular weight and highest charge density due to highest contant of cyclam exhibited 
the highest cytotoxicity among all PCXG2. However, PCXG2-1 with lowest cyclam content 
exhibited the lowest toxicity. Moreover, all of PCXG2 had dramatically less toxic than the 
commercial control PEI, indicating the potential usage of PCXG2 in vivo. 
4.1.4 CXCR4 antagonism of PCXG2 
High content screening (HCS) analysis was used to study the CXCR4 antagonist 
activity of monocyclam monomers and PCXG2 polymers by monitoring the degree of 
inhibition of SDF-1 triggered internalization of membrane-localized EGFP-CXCR4 fusion 
protein to endosomes in human osteosarcoma cell line U2OS. HCS is a phenotypic assay 
that in this case uses automatic image analysis to quantify the extent of EGFP-CXCR4 
internalization into the cells. As shown in Figure 5a, the untreated cells display punctate 
fluorescence documented by EGFP-CXCR4 internalization into endosomes. However, the 
control small-molecule CXCR4 antagonist AMD3100 inhibits EGFP-CXCR4 
internalization, as indicated by the diffuse pattern of fluorescence. The usage of propylene 
linker in 7b led to 2.6-fold higher activity than that of ethylene linker in 7a (EC50 = 41.2 vs. 
105.5 ng/mL ~ 69 vs. 180 nM). After removal of Boc-groups, the CXCR4 antagonism of 
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all PCXG2 was calculated and compared with the activity of corresponding monomers 
(Figure 5b). Control polymer PABOL exhibited no CXCR4 antagonism. Homopolymer 
PCXG2-4 exhibited higher CXCR4 inhibitory activity than PCXG2-2, which corresponded 
with less potent of 7a than 7b (EC50 = 21.4 vs. 28.2 ng/mL). Copolymers (PCXG2-1 and 
PCXG2-3) showed decreased CXCR4 potency due to less content of the CXCR4 binding 
moieties by incorporation of ABOL. Therefore, the polymerization of the monocyclam 
monomers improved the CXCR4 antagonism dramatically. To determine the influence of 
polymerization on CXCR4 antagonism of the repeating monocyclam unit, the potency was 
calculated based on the activity per cyclam in polymers. As shown in Figure 5b, 
polymerization increased activity of 7a more than 5-fold and the activity of 7b increased 
about 3-fold after incorporation into the polymer chain of PCXG2. Moreover, decreasing 
the content of the monocyclam monomers in PCXG2 did not impact the activity of the 
repeating units. However, polymerization of AMD3100 caused a significantly decrease in 
CXCR4 inhibitory activity per repeating units in the first generation of PCX (PCXG1) (2 vs. 
139.1 ng/mL). The activity of PCXG2 was significantly higher than that of PCXG1, indicating 
that better presentation of the CXCR4-binding moieties in polymeric CXCR4 antagonists 
is important for improving the CXCR4 potent activity. In order to investigate the duration 
of CXCR4 inhibition of PCX, U2OS cells were incubated with AMD3100 (0.15 µg/mL) or 
the most potent PCXG2 (PCXG2-4, 1.5 µg/mL) respectively for 30 min and the extent of 
CXCR4 inhibition was quantified at different time points (Figure 5c). AMD3100 has a high 
affinity to CXCR4 receptors and results in long lasting inhibitory effect [200]. In comparison 
with AMD3100, there was no significant differences in the duration of CXCR4 inhibition 
between AMD3100 and PCXG2-4. We noticed that both treatments maintained CXCR4 
inhibition above 80% for at least 36 h and about 50% until 48 h, suggesting the long lasting 
antagonist effect and high affinity of PCXG2.  
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Polymer 
IC50 [μg/mL] 
U2OS HepG2 
PCXG2-1 79.8±1.6a),b) > 200a),b) 
PCXG2-2 26.7±0.4a),d) 105.7±1.9a),d) 
PCXG2-3 40.4±0.8a),c) > 200a) 
PCXG2-4 38.5±0.1a) 171.4±1.3a) 
PABOL > 200a) > 200a) 
PEI 4.4±0.1 14.3±0.5 
 
Figure 4. Cytotoxicity of PCXG2 in U2OS and HepG2 cells. The IC50 curves were 
constructed using mean cell viability ± SD (n=3). One-way ANOVA with Tukey-Kramer 
multiple comparisons test (a)(P<0.001 vs. PEI); b)(P<0.001 vs. PCXG2-2); c)(P>0.05 vs. 
PCXG2-4); d) (P<0.001 vs. PCXG2-4)). 
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Sample 
CXCR4 antagonism 
EC50 
[ng/mL] 
EC50  per 
antagonist moiety 
[ng/mL] 
PCXG2-1 56.8 19.9 
PCXG2-2 28.2 19.5 
PCXG2-3 29.9 13.3 
PCXG2-4 21.3 14.9 
7a 105.5 105.5 
7b 41.2 41.2 
PCXG1 103.0 76.5 
AMD3100 2.0 2.0 
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Figure 5. CXCR4 antagonism of PCXG2. (a) Effect of AMD3100 on redistribution of EGFP-
CXCR4 receptor in U2OS cells. (b) Effect of monomer type and content on CXCR4 
antagonism. EC50 values determined from receptor redistribution assay in U2OS cells 
(n=3). (c) Duration of CXCR4 antagonism (n=3). 
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4.1.5 Inhibition of cancer cell invasion by PCXG2 
The activity of CXCR4 induced by SDF-1 contributes to migration and invasion of 
a series of cancers, which can be inhibited by CXCR4 antagonists like AMD3100. To 
investigate if the CXCR4 antagonism of the synthesized PCXG2 polymers was also 
manifested by inhibition of cancer cell invasion, a Boyden chamber method was used. 
Treatment of CXCR4+ U2OS cells with control AMD3100 resulted in maximum 83% of 
cancer cells from invading and migrating through the layer of Matrigel (Figure 6). All 
PCXG2 exhibited effective inhibition of invasion ranging from 62 to 82% at concentrations 
relevant for subsequent transfection experiments. And the ability of PCXG2 to prevent 
cancer cell invasion increased with the higher content of the incorporated monocyclam 
units. PCXG2-4 was the most potent CXCR4 antagonist and showed the highest inhibition 
of cancer cell invasion (82%), which was fully comparable to AMD3100. However, the 
negative control PABOL was unable to inhibit cell invasion due to no CXCR4 potency. 
4.1.6 Transient mobilization of peripheral blood leukocytes (PBLs) 
CXCR4 contributes to tethering leukocytes and hematopoietic stem and progenitor 
cells to the bone marrow and the leukocytosis associated with CXCR4 inhibition has been 
used as an indicator of the mobilization of hematopoietic stem and progenitor cells. Small 
molecule CXCR4 antagonists such as AMD3100 induce a transient leukocytosis in 
humans, dogs, mice and rats. An increase in PBL is normally observed within 1 h after 
administration of AMD3100 both in humans and animals [201]. We evaluated if the CXCR4 
antagonism of PCXG2 observed in vitro will be manifested also by leukocytosis and thus 
indirectly assessed the PCXG2 ability to mobilize hematopoietic stem and progenitor cells. 
We selected the best performing PCXG2-4 with the highest CXCR4 antagonism in vitro 
and administered it intravenously to BALB/c mice.  
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Before we started the experiment, the maximum tolerated dose of PCXG2 was 
tested in Balb/c mice. PCXG2-4 showed the lowest toxicity in vivo with MTD of 5 mg/Kg by 
i.v. injection (Figure 7a). We selected a relatively low dose of PCXG2-4 (1.25 mg/kg) to 
avoid any possible side effect related to potential polycation toxicity. Positive control 
AMD3100 was given subcutaneously at 5 mg/kg according to a standard protocol. A 
widely used polycation PEI was also injected as a negative control, which was with no 
known CXCR4 activity. As shown in Figure 7b, the total number of PBL was compared 
after administration for 1 h. PCXG2-4 induced 1.6-fold increase in the total number of PBL 
when compared with PBS-treated group, which was fully comparable with the effect of 
AMD3100 (P>0.05). Different populations of PBL were also analyzed to identify any 
possible differences among the tested samples. Administration of both PCXG2-4 and 
AMD3100 resulted in a significant increase in the number of lymphocytes and monocytes, 
while no significant effect was observed for eosinophils, neutrophils and basophiles. No 
statistically significant differences were observed in the ability of PCXG2-4 and AMD3100 
to mobilize different PBL populations. We did not observe leukocytosis in the PEI control 
group, indicating that the increase in the number of PBL by administration of PCXG2-4 was 
indeed due to the inhibition of CXCR4 and not related to any nonspecific polycation-related 
toxicity. It is our first time to show that the polymeric CXCR4 antagonists can rapidly and 
efficiently mobilize PBL and thus possibly have the potential to mobilize hematopoietic 
stem and progenitor cells as AMD3100 used in clinics.  
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Figure 6. Inhibition of cancer cell invasion by PCXG2 (2 µg mL-1) and polyplexes (w/w = 5, 
total polymer = 2.5 µg mL-1). Statistical comparisons were done using the One-way 
ANOVA with Tukey-Kramer Multiple Comparisons Test (***P<0.001 compared with 
AMD3100 treated cells). 
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Figure 7. (a) MTD of PCXG2-3 and -4 in Balb/c mice. (b) Mobilization ability of PCXG2-4 
polymer. Results are expressed as mean PBL numbers ± SD (n=5 mice per group). 
Statistical comparisons were done using the One-way ANOVA with Tukey-Kramer Multiple 
Comparisons Test (*P<0.05, **P<0.01, ***P<0.001 compared with PBS treated mice; 
AMD3100 vs. PCXG2-4, ns, P>0.05). 
(a) 
(b) 
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4.1.7 DNA condensation and transfection activity by PCXG2 
After evaluation of PCXG2 CXCR4 antagonism and ability to inhibit cancer cell 
invasion, we have investigated the capability of PCXG2 to function as gene delivery vectors. 
First, the ability of all PCXG2 to condense DNA and form polyplexes was confirmed using 
ethidium bromide (EtBr) exclusion assay. Figure 8 showed that the DNA condensation 
ability increased with increasing content of the cyclam monomers in PCXG2. In agreement 
with previous reports [202, 203], the ability of PABOL to condense DNA was poor in the 
studied range of polymer/DNA w/w ratios. The length of spacer in the cyclam monomers 
had no discernible effect on DNA condensation ability. Hydrodynamic size and zeta 
potential of PCX/DNA polyplexes were determined by dynamic light scattering at 
polymer/DNA w/w ratio of 5, which corresponded to about 3-fold excess of PCXG2 relative 
to the minimum amount required to fully condense DNA. The sizes of PCXG2/DNA 
polyplexes ranged from 56 to 122 nm and the polyplexes were all positively charged with 
zeta potential 17 to 31 mV (Table 3). Control PABOL cannot condense full condense DNA 
at w/w ratio of 5, which was reflected by a large hydrodynamic size and slightly negative 
zeta potential. Moreover, PCXG2/DNA polyplexes prepared at w/w 5 were also evaluated 
for their ability to inhibit CXCR4-mediated cancer cell invasion. All the PCXG2 polyplexes 
(polymer concentration 2.5 μg/mL) showed effective inhibition of cancer cell invasion that 
was fully comparable to AMD3100 (Figure 6). 
In vitro transfection activity of PCXG2/DNA polyplexes at varying polycation/DNA 
(w/w) ratios was evaluated in U2OS and B16F10 cells both in the presence and absence 
of 10% FBS (Figure 8). PEI/DNA polyplexes at w/w ratio of 1.2 was used as a control.  A 
single DNA dose of 2.35 µg/mL was used in all transfection experiments. The transfection 
activity of PCX/DNA polyplexes in U2OS was almost independent of the type and content 
of cyclam monomer at the lowest tested w/w ratio of 5. There was a marked decrease in 
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serum-free transfection with increased cyclam content at higher w/w ratios because of the 
polymer toxicity. In contrast, no such effect was observed in the presence of 10% serum 
as the transfection increased 7-fold when increasing the cyclam content (PCXG2-2 vs. 
PCXG2-1). Transfection in B16F10 was much less sensitive to PCXG2 toxicity and cyclam 
content, although weak tendency for transfection to increase with increasing cyclam 
content was observed. The type of cyclam monomer had no discernible effect on 
transfection. Overall, transfection of PCXG2 polyplexes was several orders of magnitude 
higher than transfection of PABOL polyplexes and comparable to transfection of PEI 
polyplexes. The low dependence of transfection on cyclam content suggests that using 
PCXG2 with lower cyclam content could be beneficial because of the lower toxicity. 
4.1.8 Cell uptake of PCXG2/DNA polyplexes 
We developed PCXG2 with the goal of combining CXCR4 antagonism with the 
ability to deliver therapeutic nucleic acids. Successful nucleic acid therapies require 
efficient internalization into cells and delivery to the appropriate intracellular organelles. 
Since PCXG2 inhibit internalization of CXCR4 receptor, it was important to determine if the 
PCXG2 antagonism negatively impacts the intracellular uptake of DNA polyplexes, which 
could compromise transfection activity. DNA was labeled with CX-Rhodamine and used 
to prepare PCX/DNA polyplexes. We first measured cell uptake of the fluorescently 
labeled PCXG2/DNA polyplexes in two cancer cell lines (U2OS and B16F10) by using flow 
cytometry (Figure 10). Based on the results, the cell uptake properties of PCXG2/DNA 
polyplexes were highly cell line dependent. In U2OS cells, higher cyclam led to lower 
uptake.  The cellular uptake of PCXG2/DNA polyplexes in U2OS cells was much higher 
than PEI control. PCXG2-1 complex with lower content of cyclam monomer had higher 
fluorescence than PCXG2-2, and PCXG2-3 complex showed a little higher cellular uptake 
than PCXG2-4. However, the opposite behavior was observed in B16F10 cells with lower 
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CXCR4 levels, there was no so much difference between PCXG2 and control PEI. 
Moreover, PCXG2-3 and PCXG2-4 showed a little better cellular uptake than PCX-1 and 
PCX-2 in serum free conditions. The overall cellular uptake of PCXG2 polyplexes was 
several folds higher than that of PABOL polyplexes. Under the consideration that higher 
CXCR4 expression in U2OS cells compared with B16F10 cells, we investigated whether 
CXCR4 receptors was involved in the process of cellular uptake of PCX polyplexes. U2OS 
cells were pretreated with CXCR4 antagonism AMD3100 for 1 h before adding PCXG2 
polyplex (Figure 10c). The relative fluorescence intensity of PCXG2 polyplexes did not 
show decrease in U2OS cells pretreated with AMD3100 in comparison with untreated one, 
suggesting that CXCR4 receptor did not affect the cellular uptake of the CXCR4-inhibiting 
polyplexes. 
4.1.9 Summary 
The above studies described the successful design and development of polymeric 
drugs PCXG2 with a dual function to simultaneously inhibit CXCR4 chemokine receptor 
and deliver genes. Polymerization improved the CXCR4 inhibitory activity of the 
synthesized monocyclam monomers significantly after incorporation into the polymer 
chains. And CXCR4 antagonism of the second generation of PCX was much higher when 
compared with the first generation, confirming the importance of a proper presentation of 
the ligands within synthetic polymers. We first reported that intravenous administration of 
PCXG2 resulted in mobilization of leukocytes from bone marrow into peripheral blood, 
which might work as synthetic polymeric mobilizers for blood stem cells or progenitor cells. 
Furthermore, PCXG2 inhibited cancer cell invasion in either formation of free polymers or 
polyplexes to a level fully comparable with AMD3100. And the gene transfection results 
indicated the ability of PCXG2 to efficiently deliver genes to cancer cells. Therefore, PCXG2 
have the potential to become a new class of polymeric drugs for cancer treatment with a 
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promising dual functionality that synergistically combine CXCR4 antagonism to inhibit 
cancer metastasis with anti-cancer therapeutic effect of the delivered nucleic acids [204].  
Polypelxes have received significant attention as promising gene delivery vectors 
due to multiple potential advantages when compared with viral vectors, including minimal 
immunogenicity, lower toxicity, and easier manufacturing and functional modifications 
[205, 206]. Safety and stability are still the major concerns to apply dual-functional 
polycationic nanoparticles in vivo. Positively charged polyplexes attached to negatively 
charged heparan sulfate proteoglycans on the cell surface to facilitate uptake into cells via 
adsorptive endocytosis [207]. During endocytosis, the decreasing pH confers "proton 
sponge effect", which causes enhanced protonation of polycations, influx of anions and 
high internal osmotic pressure, leading to burst of endosome membrane, escape of 
complexes from endosomes and high transfection efficiency in vitro [208]. However, high 
density of positive charges damages negatively charged cell membranes and contributes 
to cytotoxicity of polyplexes [209]. Positively charged polyplexes are colloidally stabilized 
by electrostatic repulsion and frequently aggregate under physiological salt conditions. 
The positive aggregation was rapidly eliminated from circulation by reticulo-endothelial 
systems (RES) [210-212]. 
In the next part of 4.2, the goal is to improve the in vivo applicability of PCX 
polyplexes by chemical modification. PCXG1 was used as the model cationic polymer. 
Nonionic polymer poly(ethylene glycol) (PEG) was applied to modify PCXG1 to shield the 
surface charges and improve colloidal stability by steric stabilization [213-216]. PEGylation 
typically prolongs circulation by increasing stability of polyplexes in physiological fluid and 
reduces the interaction of polyplexes with extracellular membrane surface to decrease iv 
vivo toxicity [217, 218]. 
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Figure 8. DNA condensation ability of PCXG2. 
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Table 3. Hydrodynamic size and zeta potential of DNA polyplexes 
 
  w/w 5 w/w 10 w/w 15 
Polyplex Size (nm) 
δ potential 
(mV) 
Size (nm) 
δ potential 
(mV) 
Size (nm) 
δ potential 
(mV) 
PABOL 870.9 ± 7.5 -2.3 ± 0.9 796.9 ± 5.9 4.0 ± 0.2 650.1 ± 8.6 6.7 ± 0.1 
PCXG2-1 121.7 ± 2.5 24.4 ± 0.5 90.4 ± 2.0 29.6 ± 0.4 87.1 ± 2.1 30.5 ± 0.7 
PCXG2-2 59.9 ± 1.1 22.0 ± 0.9 56.3 ± 2.6 17.3 ± 0.5 64.9 ± 0.9 20.6 ± 1.0 
PCXG2-3 84.6 ± 2.5 29.9 ± 0.9 70.3 ± 0.1 29.1 ± 0.8 65.1 ± 0.3 27.8 ± 1.5 
PCXG2-4 75.0 ± 0.8 30.5 ± 0.5 65.1 ± 0.4 28.6 ± 1.0 64.0 ± 1.6 25.6 ± 0.3    
PEI (N/P 10)  52.4 ± 5.5 20.8 ± 1.2     
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Figure 9. Transfection activity of PCXG2/DNA polyplexes in U2OS and B16F10 cells. The 
transfections were conducted in the absence and presence of 10% FBS and the results 
are expressed as luciferase expression in RLU/mg protein ± SD (n=3). 
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Figure 10. Cell uptake of PCXG2/DNA polyplexes in (a) U2OS and (b) B16F10 cells. 
Polyplexes were prepared with fluorescently labeled DNA at w/w ratio of 5 and incubated 
with cells in the presence of 10% FBS. Results were shown as mean fluorescence 
intensity (RFI) ± SD (n=3). (c) Effect of AMD3100 on cell uptake of PCXG2-3/DNA 
polyplexes in U2OS cells (n=2). (*P<0.05, **P<0.01, ***P<0.001 and “ns” for P>0.05).  
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4.2 PEGylation of Poly(amido amine) CXCR4 Antagonists to Enhance Safety and 
Colloidal Stability for Gene Therapy in Cancer 
Please note that the data of this part was from the paper published in the 
Pharmaceutical Research [151]. The authors include Dr. Jing Li, Dr. David Oupický and 
me. As the first author, I performed all the experiments, analyzed data and wrote the draft 
of manuscript. Dr. Jing Li and Dr. Oupický helped to revise it and made it publishable. All 
the authors agreed with including their work in this dissertation. 
 
The goal of PEGylation was to improve physical properties and safety of 
polycationic PCXG1. However, it would decrease the transfection activity due to minimizing 
cellular association, cell uptake, endosomal escape, and gene release [219, 220]. To 
optimize the physicochemical characteristics and biological activities, proper PEG content 
should be carefully balanced. In the following studies, how the presence of PEG affects 
colloidal stability, safety, CXCR4 antagonism, inhibition of cancer cell invasion, and 
transfection activity of the polymers and their polyplexes would be evaluated. We would 
develop proper polyplex formulations that retain CXCR4 antagonism of PCXG1, while 
exhibiting enhanced colloidal stability, decreased cytotoxicity, but improved transfection 
activity under physiologic conditions (Scheme 4).  
4.2.1 Synthesis and characterization of PEG-PCXG1  
PCXG1 was synthesized in the form of a poly(amido amine) by Michael polyadditon 
of secondary amines present in AMD3100 with bisacrylamide monomer HMBA (Figure 
11). Plerixafor functions as a hexafunctional monomer in the Michael polyaddition and 
leads to insoluble crosslinked PCXG1 at high temperature and high monomer 
concentrations [221, 222]. A more gentle condition resulted in a soluble PCXG1 with 
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weight-average molecular weight (Mw) of 10.6 kDa and unimodal distribution of molecular 
weights (Figure 12). Owing to excess and high reactive secondary amines in the 
AMD3100 structure, PEG chain could be introduced into the polymer by the reaction of 
mPEG-acrylamide with the secondary amines of PCXG1 (Figure 11). In contrast to 
common amide coupling, using Michael addition for the PEGylation allowed us to 
conserve the overall number of protonizable amines in PCXG1. Three copolymers with 
increasing content of PEG were synthesized and named according to their PEG content 
as described in Table 4. The copolymers were isolated by precipitation in diethyl ether 
and collected as hydrochloride salts after extensive dialysis. The content of PEG in the 
copolymers was calculated from 1H-NMR integral intensity of the PEG methylene protons 
at 3.7 ppm and aromatic protons of AMD3100 at 7.4-7.8 ppm (Figure 13). As shown in 
Table 4, a slight higher content of PEG was gained in comparison with original feed 
composition, which could be explained by the preferential removal of lower molecular 
weight polymer fraction by precipitation process in organic solvent and removal of the low 
molecular weight polymer fractions rich in PCXG1 during dialysis. The successful synthesis 
of PEGylated polymer and absence of unreacted mPEG-acrylamide can also reflect from 
GPC trace (Figure 13) of starting material PEG-acrylamide and those polymers. The 
PEGylated polymers with higher PEG composition showed earlier elution time, suggesting 
higher molecular weight. The polydispersity index (PDI) of the polymers ranged from 1.1 
to 1.4, suggesting a good control of the polymerization. Therefore, the direct PEG 
modification of PCXG1 with a range of conformed substitution was developed, and the 
effects of PEGylation on PCXG1 in respect to DNA condensation, polyplexes stability, 
toxicity, transfection as well as CXCR4 antagonism would be studied comprehensively. 
  
91 
 
 
Scheme 4. Mechanism of dual-function PEG-PCXG1 as gene delivery vector and CXCR4 
antagonist inhibiting cancer cell invasion. 
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Figure 11. Synthesis of PCXG1 and PEG-PCXG1. 
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Table 4. PEG content in PEG-PCXG1 determined by 1H-NMR. 
Polymer 
PEG content (wt %) 
in feed 
in 
copolymer 
PCXG1 0 0 
PEG12-PCXG1 10 12 
PEG41-PCXG1 35 41 
PEG52-PCXG1 50 52 
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Figure 12. Gel permeation chromatograms of PCXG1 and PEG-PCXG1. 
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Figure 13. Typical 1H-NMR spectrum of PEG-PCXG1 (PEG12-PCXG1 in D2O) used in the 
determination of the PEG content (a – aromatic phenylene protons of AMD3100, b – 
methylene protons of PEG).  
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4.2.2 Preparation and characterization of PEG- PCXG1 polyplexes 
The effect of PEGylation on DNA condensation ability of PCXG1 was investigated 
by EtBr exclusion assay as shown in Figure 14. All the PEG-PCXG1 exhibited similar 
condensation curves with a typical sigmoidal shape and were able to condense plasmid 
DNA to the same extent as PCXG1 as indicated by the same residual fluorescence at the 
highest polymer/DNA ratios. With increasing PEG content, the DNA condensation curves 
shifted to higher w/w ratios. However, if we only considered the polycation part and 
transformed PEG-PCXG1 into equivalent content of PCXG1, the DNA condensation curves 
almost overlaid, suggesting that DNA binding properties of PCXG1 part in the copolymer 
are not affected by the presence of PEG chain. A similar finding was recently reported by 
Fitzsimmons and Uludağ [223].  
One of the key motivations for PEGylation is to shield the positive surface charge 
of polyplexes by neutral PEG chains. The influence of PEGylation on polyplex surface 
charge was investigated. Our results confirmed that the use of PEG-PCXG1 significantly 
decreases surface charge of the polyplexes as documented by the decrease in the 
measured zeta potential (Figure 15). The PEGylated polyplexes showed almost neutral 
surface charge (3.3-5 mV) in 10 mM HEPES buffer, pH 7.4. However, unPEGylated 
PCXG1/DNA showed zeta potential of + 20 mV. PEGylation significantly reduced polyplex 
surface charge, which is consistent with other researches on influence of PEGylated 
polyplexes [224-226].  
The positive surface charge provides electrostatic stabilization to the polyplex 
nanoparticles at low concentration buffers. However, physiological ionic conditions would 
cause aggregation and destabilization of polyplexes by non-specific interactions [227, 
228]. Steric stabilization by PEG can typically overcome the problem of low colloidal 
stability of polyplexes [229]. We have prepared PEG-PCXG1 and PCXG1 polyplexes in 10 
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mM HEPES buffer (pH 7.4) at polymer/DNA (w/w) ratio of 5 and measured their 
hydrodynamic diameter. Then polyplexes were incubated in phosphate-buffered saline 
(PBS) (pH 7.4) to mimic the physiologic ionic conditions and observed changes in polyplex 
size during the following period of 12 h were monitored by DLS (Figure 16). The results 
showed that PCXG1 polyplexes displayed an immediate aggregation after PBS addition as 
documented by the increase of their size from ~60 nm to ~430 nm in the span of only 15 
min. The size of PCXG1 polyplexes increased to nearly 1 µm within 1 h of PBS addition. In 
contrast, polyplexes prepared with PEG-PCXG1 exhibited markedly improved colloidal 
stability. Polyplex containing 12% PEG showed an improved stability up to 1 h in PBS, but 
it was ineffective in long-term evaluation as documented by the increase in size from 58 
nm to 690 nm within 12 h of PBS addition. In contrast, polyplexes containing 41% and 52% 
PEG totally prevented aggregation up to 12 h with stable size lower than 200 nm. 
Modification with PEG chain is an efficient method to stabilize particles against 
physiological salts. PEG chains formed a hydrophilic corona surrounding the particle core 
and protected them from aggregation through electrostatic interaction between polyplexes 
and physiological ionic components [225, 230].  
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Figure 14. DNA condensation ability of PCXG1 and PEG-PCXG1 determined by ethidium 
bromide exclusion assay.  
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Figure 15. Zeta potential of DNA polyplexes prepared at polymer/DNA (w/w) ratio of 5 
and measured in 10 mM HEPES (pH 7.4) (mean ± SD, n = 3). 
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Figure 16. Effect of PEG on colloidal stability of PCXG1 polyplexes (w/w 5) in phosphate-
buffered saline (PBS). Results are shown as mean ± SD (n=3). 
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4.2.3 Cytotoxicity of PEG-PCXG1 
Usually, cationic polymers display cytotoxicity by disturbing cell membrane such 
as high density of positive charge mediated membrane damage and phospholipids 
reshuffling [209]. PEGylation could produce a hydrophilic shell on the particle surface to 
efficiently decrease the charge density and block intermolecular interaction, avoiding 
extracellular mechanism of cytotoxicity. Cytotoxicity of PEGylated polymers and control 
PEI was evaluated by MTS assay in HepG2 and U2OS cells (Figure 17). HepG cells are 
widely used for prediction of liver toxicity [199]. The PEGylated polymers showed lower 
toxicity than the unPEGylated polymer as expected [219, 231, 232]. Importantly, similar 
trend was observed also when only the polycation part of the copolymers was considered 
in calculating IC50. The measured IC50 value for PCXG1 was 72 µg/mL. The IC50 values of 
PEG-PCXG1 were calculated considering only the PCXG1 polycation content. In such case, 
the cytotoxicity of PEG12-PCXG1 was similar to that of PCXG1 (77 µg/mL). The two 
copolymers with higher PEG content exhibited significantly decreased cytotoxicity with 
their IC50 values above the maximum tested polycation concentration of 100 µg/mL. In 
order to establish a safe, nontoxic working concentration range of PCXG1, we tested U2OS 
cells which were then used throughout this study in evaluating CXCR4 antagonism, cell 
invasion inhibition, and transfection of PCXG1. IC50 values for PCXG1 and PEG12-PCXG1 
were indistinguishable at ~17 µg/mL but they increased to 25 µg/mL and 41 µg/mL in case 
of PEG41-PCXG1 and PEG52-PCXG1 respectively, which were all higher than control PEI 
(22.0 µg/mL). In conclusion, the cell viability study proved that PEGylation effectively 
decreased the cytotoxicity profile of polycations not only by simply reducing the cationic 
content in polymers but also by decreasing the interactions of the toxic part with cellular 
membranes and vital intracellular proteins, which are unlike existing reports [223, 232].  
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Figure 17. Effect of PEG on cytotoxicity of PCXG1 in HepG2 and U2OS cells. Cell viability 
was measured by MTS assay after 24 h incubation with increasing concentrations of 
polymers. Polymer concentration for PEG-PCXG1 copolymers is expressed as PCXG1 
concentration only (i.e., excluding PEG). Results are expressed as mean ± SD (n=3). 
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4.2.4 CXCR4 antagonism of PEG-PCXG1 
Binding of PCXG1 to CXCR4 receptor is required for the copolymers to exhibit 
CXCR4 inhibitory activity. However, steric barrier created by PEGylation might cause the 
negative effect on binding of polymers to receptors. Therefore, CXCR4 redistribution 
assay was used to evaluate the influence of PEGylation on CXCR4 antagonism of PCXG1 
polymer and PCXG1/DNA polyplexes. This assay is based on monitoring the degree of 
inhibition of SDF-1 triggered endocytosis of membrane-localized EGFP-tagged CXCR4 
receptor using HCS analysis. Figure 18a showed the difference in the fluorescence 
pattern of EGFP-CXCR4 between untreated cells (punctate fluorescence) and cells 
treated with CXCR4 inhibitor (diffuse pattern of fluorescence). The CXCR4 inhibitory 
activity of PEG-PCXG1 was tested at equal concentrations of the polycationic (PCXG1) 
content and expressed as % CXCR4 antagonism relative to the control AMD3100 (Figure 
18b). The CXCR4 antagonism of PEG-PCXG1 at the lowest tested concentration (0.05 
µg/mL) ranged from 57-77% of AMD3100 activity, which had no statistically significant in 
a one-way ANOVA analysis in comparison with PCXG1. At two higher tested 
concentrations of 0.15 μg/mL and 0.5 μg/mL, all PEG-PCXG1 and PCXG1 exhibited 
comparable CXCR4 inhibitory activity to the control AMD3100, indicating that PEG did not 
affect the binding properties of polymers with CXCR4 receptors. We also tested whether 
PEG-PCXG1 polyplexes prepared at two different w/w ratios (1.5 and 5) retained the 
CXCR4 inhibitory functionality of the free polymers under practically relevant experimental 
conditions employed in transfection assays (Figure 18c). Both polyplex formulations 
achieved nearly 100% CXCR4 inhibition According to the EtBr exclusion assay, polymers 
were just used to fully condense DNA and little amount of free polymers were present in 
polyplexes at w/w of 1.5, indicating the ability of polyplexes to inhibit CXCR4. At w/w of 5, 
the observed CXCR4 antagonism came from the free polymer in the formulation. The 
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cyclam ring of AMD3100 was totally 2+ charged at physiological pH and formed a stable 
trans-III R,R,S,S-type conformation regarding to the four nitrogen atoms, which permitted 
AMD3100 to bind tightly with CXCR4 receptor by hydrogen bond interactions with 
carboxylic acid group [233]. PEGylation does not negatively affect pharmacologic activity 
of PCXG1 to fully inhibit CXCR4 even in polyplex formulations. The possible reason might 
be that PEG chain did not decrease the overall charge profiles of cyclam rings and 
maintained their binding ability with Asp262, Glu318 or Asp 171 to fit into the main ligand-
binding pocket of CXCR4 receptors [234]. 
4.2.5 Inhibition of cancer cell invasion by PEG-PCXG1 
As we know, CXCR4/SDF-1 axis plays a significant role in regulation of stem cell 
trafficking, neovascularization as well as cancer migration [235-241]. However, CXCR4 
antagonists like AMD3100 can inhibit invasion of those cancer cells towards SDF-1 
concentration gradient. In this study, Boyden chamber method was used to evaluate the 
effect of PEGylation on the ability of PCXG1 polyplexes to inhibit invasion of cancer cells. 
As shown in Figure 19, all PEG-PCXG1 polyplexes prepared at equivalent PCXG1/DNA 
w/w ratio 5 effectively prevented 77.1-79.8% cancer cells from invading and migrating 
through Matrigel, which was comparable to that of AMD3100 (81.3%). Therefore, the 
ability of PCXG1 polyplexes to inhibit cancer cell invasion was not negatively impacted by 
PEGylation, suggesting that PEG-PCXG1 could be well-suited for applications in the 
treatment that aim at preventing or delaying metastasis. To apply the PEG-PCXG1 for gene 
therapy, the gene transfection efficiency would be tested and formulation studied would 
be discussed. 
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Figure 18. CXCR4 antagonism of PEG-PCXG1 polycations and polyplexes. (a) Effect of 
AMD3100 on redistribution of EGFP-CXCR4 receptor in U2OS cells. CXCR4 antagonism 
of PCXG1 and PEG-PCXG1 (b) and their polyplexes (c). The results are shown as mean % 
CXCR4 inhibition relative to AMD3100 ± SD (n=3). 
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Figure 19. Inhibition of cancer cell invasion by PEG-PCXG1 polyplexes. Polyplexes were 
prepared at w/w ratio of 5 (total PCXG1 concentration 2.5 µg/mL). Cells were allowed to 
invade through a layer of Matrigel toward SDF-1 concentration gradient for 19 h before 
fixation and imaging. Average numbers of invaded cells were counted in randomly 
selected 5-10 imaging areas at 20x magnification (Scale bar = 200 µm). 
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4.2.6 Transfection activity of PEG-PCXG1 polyplexes  
To study the effect of PEGylation on gene transfection activity, B16F10 and U2OS 
cell lines were incubated for 4 h with PEG-PCXG1 polyplexes formed with luciferase 
reporter plasmid in the absence or presence of 10% of FBS and continuously cultured in 
fresh medium for another 24 h (Figure 20). PCXG1 and PEG12-PCXG1 polyplexes 
displayed fully comparable transfection efficiency, however, the transfection decreased 
dramatically for polyplexes containing higher amount of PEG in either absence or 
presence of FBS. The possible reasons of reduced gene transfection of PEGylated 
polyplexes are that decreasing surface charge decreased cellular association and 
internalization, leading to a low transfection activity [219, 230]. DNA unpackaging from 
PEGylated polyplexes decreased, which might be another reason for poor luciferase 
expression. Unmodified polyplexes may escape more easily from endosome because 
aggregated particles filled intracellular vesicles and distort the membrane, however, the 
vesicles with PEGylated particles had more smooth appearance and would restrict the 
endosome escape [230]. In conclusion, the effect of PEGylation on transfection activity of 
polyplexes are due to restricted interaction with cellular membranes, resulting in 
decreased cellular uptake and compromised endosomal escape of polyplexes [219, 229].  
4.2.7 Mixture formulation of PCXG1 and PEG-PCXG1 
With the increasing content of PEG in the polyplexes, the colloidal stability 
enhanced but transfection activity reduced correspondingly. As discussed above, several 
strategies have been developed to overcome the negative effect of PEGylation on 
transfection activity. In an attempt to solve the problems and easily control the amount of 
PEG, we have utilized a mixed polyplex strategy to prepare polyplexes with acceptable 
colloidal stability, near-neutral zeta potential, and high transfection activity. The mixed 
polyplex strategy depends on using a mixture of non-PEGylated and PEGylated 
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polycations. The mechanism is that the non-PEGylated polycation provides effective DNA 
condensation and facilitates endosomal escape of the polyplexes, while the PEGylated 
polycation equips the polyplexes with favorable surface properties and colloidal stability. 
This strategy has been successfully utilized with several different types of polycations 
[242-244]. We optimized PEG/polycation amounts by mixing PCXG1 and its PEGylated 
counterpart PEG52-PCXG1 to obtain largest range of PEG composition (Figure 21).  
As shown in Figure 21a, with increasing PEG content, the DNA condensation 
curves of the mixed formulations shifted to higher w/w ratios. However, the condensation 
efficiency of PCXG1 part in the formulation was not affected because the curves overlaid 
when re-plotted as relative fluorescence vs. PCXG1/DNA ratio (not shown).  Using a 
mixture consisting of 80% PCXG1 and 20% PEG52-PCXG1 leads to positively charged 
polyplexes and rapid increase in size and aggregation in PBS (Figure 21b). However, 
increasing the content of PEG52-PCXG1 in the mixture to 40 and 70% resulted in 
decreased zeta potential and formulation of colloidally stable polyplexes.  
In order to investigate the influence of mixture formulation on gene transfection, 
we tested the polyplexes above in both U2OS and B16F10 cells in the absence or 
presence of 10% FBS (Figure 21c). The transfection results showed that even polyplexes 
formed with 70% PEG52-PCXG1 retained transfection activity that was similar to that of 
non-PEGylated PCXG1 polyplexe, confirming that the mixed polyplex strategy is a suitable 
approach to prepare polyplexes with low surface charge, good colloidal stability as well as 
high transfection activity. 
CXCR4 antagonism and the ability to inhibit cancer cell invasion are required for 
the mixed polyplexes. We also confirmed them in the CXCR4+ U2OS cells as displayed 
in Figure 22 and 23. All of the mixed polymers and polyplexes exhibited comparable 
CXCR4 inhibitory activity at all tested concentrations and w/w ratios. Similarly, mixed 
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formulation retained the ability to prevent cancer cell invasion, which was fully comparable 
with AMD3100. Those results indicated that mixed PCXG1 and PEG52-PCXG1 can be well-
suited for applications in treatment that aim at combining gene therapy with preventing 
cancer metastasis.  
4.2.8 DNA biodistribution in vivo 
The ability of mixed PCXG1 and PEG-PCXG1 to deliver intact DNA in vivo was 
detected in 4T1 mice model. Linear PEI was used as positive control. Before the 
experiment, the size and zeta potential of DNA polyplexes prepared in HBG buffer were 
investigated. As shown in Figure 24, using a mixture consisting of 60% PCXG1 and 40% 
PEG52-PCXG1 leads to the smallest size with near-neutral zeta potential. This formulation 
was administrated in 4T1 mice and RT-PCR was used to study the biodistribution of intact 
DNA delivered to different organs. Figure 25 revealed that the large amount of DNA was 
delivered to liver and spleen, which caused the sever off-target effect. However, in 
comparison with positive control PEI, PCXG1 and the mixed PEGylated formulation 
reduced the off-target effect as well as improved the ability to deliver DNA to tumors with 
5.8-fold and 10.8-fold increase, respectively. Therefore, mixed PCXG1 and PEG52-PCXG1 
would be a good option to target tumors and deliver nucleic acid for gene therapy. 
4.2.9 Conclusion 
To conclude, polymeric CXCR4 antagonism is a potential dual-fucntion vector, 
which are capable to inhibit cancer cell invasion and deliver efficient gene transfection. In 
order to perform colloidal stability, retain CXCR4 antagonism and exhibit high transfection 
activity, combination of PEGylation of PCXG1 with using a mixed polyplex approach is a 
viable strategy. The ability of PCXG1 to deliver DNA has been comprehensively studied, 
however, the siRNA delivery by the dual-funtional PCX still need to be further investigated.  
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Figure 20. Transfection activity of PEG-PCXG1 polyplexes in B16F10 and U2OS cells. 
Polyplexes were prepared at PCXG1/DNA (w/w) ratio 10 in B16F10 transfections and 5 in 
U2OS transfections. Results are expressed as luciferase expression in RLU/mg protein ± 
SD (n=3). 
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Figure 21. Properties of mixed PCXG1/PEG-PCXG1 polyplexes. (a) DNA condensation 
ability of the PCXG1/PEG-PCXG1 mixture determined by ethidium bromide exclusion assay. 
(b) Colloidal stability (left) and zeta potential (right) of polyplexes (w/w 5) prepared with 
increasing content of PEG52-PCXG1 in a mixture with PCXG1. (c) Transfection activity of 
the mixed polyplexes.  
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Figure 22. CXCR4 antagonism of mixed PCXG1/PEG-PCXG1 polymer and polyplexes in 
U2OS cells. The results are shown as mean % CXCR4 inhibition relative to AMD3100 ± 
SD (n=3). 
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Figure 23. Inhibition of cancer cell invasion by mixed PCXG1/PEG-PCXG1 polyplexes. 
Polyplexes were prepared at equivalent PCXG1/DNA w/w ratio of 5 (total equivalent PCXG1 
concentration 2.5 µg/mL). Cells were allowed to invade through a layer of Matrigel toward 
SDF-1 concentration gradient for 19 h before fixation and imaging. Average numbers of 
invaded cells were counted in randomly selected 5-10 imaging areas at 20x magnification 
(Scale bar = 200 µm).  
Untreated AMD3100 0%PEG52-PCXG1
20%PEG52-PCXG1 40%PEG52-PCXG1 70%PEG52-PCXG1
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Figure 24. Size (left) and zeta potential (right) of mixed PCXG1/PEG-PCXG1 polyplexes at 
equivalent PCXG1/DNA w/w 3 in HBG buffer. Results are shown as mean ± SD (n=3). 
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Figure 25. DNA biodistribution by polyplexes in BALB/c mice. Results are expressed as 
luciferase DNA ng/g tissue ± SD (duplicate of two mice). Statistical comparisons were 
done using the One-way ANOVA with Tukey-Kramer Multiple Comparisons Test (*P<0.05 
and **P<0.01). 
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4.3 Cholesterol Modification of Poly(amido amine) CXCR4 Antagonists to Improve 
siRNA Delivery for Combined Anticancer Therapies 
Please note that the data of this part was from the paper published in the 
Biomaterials Science with permission from The Royal Society of Chemistry [152]. The 
authors include Dr. Jing Li, Yi Chen and Dr. David Oupický and me. As the first author, I 
performed all the experiments, analyzed data and wrote the draft of manuscript. Dr. Jing 
Li and Dr. Oupický revised it and made it publishable. All the authors agreed with including 
their work in this dissertation.  
 
Therapy with nucleic acids has potential in a broad range of disease. For 
instance, small interfering RNA (siRNA) was capable to achieve sequence-specific 
gene silencing effect in mammalian cells, and emerging as one of the most potential 
agents for the treatment of various diseases, such as viral infections, gene 
disorders as well as cancers [245-247]. Polyelectrolyte complexes of nucleic acids 
with polycations have been under development as delivery vectors for over two 
decades and received significant attention for multiple potential advantages, 
including lower toxicity, minimal immunogenicity, easier manufacturing and 
functional modifications [205, 206]. However, low bioavailability of siRNA has 
hampered its therapeutic application in clinical. Enzymatic degradation, 
accumulation in non-targeted tissues, insufficient cellular uptake, 
endosomal/lysosomal escape, and dissociation of siRNA from gene carriers must 
be circumvented when developing safe and efficient siRNA delivery vectors [248-
250]. 
In comparison with lipid based delivery methods, the use of siRNA polyplexes 
remains hindered by a relatively low efficacy [249, 250]. And polyplex formulations 
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optimized for delivery of large DNA often perform poorly when delivering siRNA [251]. 
Many efforts have been made to develop various types of siRNA-loaded 
nanoparticles to overcome biological hurdles of siRNA delivery in recent years [252, 
253]. Modification of polycations with hydrophobic moieties (e.g., cholesterol) have been 
among the most successful approaches [254, 255]. Cholesterol is a naturally occurring 
lipid and metabolized in the body. It also plays an important role in self-assembly of 
lipopolymer into miclelles or nanoparticles in biological environment, reducing 
cytotoxicity and facilitating endocytosis [256-258].  For example, water-soluble 
lipopolymers based on polyethylenimine and cholesterol exhibited high serum 
compatibility, enhanced cellular uptake, and  better gene delivery than 
commercially available PEI, which were due to favourable interactions between 
cholesterol moiety and cell membrane [259]. In another example, a series of bio-
reducible cholesterol-grafted poly(amidoamines) were synthesized and able to self-
assemble into cationic nanoparticles in aqueous solution, which possessed high 
cell uptake, offered effective VEGF gene silencing in vitro as well as exhibited 
effective inhibition of tumor growth in vivo [260].  
In this section of study, we focus on further development of PCXG1 as siRNA 
delivery vectors to achieve combined antimetastatic and antitumor effect by inhibiting 
CXCR4 activity. Based on available evidence, we proposed that modification of PCXG1 
with cholesterol will improve overall stability and improve cell uptake and intracellular 
trafficking of siRNA polyplexes. We would synthesize a series of copolymers with different 
cholesterol grafting degress. The influence of cholesterol modification on siRNA 
complexation, colloidal and enzymatic stability of polyplexes, and the ability to inhibit 
CXCR4 and deliver anticancer siRNA against PLK1 will be investigated (Scheme 5). 
4.3.1. Synthesis and characterization of Chol-PCXG1 
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The synthesized PCXG1 was described before by Michael-type polyaddition of 
sencondary amines present in AMD3100 and acryloyl group of bisacrylamide HMBA at 
equal molar ratio. AMD3100 functions as a hexafunctional monomers and HMBA reacted 
randomly with one of the six amines, resulting in a branched water-soluble polymer when 
the reaction was performed at relatively low temperature and monomer conentrations [221, 
222]. The weight-average molecular weight of PCXG1 was 13.9 kg/mol with a 
polydispersity of 1.9 as determined by gel permeation chromatography. As shown in 
Figure 26, the Chol-PCXG1 copolymers were synthesized by amidation reaction between 
the cholesteryl chloroformate and the remaining secondary amines in PCXG1.  The content 
of cholesterol moiety in the copolymers could be tuned by changing the feed ratio of 
cholesteryl chloroformate to PCXG1 in the reaction. Three copolymers with increasing 
content of cholesterol were synthesized and named according to their cholesterol content 
(Table 5). The content of cholesterol in the copolymers was determined from 1H-NMR 
integral intensity of the methyl group b directly linked to the cyclic hydrocarbon at chemical 
shift of 0.65 ppm in cholesterol and aromatic protons a of AMD3100 at 7.1-7.5 ppm (Figure 
27). The weight-average molecular weight of each synthesized Chol-PCXG1 was 
calculated based on the Mw of PCXG1 and the cholesterol grafting degree as estimated by 
1H-NMR.  
4.3.2 Critical Micelle Concentration of Chol-PCXG1 
Hydrophobic cholesterol moieties were linked to the hydrophilic PCXG1, which 
made copolymers amphiphilic and be possible to self-assemble into micelles in aqueous 
media. This potential self-assembly into micelles could change the nature and dynamic of 
the complexation with siRNA, which depended on whether the copolymers bind the nucleic 
acid as a unimer or as assembled micelles.  Fluorescence spectroscopy was used to 
estimate the CMC values of these copolymers in distilled water with pyrene as a 
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hydrophobic fluorescent probe [179, 260-262]. Above CMC (in the presence of micelles), 
pyrene could be incorporated into the hydrophobic core in the micelles, leading to the 
increase in the ratio of two fluorescence intensity peaks (I3/I1). CMC of each Chol-PCXG1 
could be determined by plotting the ratio of I3/I1 against the polymer concentration. The 
CMC values decreased from 63.1 µg/mL for Chol17-PCXG1 to 89.1 µg/mL for Chol25-
PCXG1 (Figure 28), indicating that the increasing cholesterol modification could reduce 
CMC values of those copolymers.  
120 
 
 
Scheme 5. Proposed mechanism of action of the dual-function Chol-PCXG1 as polymeric 
CXCR4 antagonists and siRNA (PLK1) delivery vectors.  
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Figure 26. Synthesis of Chol-PCXG1.  
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Figure 27 Typical 1H-NMR spectrum of Chol-PCXG1 used in the determination of the 
cholesterol content (spectrum of Chol25-PCXG1 in DMSO shown). 
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Table 5. Characterization of Chol-PCXG1 copolymers. 
 
Polymer 
Cholesterol content (wt %) Mw 
(kg/mol) In Feed In copolymera  
PCXG1 0 0   13.9b 
Chol17-PCXG1 15 17 16.7c 
Chol25-PCXG1 25 25 18.5c 
Chol34-PCXG1 36 34 21.1c 
a From 1H-NMR. 
b From GPC. 
c Calculated from the Mw of PCXG1 and cholesterol content.  
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Figure 28. Critical micelle concentration (CMC) of Chol-PCXG1 determined by 
fluorescence spectroscopy. CMC was determined as the concentration at the inflection 
point of the curve where I3/I1 was plotted against Chol-PCXG1 concentration (n=3).  
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4.3.3 Preparation and characterization of Chol-PCXG1/siRNA polyplexes 
Agarose gel electrophoresis assay was used to investigate the influence of 
cholesterol grafting on the ability of PCXG1 to complex siRNA into polyplexes (Figure 29a). 
The complete retardation of siRNA mobility was achieved for all complexes at equivalent 
PCXG1/siRNA w/w ratio of 1. The siRNA binding ability of the parent PCXG1was slightly 
better than that of cholesterol modified copolymers as shown by the minimum siRNA 
releasing from complexes at w/w ratio 0.5. The better complexation ability of PCXG1 is 
likely due to that cholesterol conjugation caused a decreased number of protonated 
amines in Chol-PCXG1. The w/w ratios in this study were expressed as equivalent 
PCXG1/siRNA ratios, not taking cholesterol content into account. In all of the following 
studies, all siRNA polyplexes were prepared above w/w of 1 to maintain complete siRNA 
complexation.  
  The hydrodynamic size and zeta potential of Chol-PCXG1/siRNA polyplexes 
prepared in 10 mM HEPES buffer (pH 7.4) at various equivalent PCXG1/siRNA w/w ratios 
were measured by dynamic light scattering (Figure 29b). The polyplexes were stabilized 
for 20 min at room temperature before measurement. Except for Chol34-PCXG1/siRNA 
prepared at lower w/w ratios, all the other polyplexes displayed small particle size ranging 
from 56 to 121 nm. All the Chol-PCXG1/siRNA polyplexes prepared at higher w/w ratios 
showed significantly smaller sizes than polyplexes prepared at lower w/w ratios, perhaps 
suggesting tighter binding. At w/w ratios above 2, Chol17-PCXG1 with the lowest 
cholesterol content exhibited the smallest sizes compared with other Chol-PCXG1/siRNA 
polyplexes, which is possibly due to that the proper content of cholesterol in copolymers 
allowed tighter hydrophobic interaction between cholesterol molecules. All Chol-
PCXG1/siRNA polyplexes exhibited positive surface charge indicated by zeta potentials 
ranging from 18 to 31 mV. 
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Figure 29. siRNA complexation and physicochemical characterization of siRNA 
polyplexes. (a) siRNA binding ability of the Chol-PCXG1 copolymers. (b) Hydrodynamic 
size and zeta potential of Chol-PCXG1/siRNA polyplexes at various w/w ratios (equivalent 
PCXG1/siRNA). Results are shown as mean ± SD of three measurements. 
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4.3.4 Colloidal and enzymatic stability of Chol-PCXG1/siRNA polyplexes 
For simulating physiologic conditions, the Chol-PCXG1/siRNA polyplexes were 
analysed for their colloidal and enzymatic stability, which are important prerequisites for 
successful application. In low concentration buffers (e.g., 10 mM HEPES, pH 7.4), 
PCXG1/siRNA polyplexes retained stable size like other polycation/siRNA polyplexes. 
However, addition of salts to reach physiologically relevant levels, polyplexes would 
aggregate into large molecules (Figure 29b vs. 30). Aggregation of polyplexes depends 
on various parameters, including the chemical structure, molar mass and hydrophobicity 
of the used polycations [263]. We prepared Chol-PCXG1/siRNA polyplexes at two different 
equivalent w/w ratios (2 and 5) and incubated them in PBS. And the changes in polyplex 
size during the following period of 12 h incubation were monitored by DLS (Figure 30). At 
w/w ratio of 2, all the Chol-PCXG1/siRNA polyplexes aggregated and reached sizes 
ranging from ~690 nm to ~2 µm within 15 min of incubation in PBS. siRNA polyplexes with 
higher cholesterol content (Chol25-PCXG1 and 34) showed significantly faster rate of 
aggregation than that of Chol-PCXG1 with low (Chol17-PCXG1) or no (PCXG1) cholesterol. 
However, all of the siRNA polyplexes prepared with Chol-PCXG1 copolymers at w/w ratio 
5 exhibited markedly improved colloidal stability with nearly constant size (< 150 nm) 
displayed for the duration of the experiment (12 h). In contrast, siRNA polyplexes prepared 
with the parent PCXG1 showed similar aggregation behavior as polyplexes prepared at 
w/w ratio of 2 and rapidly formed large aggregates. This similar findings were also reported 
in DNA polyplexes where increasing the amount of cholesterol resulted in polyplexes with 
enhanced colloidal stability [264]. For the reasons of maintaining good colloidal stability at 
w/w 5, we propose that as the surface positive charge of polyplexes is reduced at 
physiological salt concentrations, more Chol-PCXG1 can bind to the particle surface via 
hydrophobic interactions and increase colloidal stability by forming an additional shell of a 
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polycation. Moreover, even the Chol-PCXG1 concentrations were below their CMC in all of 
the above experiments.  The concentration of the local copolymer within each polyplex 
particle was possibly significantly higher than CMC, which provided another contribution 
to improve the stability.  
Enzymatic degradation is one of the main factors, which hampered effective siRNA 
delivery in vivo. Therefore, we evaluated the stability of those Chol-PCXG1/siRNA 
polyplexes against RNase I degradatin. siRNA polyplexes were formed at at various 
equivalent w/w ratios ranging from 1 to 5, and followed by the incubation  with 0.5 U RNase 
I for 30 min. In order to evaluate siRNA integrity, the samples were incubated with 200 
µg/mL of heparin for another 30 min to dissociate polyplexes. Gel electrophoresis was 
used to examine the siRNA integrity and the intensity of each band was quantified and 
normalized to free siRNA.  As shown in Figure 31, naked siRNA was not stable and 
completely degraded after half hour in the presence of RNase I. All the polymers, including 
parent PCXG1, were able to provide protection of the siRNA against RNase I. PCXG1 with 
lower cholesterol modification (Chol17-PCXG1 and 25) displayed improved ability to 
protect siRNA when compared with the parent PCXG1 at the same equivalent w/w ratio, 
which might be due to the proper hydrophobic interaction of cholesterol molecules. Similar 
to PCXG1, Chol17-PCXG1 and Chol25-PCXG1 also exhibited improved resistance to RNase 
I with increasing w/w ratios, indicating important role of excess polycations in properties 
of polyplexes. At w/w of 4, Chol25-PCXG1/siRNA polyplexes prepared demonstrated the 
best protection against RNase I degradation with ~80% siRNA remaining intact after 
exposure. However, Chol34-PCXG1 with the highest cholesterol content remained only 50% 
siRNA intact when the polyplexes were prepared at w/w 1.5 and displayed decreasing 
ability to protect siRNA above w/w 2, indicating that proper content of cholesterol were 
needed to take into consideration.  
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Figure 30 Colloidal stability of Chol-PCXG1/siRNA polyplexes in PBS up to 12 h. Results 
are shown as mean ± SD of three measurements. 
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Figure 31. Stability of Chol-PCXG1/siRNA polyplexes against RNase I. Polyplexes 
prepared at various w/w were exposed to RNase I, followed by incubation with heparin to 
release the siRNA for agarose gel electrophoresis. siRNA band intensity was quantified 
to calculate % siRNA remaining compared with untreated free siRNA. 
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4.3.5 Cytotoxicity of Chol-PCXG1 
Cytotoxicity is a major concern for application of polycations in clinical. Several key 
factors relate with cytotoxicity of polycation-based gene delivery systems, such as molar 
mass of the polycations, polymer structure, charge density and biodegradability [265-267]. 
The influence of hydrophobic modification on polycations has been reported with both 
positive and negative effects [255]. For instance, some hydrophobic moieties are common 
endogenous physiological molecules, so that the conjugated polycation should be non-
cytotoxic. However, in some cases, high content of hydrophobic chains could cause cell 
membrane disruption and result in cell death [268]. Thus it was important to evaluate how 
cholesterol affects toxicity of PCXG1 to avoid or minimize any undesired toxic side effects. 
Cytotoxicity of Chol-PCXG1 was investigated in human osteosarcoma U2OS cell line by 
MTS assay (Figure 32). U2OS cells would be used to determine the safe dosing window 
to study the biological activity of the Chol-PCXG1/siRNA polyplexes. The cute 24 h toxicity 
of those polymers was assessed, which could be mostly attributed by the polycation 
character of the polymers. In order to directly evaluate the effect of cholesterol modification 
on the toxicity of the polycation, Chol-PCXG1 concentrations were expressed as PCXG1 
concentration only and the IC50 values were calculated based on the PCXG1 content. The 
benchmark 25 kDa branched PEI was used here as a control with IC50 of 4.2 µg/mL. Parent 
PCXG1 showed IC50 12.8 µg/mL, which was significantly higher than PEI control. Chol-
PCXG1 was slightly more toxic than PCXG1 with IC50 10.3 µg/mL. However, for the 
polycations with higher content of cholesterol (Chol25-PCXG1 and Chol34-PCXG1), the IC50 
values increased to 16.7 µg/mL and 33.4 µg/mL, respectively. The formation of amido 
bonds after cholesterol modification decreased the protonable amine group in PCXG1 
available for interaction with cell membranes, which possibly induced the decreased 
cytotoxicity in polycations with higher content of cholesterol.  
132 
 
1 10 100
0
25
50
75
100
PEI
PCX
G1
Chol17-PCX
G1
Chol25-PCX
G1
Chol34-PCX
G1
C (g/mL)
 C
e
ll
 v
ia
b
il
it
y
 (
%
)
 
Figure 32. Cytotoxicity of Chol-PCXG1. Cell viability was measured by MTS assay after 24 
h incubation with increasing concentrations of polymers. Chol-PCXG1 concentrations are 
expressed as PCXG1 concentration only (i.e., excluding cholesterol). Results are 
expressed as mean cell viability ± SD (n=3). 
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4.3.6 CXCR4 antagonism of Chol-PCXG1 and Chol-PCXG1/siRNA 
Binding of PCXG1 to CXCR4 receptor is required for the pharmacologic activity of 
the polymers and polyplexes. The accessibility of the receptor-binding cyclam moieties in 
the polycation structure is necessary for PCXG1 binding with CXCR4 to exhibit inhibitory 
activity. Not all of the eight amino groups in the AMD3100 are required for CXCR4 binding 
and inhibition [197]. However, binding of polymers to receptors on the cell surface can be 
negatively affected by the configuration alternation created by cholesterol. Therefore, it is 
important to investigate the influence of cholesterol on CXCR4 antagonism and confirm 
that the proposed dual functionality of the vector is preserved. We evaluated the CXCR4 
inhibition of SDF1-triggered endocytosis of EGFP-CXCR4 receptors in U2OS 
osteosarcoma cells by CXCR4 receptor redistribution assay, as described before. The 
different fluorescence patterns of EGFP-CXCR4 between untreated and AMD3100 
treated cells are illustrated in Figure 33a.  
In order to permit direct evaluation of the effect of cholesterol moieties on CXCR4 
antagonism of PCXG1, we have tested activity of the synthesized copolymers at equal 
concentrations of the polycationic (PCXG1) part of the copolymers. Activity of PAMD-Ch 
was analyzed and expressed as % CXCR4 antagonism relative to the control AMD3100 
(300 nM) (Figure 33b). We tested Chol-PCXG1 at two different concentrations (0.6 and 2 
µg/mL) and evaluated Chol-PCXG1/siRNA polyplexes prepared at w/w ratios (1.5 and 5). 
The selected w/w ratios allowed us to achieve the same polymer concentrations as in the 
experiment with free copolymers. CXCR4 antagonism of Chol-PCXG1 copolymers and 
their siRNA polyplexes exhibited similar concentration-dependent behavior. When 
compared with the free polymer at the same concentration, Chol-PCXG1 polyplexes 
showed slightly decreased CXCR4 inhibition, which might be due to a result of 
sequestration of a portion of the copolymers in the core of the siRNA polyplexes. A 
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decrease in CXCR4 antagonism showed up with the increasing content of cholesterol 
grafting degree. Chol34-PCXG1 with the highest cholesterol content displayed the lowest 
CXCR4 antagonism among all the tested polymers. However, at a low w/w ratio of 1.5, 
Chol17-PCXG1/siRNA polyplexes achieved nearly 100% CXCR4 inhibition. And Chol25-
PCXG1/siRNA polyplexes achieve similar levels of CXCR4 antagonism at w/w 5. Those 
results indicated that there is a fine balance between the hydrophobicity caused by 
cholesterol moiety and CXCR4 binding. 
4.3.7 Delivery of anti-PLK1 siRNA (siPLK1) by Chol-PCXG1  
PLK1 expression is elevated in multiple types of human cancers, which is a key 
mitotic regulator in mammalian cells, has prognostic value for predicting aggressiveness 
of cancer as well as target values for cancer treatment [269-271]. Inhibition of PLK1 could 
be achieved by small molecule inhibitors or using PLK1 gene silencing with siRNA. Both 
of them caused cell apoptosis and inhibition of tumor growth in vivo [272-274].  
We proposed that combination of antimetastatic effect by Chol-PCXG1 and 
antitumor activity by PLK1 silencing would be promising for cancer treatment. Therefore, 
the investigated the ability of Chol-PCXG1 to deliver siPLK1 in U2OS osteosarcoma cells. 
PEI/siPLK1 polyplexes prepared at w/w 1.5 were used as a positive control. Scrambled 
siRNA (siScr) was used in control experiments to assess toxicity of the studied polyplexes. 
As shown in Figure 34a (left), in serum-free conditions, the safety of the selected polyplex 
formulations were evaluated with acceptable cell viability above 85%. The anticancer 
activity of Chol-PCXG1/siPLK1 polyplexes was determined from their ability to induce 
cancer cell death as a result of PLK1 gene silencing. Different anticancer activities were 
shown with different grafting degrees of cholesterol in PCXG1 polymers. Chol17-PCXG1 
and Chol25-PCXG1 polyplexes polyplexes exhibited better anticancer activity than 
unmodified PCXG1 at equivalent PCXG1/siRNA w/w ratios. The best performing Chol17-
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PCXG1/siPLK1 polyplexes showed cell killing activity (48-62%) fully comparable to the 
PEI/siPLK1 control.  Although grafting degree of cholesterol reached 34% in Chol-PCXG1 
polymer, the siPLK1 induced cell killing was not further improved, indicating that it was 
necessary to optimize cholesterol content in the preparation of copolymers and 
investigated the best percentage. 
In order to investigate the practical application of Chol-PCXG1/siRNA polyplexes, 
we also evaluated the anticancer activity in the presence of 10% serum (Figure 34b). In 
the presence of serum, the safety of the tested polyplex formulations was improved, as 
indicated by the negligible effect on cell viability by Chol-PCXG1/siScr polyplexes. Serum 
compromised the the ability of most of the tested polyplexes to deliver siPLK1 as indicated 
by nearly-background levels of cell killing. For instance, both PCXG1/siPLK1 and 
PEI/siPLK1 lost nearly all their anticancer activity when compared with the serum-free 
conditions. However, Chol17-PCXG1 and Chol25-PCXG1 achieved optimal activity at w/w 
1.5 and 2. Especially, Chol17-PCXG1/siPLK1 polyplexes maintained the significant cell 
killing activity at w/w 2, which was comparable to the activity in serum-free conditions. 
While in the case of Chol34-PCXG1, the highest activity was obtained at w/w 2.5. These 
findings suggest that cholesterol modified copolymers can protect siRNA from degradation 
in serum and facilitate efficient siRNA delivery, but the content of cholesterol and proper 
ratio of polymer/siRNA have to be optimized to achieve maximum anticancer activity. 
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Figure 33. CXCR4 antagonism of Chol-PCXG1 and Chol-PCXG1/siRNA polyplexes. (a) 
Illustration of EGFP-CXCR4 receptor redistribution assay: untreated cells (0% CXCR4 
antagonism) and cells treated with 300 nM AMD3100 (100% CXCR4 antagonism). (b) 
CXCR4 antagonism of Chol-PCXG1 and their siRNA polyplexes. The results are shown as 
mean % CXCR4 inhibition relative to positive control 300 nM AMD3100 ± SD (n=3). 
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Figure 34. siRNA delivery by Chol-PCXG1 in U2OS cells. Transfections were conducted 
either in the absence (a) or the presence of 10% serum (b). Polyplexes were prepared 
with control siScr (left) or siPLK1 (right) at various equivalent PCXG1/siRNA w/w ratios and 
cell killing mediated by PLK1 knockdown was measured (n=4). 
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4.3.8 Intracellular distribution of Chol-PCXG1/siRNA polyplexes 
To gain the expected therapeutic effect, siRNA has to be protected in the 
polyplexes, internalized by the cells and released in the cytoplasm. Proper intracellular 
trafficking is significant for successful delivery of functional siRNA by polyplexes. It was 
reported that introducing hydrophobic moiety like cholesterol into polycations showed 
positive effects on enhancing nucleic acid delivery [255, 260]. Hydrophobic moiety can 
promote cell membrane adsorption, alleviate serum inhibition and facilitate nucleic acid 
dissociation from polycations. In order to visualize both components of the polyplexes, 
copolymers were lablelled with AlexaFluor 647 and form polyplexes with commercially 
available siRNA labelled with AlexaFluor 555. Side-by-side comparison was conducted 
between the best performing Chol17-PCXG1/siRNA polyplexes and parent PCXG1/siRNA 
polyplexes (Figure 35). Confocal microscopy was used to investigate the influence of 
cholesterol modification on the cellular uptake and intracellular distribution of the Chol-
PCXG1/siRNA polyplexes. 
Cellular uptake is one of the main factors determining the success of siRNA 
delivery by the dual-function PCXG1 polyplexes. As shown in Figure 35, polyplexes that 
exhibited high transfection activity also exhibited high levels of cellular internalization. 
Serum contains large amount of anionic proteins that can bind to cationic polyplexes and 
impact the extent and mechanism of cell uptake and intracellular trafficking [275]. The 
effect of serum on the polyplex uptake and intracellular distribution was evaluated. The 
severe adverse effect of serum on the cellular uptake of PCXG1/siRNA polyplexes was 
observed. PCXG1/siRNA polyplexes prepared at w/w 2 exhibited considerably much lower 
cellular uptake and distribution to the cytoplasm than that of Chol17-PCXG1/siRNA 
polyplexes, which correlated to the previous reports that hydrophobic modification of 
polycations can enhance serum compatibility [276, 277]. Moreover, less co-localization of 
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the Chol17-PCXG1 and siRNA signal (bright pink) were shown when compared with 
PCXG1/siRNA where nearly all siRNA was associated with the polycation. The reduced 
co-localized points were due to enhanced intracellular dissociation of the polyplexes and 
release of free siRNA. Incorporating hydrophobic moieties have been reported to facilitate 
intracellular polyplex dissociation [278, 279].  
We have demonstrated that the internalization of PCXG1/DNA polyplexes was 
independent of the CXCR4 trafficking pathway. However, the interaction mechanism of 
polyplexes with cell membranes and membrane receptors might be altered by cholesterol 
modification. Therefore, it was necessary to investigate if the CXCR4 trafficking was 
involved in the intracellular distribution of siRNA polyplexes. EGFP-CXCR4 expressing 
U2OS cells were treated with fluorescently labelled Chol17-PCXG1/siRNA polyplexes (w/w 
5) and 10 nM SDF-1 for 1 h, which allowed Chol17-PCXG1 polyplexes to directly compete 
with the chemokine ligand for binding with CXCR4. As shown in the confocal microscopy 
pictures (Figure 36), Chol17-PCXG1/siRNA polyplexes can efficiently inhibit CXCR4 as 
indicated by the diffuse pattern of EGFP-CXCR4 fluorescence. And there were only a 
small amount of internalized receptors as shown by the discrete green puncta. A fraction 
of the Chol-PCXG1/siRNA polyplexes overlapped with the CXCR4 trafficking as 
demonstrated by the colocalization of siRNA and CXCR4 (yellow) as well as the Chol17-
PCXG1 and CXCR4 (bright blue), indicating that cholesterol modification might change the 
interaction of polyplexes with CXCR4 and facilitate siRNA internalization. However, more 
details of this mechanism have to be further studied. 
  
140 
 
 
Figure 35. Intracellular distribution of PCXG1/siRNA and Chol17-PCXG1/siRNA polyplexes 
in U2OS cells using siRNA labelled with AlexaFluor 555 (red) and polymers labelled with 
AlexaFluor 647 (blue) (cell nuclei stained with Hoechst 33258 (shown as white)).  
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Figure 36. Intracellular distribution of fluorescently labelled Chol17-PCXG1/siRNA 
polyplexes in U2OS cells expressing EGFP-CXCR4 receptors. Cells were incubated with 
polyplexes and 10 nM SDF-1 for 1 h and imaged using a confocal microscope: siRNA 
(red), Chol17-PCXG1 (blue), EGFP-CXCR4 (green), cell nuclei (white).   
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4.3.9 Conclusion 
PCXG1 was modified with different contents of cholesterol and developed for siRNA 
delivery vector. The above findings showed that proper cholesterol modification provided 
the Chol-PCXG1/siRNA polyplexes with increased colloidal stability, improved enzymatic 
stability against RNase, and greatly enhanced siRNA transfection in the presence of 
serum, while retaining strong CXCR4 antagonism. Furthermore, investigation of 
combining Chol-PCXG1 with therapeutic siPLK1 showed promising cell killing effects in 
cancer cells. Therefore, Chol-PCXG1/siRNA polyplexes would be a novel and potential 
dual-functional strategy to treat metastatic cancer. 
As we know, cancer metastasis caused nearly 90% death of cancer patients, which 
is the main reason for the failure of cancer treatment [2]. For instance, less than 20% of 
PC patients are candidates for surgery because it has spread beyond the pancreas at the 
time of diagnosis. Late diagnosis, complex microenvironment and early metastasis in PC 
contributes to the extremely low five-year survival rate (~7%) [30-32]. Better therapeutic 
strategies are needed to be designed to treat PC. Dual-functional PCX nanoparticles will 
be further investigated for PC treatment by combining prevention of cancer metastasis by 
inhibiting CXCR4/SDF-1 axis and ability to deliver therapeutic nucleic acids to tumors. 
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4.4 Polyplex-Mediated Inhibition of CXCR4 and NCOA3 Impedes Pancreatic Cancer 
Progression and Metastasis 
Please note that the data presented in this chapter were published in Biomaterials 
[280]. The authors include Dr. Sushil Kumar, Dr. Satyanarayana Rachagani, Dr. 
Balasrinivasa R. Sajja, Ying Xie, Yu Hang, Dr. Maneesh Jain, Dr. Jing Li, Dr. Michael D. 
Boska, Dr. Surinder K. Batra, Dr. David Oupický and me. I contributed equally with Dr. 
Sushil Kumar to this paper. I prepared polyplexes, characterized their physicochemical 
properties, toxicity, and in vitro activity. I helped to analyze data and wrote early draft of 
the manuscript. Dr. Sushil Kumar designed the in vivo experimental plan and analyzed 
NCOA3 expression in primary tumors by RT-PCR, analyzed primary tumor necrotic area 
and Muc4 expression by immnuohistochemistry staining. Ying Xie helped me with the 
operation of flow cytometry to measure CXCR4 expression. The animal surgery, tumor 
implantation, and IVIS measurements were done by Dr. Satyanarayana Rachagani with 
my help. Perfusion measurement by MRI and data analysis were performed by Dr. Boska 
and Dr. Sajja. Drs. Li, Kumar, Jain, Batra, and Oupicky wrote and revised the manuscript 
and made it published. All the authors agreed with including their work in this dissertation. 
 
PC is one of the worst prognoses of all cancer with a prediction of 53,070 new 
cases and 41,780 deaths in US of 2016 [281]. By 2030, PC might become the second 
leading cause of cancer-related mortalities [29]. PC is unique among solid tumors due to 
the extremely dense desmoplstic reaction, which presents substantial barriers to 
perfusion, diffusion, and convection of antitumor therapeutics into the PC tissues, resulting 
in acquired resistance [34]. Desmoplasia contains extracellular matrix (ECM) proteins, 
myofibroblastic pancreatic stellate cells, and immune cells, which provide growth factors 
and immune modulators to support PC growth [35]. The proliferation of fibroblasts and 
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increased stromal fibrosis induces desmoplastic PC microenvironment with high interstitial 
pressure, dense stroma and vascular dysfuction [39, 40]. Aberrant expression of mucins 
has been found as one of the characteristic features of PC and increases with PC 
progression [93, 94, 282-284]. Mucins induce PC progression, metastasis and 
chemoresistance by interaction with receptor tyrosine kinase, extracellular matrix and 
signal via the cytoplasmic tails [85, 285].  NCOA3 is a crucial regulator of mucin expression 
at both transcriptional and post-translational levels [85]. Furthermore, NCOA3 also 
promote the expression of chemokines in PC microenvironment, which involve in the 
recruitment of immune cells, activation of pancreatic stellate cells and maintenance of 
proinflammatory conditions [286]. Chemokine pathway CXCR4/SDF-1 axis has been 
significantly studied for its role in PC invasion, angiogenesis and proliferation [123, 124]. 
Abundant SDF-1 is produced by PC stromal cells and activates CXCR4 expression in PC 
cells, which also augments Shh pathway to elevate desmoplasia, enhance 
chemoresistance as well as promote invasion in PC [125, 126]. Multiple retrospective 
clinical studies have directly linked the expression of CXCR4 with poor survival and 
metastasis in PC patients [127, 128]. Given the critical role of NCOA3 and CXCR4 in the 
progress of PC, we can develop novel treatment by delivery of NCOA3-silencing siRNA 
using PCX. Our hypothesis is that combination of NCOA3 gene silencing and CXCR4 
inhibition will reduce mucin expression, regulate tumor microenvironment, decrease 
desmoplasia, prevent metastasis, chemosensitize tumor cells and improve the overall 
anticancer activity in PC treatment (Scheme 6). 
4.4.1 PCX selection 
All of the PCX polymers were obtained by Michael-type polyaddition of cyclam-
based CXCR4 antagonists as described in 4.1-4.3 [149, 152, 287]. However, the ability of 
the polymers to condense and deliver siRNA in PC cells was never compared 
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simultaneously. In order to select PCX polymers with the most optimized properties, we 
chose two unmodified PCX as shown in Figure 37: branched PCXG1 synthesized from a 
commercial CXCR4 antagonist AMD3100 and linear PCXG2 synthesized from a 
monocyclam monomers with CXCR4 antagonism. We also chose cholesterol modified 
PCXG1 (Chol17-PCXG1 and Chol25-PCXG1) with high enzymatic stability again RNase and 
improved siRNA delivery. Then, PEGylated PCXG1 in the mixed formation was selected to 
prepared polyplexes with decreased positive surface charge and acceptable colloidal 
stability. All of the above PCX polymers would be screened simultaneously in a series of 
experiments, such as cytotoxicity, siRNA condensation, CXCR4 antagonism, NCOA3 
gene silencing and inhibition of PC cell migration to obtain the most favorable formulation 
for in vivo studies. 
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Scheme 6. Proposed mechanism of action of PCX/siNCOA3 polyplexes.  
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Figure 37. Chemical structures of polymeric CXCR4 inhibitors PCXG1 and PCXG2. 
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4.4.2 Cytotoxicity 
Before the in vitro experiments, toxicity of polycations have to be investigated to 
predict their application for delivery nucleic acid. HepG2 cells were utilized to evaluate the 
possible toxicity of novel compounds in liver. A shown in Figure 38a, all PCX exhibited 
significantly less toxic in comparison with benchmark commercial control PEI. Linear 
PCXG2 had lower molecular weight as well as charge density than the branched PCXG1 
and displayed the least toxic of all the tested polymers. PEG-PCXG1 showed the lowest 
toxicity of the polymers on the basis of PCXG1 due to the steric hindrance of PEG that 
prevents interaction of the polycations with cell membranes and vital intracellular proteins 
[198, 288]. Cholesterol modification of PCXG1 did not impact the cytotoxicity in HepG2 
cells, indicating that proper content of hydrophobic moieties would not cause cell death 
induced by cell membrane disruption. PC cell line CD18/HPAF.luc was used to determine 
the cytotoxicity of PCX and establish safe concentration for the subsequent optimization 
studies in vitro. As shown in the table of Figure 38, all of the PCX polymers displayed less 
toxicity than control PEI. However, the sensitivity of PC cells to PCX increased and the 
differences of IC50 values between PCX and PEI reduced. The preferred cytotoxicity and 
sensitivity of PC cells to PCX may have the potential to improve anticancer activity of PCX 
delivery system. More studies need to conduct to explain the phenomenon.  
4.4.3 Preparation of PCX/siNCOA3 polyplexes 
The ability of PCX to form polyplexes with siNCOA3 was first investigated by 
agarose gel electrophoresis (Figure 38b). All w/w ratios in this study are expressed as 
equivalent PCX/siRNA ratios without taking cholesterol or PEG content into consideration. 
The polyplexes were prepared at increasing PCX-to-siNCOA3 w/w ratios and incubated 
at room temperature for 20 min before use. All PCX were able to fully complex siNCOA3 
at or above w/w ratio 2. The siNCOA3 binding ability of PEG-PCX was slightly weaker 
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than the other PCX at w/w 1, as suggested by a stronger smear of siNCOA3 releasing 
from loading well. The weaker complexation ability of PEG-PCX is likely due to 
interference of the interaction between polymer and siRNA by the long PEG chains. 
Therefore, all siNCOA3 polyplexes used in the following studies were prepared at w/w 2 
to assure complete siRNA complexation. 
4.4.4 Characterization of PCX/siNCOA3 polyplexes 
Hydrodynamic size and zeta potential of PCX/siNCOA3 polyplexes were evaluated 
by dynamic light scattering (Figure 38c). Polyplexes were prepared in HBG buffer at 
equivalent w/w ratio of 2 and were allowed to stabilize for 20 min at room temperature 
before measurement. Except for PCXG2/siNCOA3, all the other polyplexes displayed small 
particle ranging from 88 to 125 nm. All PCX/siNCOA3 polyplexes exhibited positive 
surface charge indicated by zeta potentials ranging from 5 to 23 mV. Cholesterol or PEG 
modified siNCOA3 polyplexes showed smaller sizes than PCXG1/siNCOA3, perhaps 
suggesting tighter binding at w/w ratio of 2. However, PEGylated PCX exhibited nearly 
neutral zeta potential because that PEGylation shielded the positive surface charge of 
polyplexes [288]. 
4.4.5 CXCR4 antagonism of PCX/siRNA polyplexes 
The CXCR4 inhibitory activity is significant for the proposed mechanism of 
polyplexes to inhibit cancer metastasis. CXCR4 redistribution assay was used to conduct 
this experiment and HCS analysis was used to quantify the extent of EGFP-CXCR4 
internalization into the cells as described before [287]. In order to avoid any potential 
confounding effects from NCOA3 silencing, negative control siRNA (siScr) was utilized to 
prepare polyplexes with PCX. As shown in Figure 39, all PCX polyplexes displayed nearly 
complete CXCR4 inhibition at w/w ratio of 2, which were comparable to positive control 
AMD3100. Cholesterol modification induced a slight decrease in CXCR4 inhibitory activity 
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of the polyplexes. Chol17-PCXG1/siScr and Chol25-PCXG1/siScr showed 96% and 91% 
CXCR4 inhibition, respectively. PCXG1, PCXG2 and PEG-PCXG1 were more effective than 
Chol17-PCXG1. Polycation PEI worked as a negative control and did not display CXCR4 
antagonism, indicating that the observed effect is due to the specific binding of PCX to the 
CXCR4 receptor, but not due to the polycationic character. After confirming the complete 
CXCR4 inhibitory activity of PCX, the ability of PCX to inhibit PC cell metastasis would be 
evaluated. 
4.4.6 CXCR4 expression in PC cell line 
CXCR4 overexpression increases PC cell motility and invasion, leading to 
enhanced metastasis [122, 289, 290]. And a growing experimental and clinical evidence 
shows that anticancer therapies can promote hypoxic environment and increase CXCR4 
expression, which may inadvertently enhance the metastatic potential of the tumors [291-
293]. It is also reported that CXCR4/SDF-1 signaling plays an important role in 
gemcitabine resistance of PC cells. Gemcitabine up-regulates CXCR4 expression in PC 
cells (Colo357 and MiaPaCa) and promotes their invasiveness, indicating that some 
current chemodrug administration may cause aggressive phenoty of PC [294]. Here, we 
used CD18/HPAF.luc cells as PC model in the study. To detect the CXCR4 expression 
after gemcitabine treatment in CD18/HPAF.luc cells, the changes of CXCR4 expression 
on cell membrane were determined by flow cytometry and changers at total protein level 
were analyzed by western blot. As shown in Figure 40, the population of CXCR4-positive 
CD18/HAPF.luc cells enhanced from 11.3% to 18% after treatment with 10 µM 
gemcitabine for 24 h. Similarly, western blot analysis corroborated this finding, as there 
was a noticeable increase in CXCR4 expression in CD18/HPAF.luc cells (1.75-fold and 
1.7-fold) at both 1 and 10 μM gemcitabine concentrations. Therefore, we will test the ability 
of PCX to prevent CXCR4-mediated migration of PC cells in the following study.  
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Figure 38. Characterization of PCX and PCX/siNCOA3 polyplexes. (a) Cytotoxicity of 
PCX in HepG2 and CD18/HPAF.luc cells. IC50 (in μg/mL) were calculated as the polymer 
concentration that achieves 50% decrease in cell viability relative to untreated cells (n = 
3). (b) Ability of PCX to form polyplexes with siNCOA3 evaluated by agarose gel 
retardation assay at increasing PCX/siNCOA3 w/w ratios. (c) Hydrodynamic size and zeta 
potential of PCX/siNCOA3 polyplexes prepared at w/w 2 (mean ± SD, n = 3). All 
polyplexes were prepared in HBG at siNCOA3 concentration of 20 µg/mL.  
  
152 
 
 
Figure 39. CXCR4 antagonism of PCX/siScr polyplexes (polymer = 1 µg/mL, w/w 2) in 
U2OS cells. (a) The results are shown as mean % CXCR4 inhibition relative to AMD3100 
± SD (n=4). One-way ANOVA with Tukey-Kramer multiple comparisons test (***P<0.001 
vs. PEI). (b) Representative images of EGFP-CXCR4 distribution in cells treated with 
different polymers. The scale bar = 200 µm. 
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Figure 40 Effect of gemcitabine (Gem) on the CXCR4 expression in CD18/HPAF.luc PC 
cells. (a) Cell surface CXCR4 expression in CD18/HPAF.luc cells by flow cytometry before 
and after gemcitabine treatment. (b) Total cellular CXCR4 expression by Western blot 
(n=2). Results are expressed as ratio of a mean relative CXCR4 expression vs. cells not 
treated with gemcitabine (n=2).  
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4.4.7 Inhibition of PC cell migration by PCX 
As we confirmed, CXCR4 expression was enhanced by gemcitabine treatment in 
CD18/HPAF.luc cells. We studied the migration of gemcitabine-treated CD18/HPAF.luc 
cells in a Boyden chamber using 10% serum as the chemotactic signal. PC cells were 
pretreated with 10 µM gemcitabine for 24 h and 105 cells were loaded into each insert on 
the next day. As shown in Figure 41, without gemcitabine treatment, seldom cells 
migrated through the membrane. However, gemcitabine promoted the aggressiveness of 
PC cells and increased their metastasis. CXCR4 antagonists can inhibit migration of 
cancer cells that are based on the CXCR4/SDF1 axis. We have shown that PCX and their 
polyplexes inhibited CXCR4-mediated migration and invasion in human osteosarcoma 
and cholangiocarcinoma cells [152, 287, 295]. Here, we would like to investigate the ability 
of PCX to prevent CXCR4-medicated migration in CD18/HPAF.luc cells (Figure 42). After 
pretreated with 10 µM gemcitabine for 24 h, 2x105 cells were loaded into each insert. 
Untreated cells migrated significantly toward the chemotactic gradient. Small-molecule 
CXCR4 antagonist AMD3100 was able to reduce the number of migrated cells by 29.5%. 
However, all tested PCX PCX were capable to effectively inhibit cell migration at 1 μg/mL, 
ranging from 38% for Chol25-PCXG1 to 43% for PCXG2, which was more efficient than 
conventional CXCR4 inhibitors. In contrast, polycation control PEI was not observed any 
inhibitory effect on cell migration, suggesting that PCX would be well-suited for 
applications in treatment of PC that aim at preventing or delaying metastasis. 
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Figure 41. Migration of PC cell enhanced after gemcitabine treatment. CD18/HPAF.luc 
were pretreated with or without  10 µM gemcitabine for 24 h. 105 cells were loaded into 
the insert and culture medium containing 10% FBS was used as chemoattractant. Images 
were taken at 10x magnification (scale bar = 400 µm).   
-Gem +Gem
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Figure 42. Inhibition of PC cell migration by PCX (1 µg/µL). CD18/HPAF.luc cells were 
treated with 10 μM gemcitabine for 24 h before the migration study. 2x105 cells were 
loaded into the insert. Migrated cells were counted in 4 randomly selected imaging areas 
at 10x magnification of triplicate samples (scale bar = 400 µm). One-way ANOVA with 
Tukey-Kramer multiple comparisons test (***P<0.001, vs. untreated cells).  
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4.4.8 NCOA3 silencing by PCX/siNCOA3 polyplexes 
After evaluating the ability of PCXs to form polyplexes with NCOA3 siRNA and 
inhibit the migration of PC cells, we have studied the capacity to deliver siNCOA3 and 
downregulate NCOA3 in PC cells. The NCOA3 silencing by PCX polyplexes at protein 
level was analysed by western blot. PCX polyplexes were formulated at w/w of 2 using 
either siNCOA3 or a negative control siRNA (siScr). PEI/siRNA (w/w 1.5) polyplexes were 
used as controls.  
As shown in Figure 43, Chol17-PCX and Chol25-PCX exhibited significantly 
higher NCOA3 knock-down (78% and 52% respectively) than other PCX polyplexes (PCX-
1 = 21%, PCX-2 = 9.6%, PEG-PCX = 3.5%). PEI displayed second high NCOA3 gene 
silencing with 59%, however, it caused significant off-target effects as indicated by 
decreased NCOA3 levels observed with PEI/siScr [296]. Chol17-PCX was chosen to form 
dual-function polyplexes with siNCOA3 to treat PC in vivo, due to the highest NCOA3 gene 
silencing and effective inhibition of cell migration. 
4.4.9 Inhibition of primary pancreatic tumor growth by PCX/siNCOA3 polyplexes 
CXCR4 and its ligand CXCL12 promote metastatic and invasive process of PC, 
fostered by the expression of matrix-metalloproteinase including MMP-2 and MMP-9 [297-
300]. Except the role of CXCR4/SDF-1 axis in PC metastasis, it also extensively involved 
in tumor proliferation [122, 289, 290]. NCOA3 is a chromatin remodelling enzyme, which 
plays a vital role in mucins regulation, creates pro-inflammatory conditions and modulates 
tumor microenvironment to promote growth and dissemination of PC cells [85]. Therefore, 
both CXCR4 and NCOA3 are involved in the proliferation of PC cells and in maintenance 
of tumor microenvironment that promotes metastatic spread.  
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First, we tested whether combining inhibition of CXCR4 and NCOA3 affects the 
growth of the primary PC tumors. The antitumor activity of Chol17-PCXG1/siNCOA3 
polyplexes was evaluated in orthotopic pancreatic cancer animal model. CD18/HPAF.luc 
cells were implanted into the pancreas of female nude mice and allowed to grow for 10 
days. As shown in Figure 44, the body weight of mice decreased less than 10% after 
tumor implantation. However, all of the mice recovered after 7 days. 
10 days after orthotopic implantation of CD18/HPAF.luc cells, the presence of the 
tumors was established by whole-body bioluminescence imaging and mice were 
randomized into three experimental groups (saline, Chol17-PCXG1/siScr, and Chol17-PCX 
G1/siNCOA3). Polyplexes were prepared at a polycation/siRNA w/w ratio of 2 and 
administrated by tail vein injections with 40 µg siRNA/mouse, 3 times per week and 13 
courses in total. None of the treatments caused any significant effect or lose on the body 
weight, indicating the nontoxicity of the injected PCX/siNCOA3 polyplexes.  
Mice were sacrificed on day 39 post-implantation. Treatments with both PCX/siScr 
and PCX/siNCOA3 slowed down the progresses of primary pancreatic tumor (Figure 45 
a-b). However, the combination of CXCR4 inhibition and NCOA3 silencing showed 
significantly better effect on slowing down the growth of primary PC than PCX/siScr, 
suggesting the superior activity of combination treatment. As shown in Figure 45c, the 
NCOA3 gene silencing in primary PC tumors was confirmed by qRT-PCR. PCX/siNCOA3 
induced 30% NCOA3 gene silencing compared with saline group, which had significantly 
statistical difference (P<0.01).  
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Figure 43. NCOA3 gene silencing by PCX/siNCOA3 polyplexes in CD18/HPAF.luc PC 
cells. NCOA3 silencing was determined by Western blot (top) using polyplexes prepared 
at w/w ratio of 2 and used at 200 nM siRNA. The percent of NCOA3 silencing (bottom) 
was calculated from NCOA3 band intensity of PCX/siNCOA3 relative to the corresponding 
PCX/siScr control. PEI polyplexes were prepared at w/w 1.5. 
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Figure 44. Average body weight after orthotopic implantation of CD18/HPAF.luc cells and 
during treatment with Chol17-PCXG1/siNCOA3 (n=6), Chol17-PCXG1/siScr (n=7), and 
saline (n=7). The results were expressed as average of relative body weights ± SD values. 
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Figure 45. Effect of systemic treatment with Chol17-PCXG1/siNCOA3 (w/w 2) on the 
growth of primary pancreatic tumor. (a) Primary tumor weights were measured after 
necropsy. (b) Photograph of resected primary PC tumors. (c) Silencing of NCOA3 
expression in the primary PC tumors by RT-PCR (results shown as ratio of mean relative 
NCOA3 expression compared with saline treated mice ± SD (n=3)). Statistical 
comparisons by unpaired t-test (***p<0.001, **p<0.01, *p<0.05). 
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4.4.10 Antimetastatic effect of PCX/siNCOA3 polyplexes  
One of the significant reasons for low survival rate in PC is early metastasis. PC 
metastasize to a broad range of organs, such as pericardium, stomach, spleen diaphragm, 
small and large intestines, gallbladder, and ovaries [301, 302]. However, the most 
common metastatic site is liver. As shown in Figure 46, the mice from saline group had 
metastasis in a wide range of organs on day 39. All saline treated mice displayed 
metastasis in the ovary and stomach, six out seven showed tumor spread to in small 
intestine and diaphragm, five out seven had metastasis in liver, spleen and lymph node. 
Furthermore, they also showed metastasis in kidney and large intestine. Treatment with 
PCX/siScr, which inhibited CXCR4 in PC, reduced the metastasis in all of the organs 
except spleen. Specifically, the incidence of stomach metastasis was much lower in the 
PCX/siScr group compared with the saline group, which had statistically significant in 
Fisher’s exact test (p=0.0047). Combination treatment with PCX/siNCOA3 greatly resulted 
in much lower incidence of metastasis in all of the organs. Statistically significant 
differences were observed in the incidences of metastases in liver, ovary and stomach 
between PCX/siNCOA3 and saline groups. And PCX/siNCOA3 showed better effect on 
preventing metastasis in liver, diaphragm, ovary, lymph node and stomach than PCX/siScr, 
indicating that both CXCR4 inhibition and NCOA3 knock-down contributed to the overall 
antimetastatic activity of the polyplexes for PC therapy. 
4.4.11 Regulation of mucin expression and hypoxic environment by PCX/siNCOA3 
polyplexes  
Mucins are critical of PC progression, metastasis and chemoresistance. NCOA3 
regulates mucin expression at both transcriptional and post-translational levels [85]. As 
confirmed by the immunohistochemistry analysis in Figure 47a, NCOA3 silencing reduced 
the expression of Muc4 significantly in PC primary tumors. Down-regulation of NCOA3 
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also has shown to cause significant decrease in the expression of LOXL2, which 
participates in fibroblast activation and hardening of desmoplasia [85]. Multiple 
chemokines in PC microenvironment are enhanced by NCOA3 overexpression and 
involves in the activation of pancreatic stellate cells, recruitment of immune cells as well 
as maintenance of pro-inflammatory conditions.  Pancreatic stellate cells secret large 
amount of collagens and extracellular matrix proteins, which are crosslinked by LOXL2, 
leading to the formation of desmoplasia, poor tumor perfusion and severe hypoxia in PC 
microenvironment. As shown in Figure 47a, the H&E staining revealed the inner structure 
of primary PC tumors. The less purple (pink) part corresponded to the tumor necrosis, 
which was induced by the hypoxia in tumor microenvironment. Figure 47b revealed that 
treatment with PCX/siNCOA3 significantly decreased the necrotic area in PC primary 
tumors from about 17% to 2.5% in comparison with PCX/siScr and saline group.  
4.4.12 Tumor perfusion enhanced by PCX/siNCOA3 polyplexes  
Desmoplasia subsequently caused collapse of the blood vessels, poor tumor 
perfusion, increased interstitial pressure, extreme hypoxia, and poor delivery of 
therapeutics. If the tumor perfusion is enhanced, more chemotherapeutics can be 
delivered into PC tissues and improve the chemosensitivity. It was reported that inhibition 
of LOXL2 reduced extracellular matrix and desmoplasia [303, 304]. In order to investigate 
whether tumor perfusion can be improved by PCX/siNCOA3 treatment, tumor perfusion 
was evaluated by magnetic resonance imaging. As shown in Figure 48, PC tumor 
perfusion was enhanced after NCOA3 silencing, which was due to its role in desmoplastic 
reaction. After treatment with PCX/siNCOA3, the tumor perfusion increased from 44.3 to 
62.5 mL/100 g/min. The enhanced tumor perfusion will facilitate drug delivery, regulate 
PC microenvironment, ameliorate hypoxia condition, improve the chemosensitivity and 
decrease the aggressiveness in PC. 
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4.4.13 Conclusion 
We have designed dual-function polyplexes to simultaneously deliver siNCOA3 
and inhibit CXCR4 chemokine receptor to treat pancreatic cancer. Our study tested a 
series of PCX formed polyplexes and screened formulations that can effectively knock 
down NCOA3 expression at protein level. Cholesterol modification of PCX provided the 
most optimized set of properties to achieve CXCR4 antagonism, siRNA delivery and 
efficient gene silencing in PC. Our results demonstrates that combining the tumor 
microenvironment regulation by NCOA3 silencing and antimetastatic effect of CXCR4 
antagonism led to slow-down of pancreatic tumor progress, prevention of tumor 
metastasis to distant organs, decrease of Muc4 expression in primary tumors and 
enhancement of perfusion in PC microenvironment. Since desmoplasia and CXCR4 
overexpression are characteristic features of both primary and metastatic PC tumors, the 
developed PCX polyplexes are suitable for delivery to both primary and metastatic PC 
sites [305]. Furthermore, regulation of tumor microenvironment led to enhanced tumor 
perfusion, however, may also facilitate cancer cell metastasis out of primary site. 
Therefore, combining tumor-microenvironment modulating strategies with simultaneous 
antimetastatic ability of CXCR4-inhibiting polymers has the potential to minimize any side 
effects. Future development of these dual-function systems will focus on optimization of 
NCOA3 silencing in vivo to decrease the treatment courses and improve overall antitumor 
effects with combination of chemodrugs. 
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Figure 46. Effect of PCX/siNCOA3 treatment on the incidence of PC metastasis in the 
orthotopic CD18/HPAF.luc PC model. The presence of metastasis in major organs and 
tissues was determined on day 39 following implantation of the PC cells in mice. Fisher’s 
exact test was used to compare the incidence of metastasis between groups and p<0.05 
was considered to be statistically significant. 
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Figure 47. Analysis of primary pancreatic tumors after treatment with Chol17-
PCXG1/siNCOA3 polyplexes. (a) H&E staining and MUC4 immunohistochemistry analysis 
(magnification 40x). (b) Extent of necrosis in primary tumor determined from the H&E 
staining. 
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Figure 48. Primary tumor perfusion on day 39 determined from magnetic resonance 
imaging. 
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Chapter 5 – Overall Conclusions, Significance and Future Studies 
Metastasis is the main cause of cancer mortality and morbidity, resulting in several 
million deaths annually. Unfortunately, existing therapeutic approaches rarely reverse or 
stop metastatic progression. For PC, less than 20% of patients are candidates for surgery 
due to spread beyond the pancreas. Gemcitabine is the first-line treatment for metastatic 
pancreatic cancer. However, the objective response rate is less than 10%. The emergence 
of desmoplasia in PC is becoming a problem which presents substantial barriers to 
perfusion, diffusion, and convection of antitumor therapeutics into the PC tissues. It results 
in collapse of the blood vessels, increases interstitial pressure, extreme hypoxia, poor 
tumor perfusion, and poor delivery of therapeutics. Thus, there is very urgent need to 
develop therapies that focus on regulating tumor microenvironment, chemosensitizing 
tumor to therapeutics and preventing metastasis. 
Small interfering RNA (siRNA) has rapidly emerged as one of the most promising 
new therapeutic agents for the treatment of many diseases. The capacity of siRNA to 
selectively destroy any mRNA sequences offers the possibility to alter the behavior of 
pathological cells. siRNA has shown great potential for therapeutic benefits even in 
complex diseases like cancer [306]. PLK1 is a key mitotic regulator in mammalian cells, 
which is an attractive target in cancer treatment [269, 270]. PLK1 expression is elevated 
in multiple types of human cancers and it has a prognostic value for predicting 
aggressiveness of cancer [271]. Inhibition of PLK1 by using gene silencing with siRNA 
results in cell apoptosis and inhibition of tumor growth. NCOA3 is a master regulator of 
musin expression in PC both at the transcriptional and post-translational levels [307]. The 
NCOA3 expression is significantly elevated in primary PC tumors and in metastatic lung, 
lymph and liver lesions. NCOA3 also upregulates the expression of chemokines to impact 
tumor microenvironment. NCOA3 silencing by siRNA leads to downregulate the 
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expression of mucins and diminish desmoplasia to enhance treatment. A major obstacle 
that currently prevents the clinical use of siRNA therapy is a lack of reliable methods to 
deliver siRNA to target cells. The short half-life of siRNA in blood circulation and the need 
for intracellular cytoplasmic delivery represent major challenges for clinical translation 
[308]. Therefore, the effective delivery system should be developed. 
CXCR4 and its chemokine ligand SDF-1 play a crucial role in the crosstalk 
between cancer cells and their microenvironment, and are involved in tumor progression, 
angiogenesis, metastasis and survival. Many clinical studies show that CXCR4 expression 
in various cancers (e.g. PC) is associated with more aggressive disease, more metastases, 
and shorter overall patient survival. This dissertation addresses the need for such 
therapies by exploiting the decisive role of CXCR4 chemokine receptor in the metastatic 
spread of PC as a target for development of combination treatments based on dual-
function nanoparticles. There is growing evidence that inhibition of CXCR4 has the 
potential to prevent metastasis and limit tumor growth. Metastasis is a systemic disease 
and therefore, effective methods of systemic delivery of the treatments are necessary. By 
developing nanoparticles capable of simultaneous CXCR4 inhibition and delivery of 
antitumor therapeutic siRNA, we are able to prevent metastasis and improve overall 
anticancer activity. 
We have successfully synthesized CXCR4-inhibiting polycations (PCX) using 
Michael polyaddition. The PCX could self-assemble into nanosized particles with nucleic 
acids through electrostatic interaction and function as efficient transfection agent while 
exhibiting effective CXCR4 antagonism. To enhance the CXCR4 antagonism, we reported 
synthesis of novel monocyclam monomers and their polymerization to PCX. The CXCR4 
inhibitory activity of the synthesized monocyclam monomers increased significantly 
following incorporation into the polymers. Furthermore, the CXCR4 inhibitory activity of 
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second generation of PCX was higher compared with the previously reported polymers 
based on commercial CXCR4 antagonist AMD3100, confirming the importance of a proper 
presentation of the ligands within synthetic polymers. To improve the physical properties 
and safety of PCX, it was modified by PEGylation. Our results demonstrated that 
modification of PCX with PEG decreased toxicity of the polymers, while preserving their 
CXCR4 antagonism. Polyplexes prepared with PEG-PCX inhibited invasion of cancer cells 
to an extent similar to the commercial CXCR4 antagonist Plerixafor. Negative effect of 
PEG on transfection activity of PEG-PCX polyplexes could be overcome by using 
polyplexes formulated with a mixture of PCX and PEG-PCX. Although efficient in DNA 
delivery, the original PCX exhibited poor siRNA delivery activity. Therefore, we developed 
PCX as siRNA delivery vectors to achieve combined antimetastatic and antitumor effect. 
PCX was modified with cholesterol, which led to increased overall stability, cell uptake as 
well as intracellular trafficking of siRNA polyplexes. After obtaining a series of dual-
function PCX polymers with the conceptually new approach to deliver therapeutic nucleic 
acids and preventing cancer metastasis, NCOA3 siRNA was chosen to form nanoparticles 
with PCX to address unresolved problems of chemoresistance and provide an immediate 
therapeutic opportunity for the lethal PC. We tested a series of PCX formed polyplexes 
and screened formulations that can effectively knock down NCOA3 expression at protein 
level. Our results demonstrate that in the combination of the tumor microenvironment 
regulation by NCOA3 silencing with antimetastatic effect of CXCR4 antagonism, slow-
down of the pancreatic tumor progress, prevention of tumor metastasis to distant organs, 
decrease of mucin expression in primary tumors and enhancement of perfusion in tumor 
microenvironment were achieved.  
Despite tremendous promise in anticancer therapies, siRNA is nearly certainly to 
be used in combination with other treatments. Our study supports the use of 
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PCX/siNCOA3 as a promising neoadjuvant or adjuvant treatment with conventional 
chemotherapeutics such as gemcitabine. Our future studies will focus on improving the 
polyplex formulations and on the anticancer and antimetastatic effect of these polyplexes 
in combination with gemcitabine. We predict that increased tumor perfusion observed here, 
together with chemosensitizing effect of NCOA3 knockdown and related mucin 
downregulation will improve activity. Further, given the well-established fact that 
gemcitabine treatment upregulates CXCR4 expression in pancreatic cancer, the use of 
PCX in the siNCOA3 delivery is an ideal choice. However, the NCOA3 silencing of dual-
function systems will be optimized in vivo to decrease the treatment courses and improve 
overall antitumor effects. 
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